AUTHOR INDEX

Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients, 1272

Abbruzzese JL, *see* Pazdur R

Abbruzzese MC, *see* Abbruzzese JL

Abeloff MD, Civin CI, Piantadosi S. In memoriam: Brigid Leventhal (obituary), 1111

— *see* Rivkin SE

Abner A, *see* Nixon AJ

Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non–small-cell lung cancer: A phase II study, 1535

Acuña LR, *see* Romero A

Adair S, *see* Camitta B

Adam H, *see* Borner M

Adam W-E, *see* Hertenstein B

Adams K, *see* Rohatiner AZS

Adams PT, *see* Datta YH

Adenis A, Bonneterre J. Are 5-hydroxytryptamine-3 receptor antagonists efficient antiemetics for chemotherapy-induced delayed emesis and do they remain effective over subsequent cycles? (letter), 2235

Adhikari A, *see* Horning SJ

Adjei A, *see* Rowinsky EK

Adkins DR, Salzman D, Boldt D, Kuhn J, Irvin R, Roodman GD, Lyons R, Smith L, Freytes CO, LeMaistre CF. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma, 1890

— *see* Spitzer G

Adler SS, *see* Ghalie R

Adluri S, *see* Livingston PO

Adrover E, *see* Martín M

Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer, 960

Aisner SC, *see* Loehrer PJ Sr

Ajani JA, *see* Pazdur R

Akerley W, *see* Choy H

Alberola V, *see* Le Chevalier T

Alberti D, *see* Bailey HH

— *see* Schiller JH

Alberto P, *see* Borner M

Alberts DS, *see* Stiff PJ

Albright AL, *see* Geyer JR

Alexanian R, *see* Dimopoulos MA

Algeri R, *see* Cocconi G

Allegra CJ, *see* Grem JL

— *see* Johnston PG

Allen JC, *see* Geyer JR

Allen SL, *see* Budman DR

Allred DC, *see* Ravdin PM

Almeida MT, *see* Maluf PT

Altomonte V, *see* Kennedy MJ

Amato R, *see* Sella A

Amato S, *see* Romero A

Ambrosetti A, *see* Nadali G

Ambrosini G, *see* Gasparini G

American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines, 2471

Ames MM, *see* Tefferi A

Amess JAL, *see* Rohatiner AZS

Amoroso M, *see* Scambia G

Andersen E, *see* d'Amore F

Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non–small-cell lung cancer: A phase II study, 1821

Anderson JR, *see* Darrington DL

— *see* Nesbit ME Jr

Andersson BS, *see* Giralt SA

— *see* Khouri IF

André M, *see* Conti JA

Andreeff M, *see* Estey E

Ansari R, *see* Einhorn LH

Antal J, *see* Bukowski RM

Antman K, *see* Ayash LJ

Antman KH, *see* Vogelzang NJ

Antoine E, *see* Spielmann M

Appel C, *see* Pienta KJ

Appelbaum FR, *see* Weaver CH

Arbit E, *see* Armstrong JG

Arbuck SG. Paclitaxel: What schedule? what dose? (editorial), 233

— *see* Grem JL

Arcenas A, *see* Vadhan-Raj S

Archer PG, *see* Shpall EJ

Archimbaud E, Thomas X, Michallet M, Jaubert J, Troncy J, Guyotat D, Fiere D. Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia, 262

Armand JP, *see* Toussaint C

Armitage A, *see* Moore MJ

Armitage JO, *see* Darrington DL

Armstrong JG, Wronski M, Galicich J, Arbit E, Leibel SA, Burt M. Postoperative radiation for lung cancer metastatic to the brain, 2340

Arnold R, *see* Hertenstein B

Arnott SJ, *see* Rohatiner AZS

Aronson FR, *see* Atkins MB

Arzoomanian R, *see* Schiller JH

Arzoomanian RZ, *see* Bailey HH

Ascensao JL, *see* Schenkein DP

Ash CM, *see* Miles DW

Ashley S, *see* Jones AL

Aster JC, *see* Stone RM

Ater JL, *see* Murray JL
Atkins CD. Tamoxifen versus medroxyprogesterone acetate for metastatic breast cancer (letter), 2515
Atkins H, *see* Lowsky R
Atkins JN, *see* Muss HB
Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI, Eckardt JR, Pereira C, Aronson FR. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma, 1553
Atkinson JB, *see* Matthay KK
Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J, Laurent G. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation, 141
— *see* Reiffers J
— *see* Sebban C
Au E, Loprinzi CL, Dhodapkar M, Nelson T, Novotny P, Hammack J, O'Fallon J. Regular use of a verbal pain scale improves the understanding of oncology inpatient pain intensity, 2751
August C, *see* Nesbit ME Jr
Austin HA III, *see* Guleria AS
Auzannet V, *see* Tomiak E
Avery L, *see* Mathew P
— *see* Pappo AS
— *see* Pratt CB
Avilés A. The international index is not useful in the classification of low-grade lymphoma (letter), 2766
Awada A, *see* Tomiak E
Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, Schnipper L, Frei E III, Antman K. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: A feasibility study, 37
Ayers D, *see* Relling MV
Ayers GD, *see* Geyer JR
Azagra P, *see* Martín M

Bacchi M, *see* Borner M
Bach F, *see* Anderson H
Bachellier P, *see* Nordlinger B
Bacon M, *see* Eisenhauer EA
Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione, 194
Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, Giannotti B, Queirolo P, Tribbia G, Bernengo MG, Menichetti ET, Palmeri S, Russo A, Cristofolini M, Erbazzi A, Fowst C, Criscuolo D, Bufalino R, Zilembo N, Cascinelli N. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma, 806
Bajorin DF, *see* Mencel PJ
— *see* Motzer RJ
— *see* Schultz PK
Baker SD, *see* Stewart CF
Balcerzak SP, *see* Meyskens FL Jr
Balis F, *see* Grem JL
Balis FM, *see* Wilson WH
Ball H, *see* Thigpen JT
— *see* Williams S
Balladur P, *see* Nordlinger B
Balmaceda C, *see* Francis P
Balshem A, *see* Lerman C
Baltzer L, *see* Kris MG
Barakat R, *see* Francis P
Barbareschi M, *see* Gasparini G
Barbhaiya RH, *see* Budman DR
Barbier N, *see* McIntyre JF
Barbieri R, *see* Romero A
Barduagni M, *see* Bajetta E
Barlogie B, *see* Salmon SE
Barni S, *see* Gasparini G
Baroja A, *see* Ispizua A
Barrett DM, *see* Zincke H
Barrett RJ, *see* Thigpen JT
Barrett S, *see* Seidman AD
Bartel J, *see* Loprinzi CL
Bartelink H, *see* Borger J
Barth NM, *see* Dillman RO
Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance, 835
—, Rizeq M, Dorfman RF, Halpern J, Horning SJ. Follicular large-cell lymphoma: Intermediate or low grade? 1349
Basser RL, Sobol MM, Duggan G, Cebon J, Rosenthal MA, Mihaly G, Green MD. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy, 1659
Bastert G, *see* Schumacher M
Bastian A, *see* Foss FM
Bastion Y, Coiffier B. Is the international prognostic index for aggressive lymphoma patients useful for follicular lymphoma patients? (editorial), 1340
Bateman M, *see* Loprinzi CL
Bates NP, Williams MV, Bessell EM, Hudson GV, Hudson BV. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: A British National Lymphoma Investigation pilot study, 288
Bates S, *see* Wilson WH
Battaglia F, *see* Scambia G
Bauer J, *see* Leyvraz S
Bauer RJ, *see* Bukowski RM
Baum M, *see* Cuzick J
Baurmann H, *see* Siegert W
Bayssas M, *see* Tomiak E
Beal JA. Appetite effect of dronabinol (letter), 1524
Beard CM, *see* Kyle RA
Bearden JD III, *see* Muss HB
Bearman SI, *see* Shpall EJ

Beck TM, *see* Hesketh PJ
Beckwith JB, *see* Green DM
Behm FG, *see* Pui C-H
Behr J, *see* Budman DR
Bell RS, *see* Davis AM
Bella M, *see* Cocconi G
Benboubker L, *see* Delain M
Benedetti F, *see* Nadali G
Benjamin D, *see* Wells RJ
Benjamin RS, *see* Murray JL
— *see* Vadhan-Raj S
Benner S, *see* Fossella FV
Benner SE, *see* Lee JS
— *see* Lippman SM
Bennett JM, Troxel AB, Gelman R, Falkson G, Coccia-Portugal MD, Dreicer R, Tormey DC, Rushing D. Myelodysplastic syndrome and acute myeloid leukemia secondary to mitolactol treatment in patients with breast cancer (letter), 874
Bensinger WI, *see* Weaver CH
Benson AB III, *see* Giovanazzi-Bannon S
Benyunes K, *see* Weaver CH
Beran M, *see* Estey E
Berard CW, *see* Sandlund JT
Berchier MC, *see* Sculier JP
Berenson RJ, *see* Shpall EJ
Berg SL, *see* Wilson WH
Berger R, *see* Reinisch W
Bergeron C, *see* Michel G
Bergin ME, *see* Shaw PJ
Bergstralh EJ, *see* Zincke H
Berinstein NL, *see* Haq R
Berkey CS, *see* Eisenberg E
Berkman E, *see* Schenkein DP
Berkow RL, *see* Castleberry RP
Bernasconi S, *see* Leyvraz S
Bernaudin F, *see* Michel G
Bernengo MG, *see* Bajetta E
Bernhard J, *see* Hürny C
Bernstein I, *see* Wells RJ
Bernstein ID, *see* Nesbit ME Jr
Berslow NE, *see* Green DM
Berthaud P, *see* Le Chevalier T
Bertino JR, *see* Conti JA
— *see* Kemeny N
Bertino JR Jr, *see* Tan CTC
Besenval M, *see* Le Chevalier T
Bessell EM, *see* Bates NP
Besson F, *see* Le Chevalier T
Betcher D, *see* Wells RJ
Betlemovic M, *see* Graf N
Bevilacqua P, *see* Gasparini G
Bewermeier P, *see* Mross K
Beyer J, *see* Siegert W
Beyerle C, *see* Schumacher M
Bezwoda WR, *see* Abratt RP
Bhadkamkar V, *see* Murray JL
— *see* Patt YZ
Bierman PJ, *see* Darrington DL
Birmingham BK, *see* Buzdar AU
Bishop MR, *see* Darrington DL
Bissent E, *see* Shea TC
Bissett D, *see* Wishart GC
Bitter M, *see* Shpall EJ
Bjarnason GA, *see* Kwan W
Blackledge GRP, *see* Cullen MH
Bladé J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: Presenting features, response to therapy, and survival in a series of 53 cases, 2398
Blaise D, *see* Michel G
Blattner S, *see* Schorin MA
Bleiberg H, *see* Hulstaert F
Blessing JA, *see* Thigpen JT
— *see* Williams S
Bleyer WA, *see* Geyer JR
Blomqvist C, *see* Porkka K
Blum R, *see* Loehrer PJ Sr
Blum RH, *see* Hochster H
Blume KG, *see* Horning SJ
— *see* O'Donnell MR
Blute ML, *see* Zincke H
Bobin S, *see* Taylor SG IV
Boccadoro M, *see* Gianni AM
Boccardo F, Cannata D, Rubagotti A, Guarneri D, Decensi A, Canobbio L, Curotto A, Martorana G, Pegoraro C, Selvaggi F, Salvia G, Comeri G, Bono A, Borella T, Giuliani L. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: Results of a multicentric Italian study, 7
Bodden W, *see* Ravikumar TS
Bode U, *see* Graf N
Boitnott JK, *see* DiGiuseppe JA
Bojar H, *see* Schumacher M
Bokemeyer C, *see* Siegert W
Boldt D, *see* Adkins DR
Boltz-Nitulescu G, *see* Reinisch W
Bonadonna G, *see* Gianni AM
Bonenkamp H, *see* Hermans J
Bonilla MA, *see* Kushner BH
Bonner JA, *see* Liengswangwong V
Bonneterre J, *see* Adenis A
Bono A, *see* Boccardo F
Boon MC, *see* Bunt AMG
Boos J, *see* Rossi R.
Booser DJ, *see* Buzdar AU
Boracchi P, *see* Gasparini G
Bordigoni P, *see* Michel G
Borella T, *see* Boccardo F
Borger J, Kemperman H, Hart A, Peterse H, van Dongen J, Bartelink H. Risk factors in breast-conservation therapy, 653
Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, Jungi WF, Thürlimann B, Cavalli F, Obrecht JP, Leyvraz S, Alberto P, Adam H, Varini M, Loehnert T, Senn HJ, Metzger U, Brunner K, the Swiss Group for Clinical Cancer Research. First isolated locoregional recurrence following mastectomy for breast cancer: Results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation, 2071
Borresen A-L, *see* McIntyre JF
Bosch F, *see* López-Guillermo A

Bosl GJ, *see* Feuer EJ
— *see* Mencel PJ
— *see* Motzer RJ
— *see* Schultz PK
Bosly A, *see* Haioun C
Boswell WD, *see* Mitchell MS
Botet J, *see* Kemeny N
Boutard P, *see* Pein F
Bowers CE, *see* Spitzer G
Bowman L, *see* Mathew P
— *see* Pratt CB
Bowman WP, *see* Sadowitz PD
Boyett JM, *see* Geyer JR
— *see* Tubergen DG
Bracken SP, *see* Brandes LJ
Bradstock KF, *see* Shaw PJ
Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, Ruka W, Priario J, Wagener T, Burgers M, Unnik JV, Contesso G, Thomas D, van Glabbeke M, Markham D, Pinedo H. Adjuvant CY-VADIC chemotherapy for adult soft tissue sarcoma —Reduced local recurrence but no improvement in survival: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, 1137
Brandes LJ, Simons KJ, Bracken SP, Warrington RC. Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, *N,N*-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents, 1281
Braun TJ, *see* Hazuka MB
Brawley OW, *see* Feuer EJ
Bready B, *see* Pazdur R
Breed WPM, *see* Somers R
Bregni M, *see* Gianni AM
Brennan MF, *see* Pisters PWT
Breslin M, *see* Shea TC
Breslow NE, *see* Green DM
Brewer H, *see* Murray JL
— *see* Perez-Soler R
Brewer Y, *see* Chauvet B
Bricker LJ, *see* Hesketh PJ
Bridgewater J, *see* Ornadel D
Brincker H, *see* d'Amore F
Briones G, *see* Weinthal J
Brisgand D, *see* Le Chevalier T
Britto JL, *see* Maluf PT
Brodeur GM, The INSS-2 Conferees. In reply (letter), 1992
Brophy NA, *see* Bartlett NL
Brosteanu O, *see* Pfreundschuh MG
Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer, 2648
Brown K, *see* Offit K
Broxmeyer HE, *see* Vadhan-Raj S
Bruijn JA, *see* Bunt AMG
Brunat-Mentigny M, *see* Pein F
Brunner K, *see* Borner M
Brunvand M, *see* Weaver CH
Bryant G, *see* Wilson WH
Bryant M, *see* Seiden MV
Bryson JC, *see* Spitzer TR
Bubley G, *see* Seiden MV
Bucana CD, *see* Murray JL
Buchanan GR, *see* Castleberry RP
— *see* Mustafa MM
— *see* Sadowitz PD
Buckley CM, *see* Wells RJ
Buckley J, Nesbit ME. In reply (letter), 1737
Buckley JD, *see* Nesbit ME Jr
— *see* Wells RJ
Buckner CD, *see* Weaver CH
Buckner J, *see* Cairncross G
Bucsky P, *see* Reiter A
Budd GT, *see* Bukowski RM
Budman DR, Igwemezie LN, Kaul S, Behr J, Lichtman S, Schulman P, Vinciguerra V, Allen SL, Kolitz J, Hock K, O'Neill K, Schacter L, Barbhaiya RH. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors, 1902
Buesa J, *see* Bramwell V
Bufalino R, *see* Bajetta E
Bui C, *see* Sella A
Bui K, *see* Buzdar AU
Bukowski RM, Budd GT, Bauer RJ, Childs A, Antal J, Finke J, Tuason L, Lorenzi V, McLain D, Tubbs R, Edinger M, Thomassen MJ. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: Clinical and immunomodulatory effects, 97
Bunjes D, *see* Hertenstein B
Bunn PA Jr, *see* Hazuka MB
Bunt AMG, Hermans J, Boon MC, van de Velde CJH, Sasako M, Fleuren GJ, Bruijn JA. Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer, 417
Burch PA, *see* Gunderson LL
— *see* Loprinzi CL
Bureau G, *see* Sculier JP
Burgers JMV, *see* Somers R
Burgers M, *see* Bramwell V
Burgess MA, *see* Shaw PJ
— *see* Vadhan-Raj S
Burke PJ, *see* Rowinsky EK
Burke TW, *see* Lehman E
Burnett AK, *see* Coiffier B
Burnham NL, *see* Goldberg RM
Burns ER, *see* Goldberg GL
Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Maillard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH Jr. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer, 14
Burt M, *see* Armstrong JG
— *see* Rusch V
Buser K, *see* Eisenhauer EA
Butler RW, Hill JM, Steinherz PG, Meyers PA, Finlay JL. The neuropsychologic effects of cranial irradiation,

intrathecal methotrexate, and systemic methotrexate in childhood cancer, 2621
Butow PN, *see* Tattersall MHN
Buyse M, *see* Hulstaert F
— *see* Piedbois P
Buzdar AU. In reply (letter), 1993
—, Hortobagyi GN, Frye D, Ho D, Booser DJ, Valero V, Holmes FA, Birmingham BK, Bui K, Yeh C, Plourde PV. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer, 50
Byrne K, *see* Meyers CA

Cabanillas F, *see* Dimopoulos MA
Cabanillas F, *see* McLaughlin P
— *see* Velasquez WS
Caffo O, *see* Gasparini G
Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr, Wainman N, Eisenhauer E, The National Cancer Institute of Canada Clinical Trials Group. Chemotherapy for anaplastic oligodendroglioma, 2013
Cairncross JG, *see* Watling CJ
Cairo M, *see* Weinthal J
Cairo MS, *see* Weinthal J
Calayag M, *see* Fossella FV
Caldarelli DD, *see* Taylor SG IV
Calves MJ, *see* Livingston PO
Calzone K, *see* McCauley DL
Camitta B, Mahoney D, Leventhal B, Lauer SJ, Shuster JJ, Adair S, Civin C, Munoz L, Steuber P, Strother D, Kamen BA. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study, 1383
Campana P, *see* Kemeny N
Campanacci M, *see* Picci P
Campbell J, *see* Segelov E
Campo E, *see* López-Guillermo A
Canal P, *see* Attal M
Candon B, *see* Remick SC
Canellos GP. An editor's thanks (editorial), 1339
— ASCO 30 years later: The state of the Society, 2509
— High-dose therapy: Here to stay or just visiting? (editorial), 5
— *see* Marcus KC
Canetta R, *see* Eisenhauer EA
Canezo S, *see* Seidman AD
Cannata D, *see* Boccardo F
Cannistra SA. Paclitaxel in ovarian cancer: How can we make it better? (editorial), 1743
Canobbio L, *see* Boccardo F
Canon JL, *see* Hulstaert F
Cantor AB, *see* Castleberry RP
Capnist G, *see* Sertoli MR
Caracciolo D, *see* Gianni AM
Carbone PP, *see* Taylor KM
Carde P. In reply (letter), 1739
— *see* Somers R
Cariddi A, *see* Del Turco MR
Carr DB, *see* Eisenberg E
Carrasco H, *see* Patt YZ
Carson LF, *see* Thigpen JT
Carswell EA, *see* Welt S
Casadei R, *see* Picci P
Casado A, *see* Martín M
Cascinelli N, *see* Bajetta E
Cascino T, *see* Cairncross G
Cascinu S, Fedeli A, Del Ferro E, Fedeli SL, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized double-blind trial with placebo, 1058
Case LD, *see* Muss HB
Cash J, *see* Mustafa MM
Castiglione M, *see* Borner M
Castleberry RP, Cantor AB, Green AA, Joshi V, Berkow RL, Buchanan GR, Leventhal B, Mahoney DH, Smith EI, Hayes FA. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: A Pediatric Oncology Group study, 1616
—, Shuster JJ, Smith EI, Member Institutions of the Pediatric Oncology Group. The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma, 2378
Catalano G, *see* Cascinu S
Catovsky D, *see* Mercieca J
Caudell MJ, *see* Sanal SM
Cavalli F, *see* Borner M
Cebon J, *see* Basser RL
Cerny T, *see* Stahel RA
Cha SS, *see* Gunderson LL
Chabner BA, *see* Johnston PG
— *see* Wilson WH
Chabot GG, *see* Toussaint C
Chachoua A, *see* Hochster H
Chalmers TC, *see* Eisenberg E
Chamness GC, *see* Ravdin PM
Champlin RE, *see* Giralt SA
— *see* Khouri IF
— *see* Meyers CA
Chan JC, *see* Perez-Soler R
Chan WC, *see* Darrington DL
Chao NJ, *see* Horning SJ
Chapman PB. Combination chemotherapy for metastatic melanoma: The importance of tamoxifen (letter), 1336
Charnsangavej C, *see* Patt YZ
Charytonowicz E, *see* Zeng Z-S
Chase J, *see* Patt YZ
Chasen M, *see* Fossella FV
Chatelut E, *see* Attal M
Chauncey T, *see* Weaver CH
Chauvet B, Félix-Faure C, Lupsascka N, Fijuth J, Brewer Y, Davin J-L, Kirscher S, Reboul F. Prostate-specific antigen decline: A major prognostic factor for prostate cancer treated with radiation therapy, 1402
Cheek R, *see* Willett CG
Chen A, *see* Grem JL
Chen B-R, *see* Cheng A-L
Chen C-C, *see* Cheng A-L

Chen Y-C, *see* Cheng A-L
Cheng A-L, Su I-J, Chen C-C, Tien H-F, Lay J-D, Chen B-R, Pu Y-S, Hong R-L, Shen M-C, Wang C-H, Chen Y-C. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot study, 1185
— *see* Yeh K-H
Cheng Y-C, *see* Rowinsky EK
Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: A review, 2216
Chessells JM, *see* Liesner RJ
Cheung L, *see* Murray JL
Cheung, N-KV, *see* Kushner BH
Child JA, *see* Cullen MH
Childs A, *see* Bukowski RM
Chilosi M, *see* Nadali G
Chisesi T, *see* Sertoli MR
Chlebowski RT, Lillington LM. A decade of breast cancer clinical investigation: Results as reported in the *Program/Proceedings of the American Society of Clinical Oncology*, 1789
Chomy P, *see* Le Chevalier T
Chorus AMJ, *see* van Leeuwen FE
Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer, 2682
Chuang V, *see* Patt YZ
Ciernik IF, Meier U, Lütolf UM. Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy, 1484
Cigolari S, *see* Le Chevalier T
Cirenza E, *see* Spitzer TR
Civin C, *see* Camitta B
Civin CI, *see* Abeloff MD
Clahsen PC, van de Velde CJH, Julien J-P, Floiras J-L, Mignolet FY, Cooperating Investigators. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer cooperative group study, 1266
Claman HN, *see* Shpall EJ
Clark GM, *see* Ravdin PM
Clark J, *see* Choy H
— *see* Talcott JA
Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PWM, Reznek R, Masud T, Gregory W, Wrigley PFM. A randomized trial of two etoposide schedules in small-cell lung cancer: The influence of pharmacokinetics on efficacy and toxicity, 1427
Clausen M, *see* Hertenstein B
Cobau CD, *see* Loprinzi CL
Cobleigh MA, *see* Ghalie R
Coccia P, *see* Gordon B
Coccia PF, *see* Gilchrist GS
— *see* Nesbit ME Jr
— *see* Tubergen DG
Coccia-Portugal MD, *see* Bennett JM
Cocconi G, Bella M, Zironi S, Algeri R, DiCostanzo F, De Lisi V, Luppi G, Mazzochhi B, Rodinò C, Soldani M, Gilli G, Finardi C. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A prospective randomized trial of the Italian Oncology Group for Clinical Research, 2687
Coen J, *see* Willett CG
Cohen A, *see* Kemeny N
— *see* Welt S
Cohen AM, *see* Zeng Z-S
Cohen HJ, *see* Schorin MA
Cohen MD. International criteria for neuroblastoma diagnosis, staging, and response to treatment (letter), 1991
Cohen PR, *see* Guana AL
Coia L, Wizenberg M, Hanlon A, Gunderson L, Haller D, Hoffman J, Kline R, Mohiuddin M, Russell A, Tepper J, Owen J, Hanks G. Evaluation and treatment of patients receiving radiation for cancer of the rectum or sigmoid colon in the United States: Results of the 1988-1989 patterns of care study process survey, 954
Coiffier B, Philip T, Burnett AK, Symann ML. Consensus conference on intensive chemotherapy plus hematopoietic stem-cell transplantation in malignancies: Lyon, France, June 4-6, 1993, 226
— *see* Bastion Y
— *see* Haioun C
Coldman A, *see* Murray N
Cole DJ, *see* Yang JC
Coleman CN, *see* Marcus KC
Colin P, *see* Taylor SG IV
Colnan L, *see* White L
Colombat P, Garrigue MA, Lamagnere JP, Muh JP, Linassier C. *bcl*-2 evaluation in patients in long-term complete remission after bone marrow transplantation (letter), 2516
— *see* Delain M
Colombo N, *see* Eisenhauer EA
Combe M, *see* Delain M
Comella G, *see* Bajetta E
Comeri G, *see* Boccardo F
Comis R, *see* Krigel RL
Compton CC, *see* Willett CG
Congiu AM, *see* Sertoli MR
Connolly JL, *see* Nixon AJ
Contesso G, *see* Bramwell V
Conti JA, Kemeny N, Seiter K, Goker E, Tong W, André M, Ragusa K, Bertino JR. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma, 695
— *see* Kemeny N
Contu A, *see* Sertoli MR
Cooper IA, Wolf MM, Robertson TI, Fox RM, Matthews JP, Stone JM, Ding JC, Dart G, Matthews J, Firkin FC, Lowenthal RM, Ironside P, The Australian and New Zealand Lymphoma Group. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma, 769
Cooper MR, *see* Figg WD
— *see* Muss HB
— *see* Vogelzang NJ
Coppin C, *see* Moore MJ

— *see* Murray N
Cordon-Cardo C, *see* Zeng Z-S
Cork A, *see* Lockhart S
Corn BW, Lanciano RM, Greven KM, Noumoff J, Schultz D, Hanks GE, Fowble BL. Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: A multivariate analysis, 510
Cornelissen JJ, Sonneveld P, Schoester M, Raaijmakers HGP, Nieuwenhuis HK, Dekker AW, Lokhorst HM. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents, 115
Corson JM, *see* Vogelzang NJ
Cortes-Funes H, *see* Mayordomo JI
Coser P, *see* Sertoli MR
Costanzi JJ, *see* Meyskens FL Jr
— *see* Rivkin SE
Cotelingam JD, *see* Foss FM
Cotter FE, *see* Johnson PWM
Coughlin K, *see* Kosty MP
Coupez DJ, *see* Taylor SG IV
Covahey C, *see* Grossman SA
Cowie F, Pinkerton CR. Enhanced toxicity of dactinomycin and vincristine by cyclosporine given to reverse multidrug resistance (letter), 1998
Cox KM, *see* Raghavan D
Cozad SC, *see* Townsend PW
Craft AW, *see* Ornadel D
Crawford ED, *see* Hussain M
Creagan ET, *see* Liengswangwong V
Creisson A, *see* Thyss A
Cripps C, *see* Browman GP
Criscuolo D, *see* Bajetta E
Crist W, *see* Mathew P
Crist WM, *see* Land VJ
— *see* Pui C-H
— *see* Sandlund JT
Cristofani LM, *see* Maluf PT
Cristofolini M, *see* Bajetta E
Crom WR, *see* Relling MV
— *see* Stewart CF
Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation-induced encephalopathy, 627
Crowley JJ, *see* Hazuka MB
— *see* Salmon SE
Cruz AB, *see* Rivkin SE
Cruz JM, *see* Muss HB
Cuevas MA, *see* Romero A
Cuffie C, *see* Hamm J
Cullen JW, *see* Tubergen DG
Cullen MH, Stuart NSA, Woodroffe C, Murphy A, Fletcher J, Blackledge GRP, Child JA, Grieve RJ, Jones EL, the Central Lymphoma Group. ChlVPP/PABIOE and radiotherapy in advanced Hodgkin's disease, 779
Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK, the North Central Cancer Treatment Group. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer, 412
Cummings G, *see* Pienta KJ
Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, Selby P, Treleavan J, Viner C, Malpas J, Slevin M, Findlay M, Raymond J, Gore ME. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma, 759
—, Paz-Ares L, Gore ME, Malpas J, Hickish T, Nicolson M, Meldrum M, Viner C, Milan S, Selby PJ, Norman A, Raymond J, Powles R. High-dose melphalan for multiple myeloma: Long-term follow-up data, 764
Cunningham JB, *see* Feuer EJ
Cunningham JE, *see* Murray JL
Curiel T, *see* Shpall EJ
Curley S, *see* Patt YZ
Curotto A, *see* Boccardo F
Cutter G, *see* Johnson TP
Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, Peto R, Baum M, Fisher B, Host H, Lythgoe J, Ribeiro G, Scheurlen H. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy, 447
Cvitkovic E, *see* Toussaint C

Dabouis G, *see* Sculier JP
Dadmarz R, *see* Schwartzentruber DJ
D'Agay MF, *see* Haioun C
Dagis AC, *see* Nademanee A
Dalgaard P, *see* Kristensen B
Dalmas AM, *see* Poizot-Martin I
Dalton V, *see* Schorin MA
Daly M, *see* Lerman C
Damasio E, *see* Sertoli MR
d'Amore F, Brincker H, Grønbæk K, Thorling K, Pedersen M, Jensen MK, Andersen E, Pedersen NT, Mortensen LS, the Danish Lymphoma Study Group. Non-Hodgkin's lymphoma of the gastrointestinal tract: A population-based analysis of incidence geographic distribution, clinicopathologic presentation features, and prognosis, 1673
D'Andrea E, *see* Ravikumar TS
D'Angio GJ, *see* Green DM
Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG, Tarantolo SR, Weisenburger DD, Kessinger A, Armitage JO. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies, 2527
Dart G, *see* Cooper IA
Dassonville O, *see* Etienne MC
— *see* Thyss A
Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction, 475
Davidson NE, *see* Kennedy MJ
Davin J-L, *see* Chauvet B

Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: A critical review, 423
Davison AG, *see* Souhami RL
de Elvira CR, *see* Ornadel D
de Elvira M-CR, *see* Souhami RL
De Gaetano A, *see* Scambia G
De Keyser P, *see* Hulstaert F
de la Hoz C, *see* Ispizua A
de la Rubia J, *see* Sanz MA
De Laurentiis M, *see* Loprinzi CL
de Leeuw K, *see* Sonneveld P
De Lisi V, *see* Cocconi G
de Mulder PHM, *see* Stoter G
de Pauw BE, *see* Somers R
de Valeriola D, *see* Tomiak E
Dean G, *see* Mitchell MS
Dearden C, *see* Mercieca J
Decensi A, *see* Boccardo F
Deeg HJ, *see* Weaver CH
Deigert FA, *see* Shaw EG
Deisseroth A, *see* Estey E
Deisseroth AB, *see* Giralt SA
— *see* Khouri IF
Dekker AW, *see* Cornelissen JJ
Del Ferro E, *see* Cascinu S
Del Turco MR, Palli D, Cariddi A, the National Research Council Project on Breast Cancer Follow-Up and the GIVIO Investigators. It is now the age to define the appropriate follow-up of primary breast cancer patients (letter), 1996
Delain M, Linassier C, Petitdidier C, Goupille P, Luthier F, Combe M, Reisenleiter M, Benboubker L, Lamagnère J-P, Colombat P. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma, 2706
Delanoff C, *see* Heiss MM
Delasalle K, *see* Dimopoulos MA
Demard F, *see* Etienne MC
— *see* Milano G
Demeocq F, *see* Michel G
Depisch D, *see* Sautner T
Desforges JF, *see* Schenkein DP
Desphieux J-L, *see* Taylor SG IV
DeVictoria C, *see* Goldberg GL
Deville A, *see* Pein F
DeVita VT Jr, *see* Longo DL
Dewitte M, *see* Hulstaert F
DeWolf W, *see* Seiden MV
Dezeuze A, *see* Attal M
Dhiver C, *see* Poizot-Martin I
Dhodapkar M, *see* Au E
Di Leo A, *see* Bajetta E
Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy (editorial), 2239
Diaz-Puente MT, *see* Mayordomo JI
Diaz-Rubio E, *see* Martín M
DiCostanzo F, *see* Cocconi G
Diegert FA, *see* Maksymiuk AW
Diehl V, *see* Pfreundschuh MG
Dieterich H-J, *see* Heiss MM
DiGiuseppe JA, Nelson WG, Seifter EJ, Boitnott JK, Mann RB. Intravascular lymphomatosis: A clinicopathologic study of 10 cases and assessment of response to chemotherapy, 2573
Dillman RO. Antibodies as cytotoxic therapy, 1497
—, Barth NM. Intensive chemotherapy with autologous peripheral-blood stem-cell rescue in metastatic breast cancer (letter), 2237
Dimopoulos M, *see* Giralt SA
Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine, 2694
—, Luckett R, Alexanian R. Primary therapy of Waldenstrom's macroglobulinemia with paclitaxel (letter), 1998
Ding JC, *see* Cooper IA
DiSaia PJ, *see* Thigpen JT
Divgi CR, *see* Welt S
Dixon P, *see* Schenkein DP
Dolan JR, *see* Stiff PJ
Donaldson SS, *see* Hunger SP
Donato NJ, *see* Perez-Soler R
Donehower RC, *see* Rowinsky EK
Donnelly M, *see* Schorin MA
Dopfer R, *see* Reiter A
Dorey E, *see* Rohatiner AZS
Dorey F, *see* Ward WG
Dorfman RF, *see* Bartlett NL
Dorr RT, Lauper D. Dosing error in protocol book (letter), 2520
Dorssers LCJ, *see* Lambrechts AC
Dorval T, *see* Spielmann M
Dose AM, *see* Goldberg RM
— *see* Loprinzi CL
Douglass EC, *see* Gajjar A
Douillard J-Y, *see* Le Chevalier T
Downing JR, *see* Pui C-H
Drake JC, *see* Johnston PG
Dray M, *see* Taylor SG IV
Dreicer R, *see* Bennett JM
— *see* Einhorn LH
— *see* Loehrer PJ Sr
— *see* Roth BJ
Dreyfus F, *see* Sebban C
Drobyski WR, *see* Datta YH
Dropcho E, *see* Cairncross G
Dubois A, *see* Spitzer TR
Dubowy R, *see* Sadowitz PD
Ducreux M, *see* Pignon J-P
Duffey PL, *see* Longo DL
Duggan G, *see* Basser RL
Dunn P, *see* Shih L-Y
Dunn SM, *see* Tattersall MHN
Dunphy FR, *see* Spitzer G
Dusol F, *see* Pein F

Eagan RT, *see* Liengswangwong V
—*see* Shaw EG
Eagle K, *see* Muss HB
Eapen L, *see* Browman GP
Earle JD, *see* Maksymiuk AW

Earle JM, *see* Foote RL
Eckardt JJ, *see* Ward WG
Eckardt JR, *see* Atkins MB
Eddy J, *see* Kushner BH
Edinger M, *see* Bukowski RM
Edison M, *see* Ihde DC
Edmonson JH, *see* Hartmann LC
Edwards CL, *see* Vadhan-Raj S
Edwards R, *see* Cuzick J
Efird J, *see* Willett CG
Efremidis A, *see* Sculier JP
Eghbali H, *see* Somers R
Egorin MJ, *see* Jodrell DI
Ehsan MN, *see* Bartlett NL
Eilber FR, *see* Ward WG
Einhorn JH, *see* Guleria AS
— *see* Yang JC
Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, Loehrer PJ. Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma, 2271
— *see* Loehrer PJ Sr
— *see* Nichols CR
— *see* Roth BJ
— *see* Saxman SB
Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: A meta-analysis, 2756
Eisenberger M, *see* Hussain M
Eisenberger MA, *see* Jodrell DI
Eisenhauer E, *see* Cairncross G
Eisenhauer EA, ten Bokkel Huinick WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabárbara P, Onetto N, Winograd B, Canetta R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion, 2654
Eissner H-J, *see* Heiss MM
Ejlertsen B, *see* Kristensen B
Elashoff R, *see* Miles SA
Elder DE, *see* Halpern AC
Elenitsas R, *see* Halpern AC
Elfenbein GJ, *see* Fields KK
Elias A, *see* Ayash LJ
— *see* Lynch TJ Jr
Elisseyeff Y, *see* Tan CTC
Ellerhorst J, *see* Sella A
Elomaa I, *see* Porkka K
Elson P, *see* Loehrer PJ Sr
Elting L, *see* Rubenstein EB
Emanuel EJ, *see* Patterson WB
Endrizzi L, *see* Sertoli MR
Erban JK, *see* Schenkein DP
Erbazzi A, *see* Bajetta E
Ernest ML, *see* Atkins MB
Esclamado RM, *see* Urba SG
Escudier S, *see* Estey E
Esper PS, *see* Pienta KJ
Esperou-Bourdeau H, *see* Michel G
Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, Pierce S, Freireich EJ, Deisseroth A, Keating M. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor, 671
— *see* Dimopoulos MA
Ethier SP, *see* Datta YH
Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renée N, Schneider M, Demard F, Milano G. Population study of dihydropyrimidine dehydrogenase in cancer patients, 2248
— *see* Milano G
Ettinger DS, *see* Rowinsky EK
Ettinghausen SE, *see* Yang JC
Etzell PS, *see* Loprinzi CL
European Lung Cancer Working Party, *see* Sculier JP
Evans WE, *see* Pui C-H
— *see* Relling MV
Evers C, *see* Thigpen JT

Fabris P, *see* Sertoli MR
Faguet GB. Chronic lymphocytic leukemia: An updated review, 1974
Fahey JL, *see* O'Donnell MR
Fair WR, *see* Schultz PK
Fairclough D, *see* Relling MV
Falkson CI, *see* Falkson G
Falkson G, Gelman R, Glick J, Falkson CI, Harris J. Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: An Eastern Cooperative Oncology Group study, 45
— *see* Abratt RP
— *see* Bennett JM
Faria P, *see* Green DM
Farmer ER, *see* Kennedy MJ
Farrar WB, *see* Rivkin SE
Faucett C, *see* O'Donnell MR
Fedeli A, *see* Cascinu S
Fedeli SL, *see* Cascinu S
Fefer A, *see* Weaver CH
Feierabend C, *see* Schiller JH
Feig S, *see* Wells RJ
Feig SA, *see* Nesbit ME Jr
Feldstein ML, *see* Taylor KM
Félix-Faure C, *see* Chauvet B
Ferrandina G, *see* Scambia G
Feuer EJ, Frey CM, Brawley OW, Nayfield SG, Cunningham JB, Geller NL, Bosl GJ, Kramer BS. After a treatment breakthrough: A comparison of trial and population-based data for advanced testicular cancer, 368
Fey M, *see* Stahel RA
Fiacchini M, *see* Nadali G
Fielding A, *see* Jones HM
Fields KK, Zorsky PE, Hiemenz JW, Kronish LE, Elfenbein GJ. Ifosfamide, carboplatin, and etoposide: A new regimen with a broad spectrum of activity, 544

Fields SZ, *see* Miller AA
Fiere D, *see* Archimbaud E
— *see* Sebban C
Figg WD, Stevens JA, Cooper MR. Adaptive control with feedback of suramin using intermittent infusions (letter), 1523
Fijuth J, *see* Chauvet B
Filho VO, *see* Maluf PT
Finardi C, *see* Cocconi G
Finberg R, *see* Talcott JA
Findlay B, *see* Moore MJ
Findlay M, *see* Cunningham D
Fine HA. Brain tumor chemotherapy trials: Slow start, but quickly gaining (editorial), 2003
Finke J, *see* Bukowski RM
Finklestein JZ, *see* Green DM
Finlay JL, *see* Butler RW
— *see* Geyer JR
Finley P, *see* Salmon SE
Finn RD, *see* Welt S
Firkin FC, *see* Cooper IA
Fischer H, *see* Patt YZ
Fischer P, *see* Motzer RJ
Fischer SG, *see* Spaulding MB
Fischmann AB, *see* Foss FM
Fisher B, *see* Cuzick J
— *see* Johnston PG
Fisher C, *see* Taylor AE
Fisher ER, *see* Johnston PG
Fisher GA, *see* Bartlett NL
Fisher RI, *see* Atkins MB
— *see* Hamm J
— *see* Longo DL
Fisher SG, Schantz SP, Vlock DR, Wolf GT. In reply (letter), 1102
Fitts D, *see* Navari RM
Fitzpatrick PJ, *see* Sutcliffe SB
Flack NE, *see* Hesketh PJ
Flaherty LE, *see* Pienta KJ
Flamant F, *see* Rousseau P
Fleishman SB, *see* Kosty MP
Fleming R, *see* Etienne MC
Flentje M, *see* Haas R
Fletcher J, *see* Cullen MH
Fletcher WS, *see* Meyskens FL Jr
Fleuren GJ, *see* Bunt AMG
Flickinger FW, *see* Sanal SM
Floiras J-L, *see* Clahsen PC
Flynn M, *see* Raghavan D
Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Jänicke F, Klijn JGM. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer, 1648
Foelber R, *see* Spitzer TR
Fogarty O, *see* Miles DW
Fojo A, *see* Wilson WH
Folkman J. Angiogenesis and breast cancer (editorial), 441
Fontanesi J, *see* Pappo AS
Foote RL, Loprinzi CL, Frank AR, O'Fallon JR, Gulavita S, Tewfik HH, Ryan MA, Earle JM, Novotny P. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis, 2630
— *see* Liengswangwong V
Forastiere AA, *see* Urba SG
Ford L, *see* Johnson TP
Forman SJ, *see* Nademanee A
— *see* O'Donnell MR
Formenti SC, *see* Uziely B
Foss FM, Ihde DC, Linnoila IR, Fischmann AB, Schechter GP, Cotelingam JD, Steinberg SM, Ghosh BC, Stocker JL, Bastian A, Phares JC, Sausville EA. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fundoides/Sézary syndrome, 2051
—, Koc Y, Stetler-Stevenson MA, Nguyen DT, O'Brien MC, Turner R, Sausville EA. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: Potential autocrine or paracrine effectors in the Sézary syndrome, 326
— *see* Cheson BD
Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S, Huber M, Perez-Soler R, Hong WK, Raber M. Phase II study of docetaxel for recurrent or metastatic non–small-cell lung cancer, 1238
Foti E, *see* Scambia G
Fowble BL, *see* Corn BW
Fowst C, *see* Bajetta E
Fox EP, *see* Nichols CR
Fox RM, *see* Cooper IA
Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, Hakes T. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer, 2301
Francis PA, Rigas JR, Kris MG, Pisters KMW, Orazem JP, Woolley KJ, Heelan RT. Phase II trial of docetaxel in patients with stage III and IV non–small-cell lung cancer, 1232
Frank AR, *see* Foote RL
Franklin WA, *see* Shpall EJ
Franssen E, *see* Haq R
Free K, *see* Segelov E
Freedman AS, *see* Stone RM
Freedman RS, *see* Vadhan-Raj S
Frei, E III, *see* Ayash LJ
—*see* Lynch TJ Jr
Freireich EJ, *see* Estey E
Frelick RW. The Community Clinical Oncology Program (CCOP) story: Review of community oncologists' experiences with clinical research trials in cancer with an emphasis on the CCOP of the National Cancer Institute between 1982 and 1987, 1718
Frey CM, *see* Feuer EJ
Freytes CO, *see* Adkins DR
Friedlander M, *see* Segelov E
Friedlander ML, *see* Segelov E
Friend SH, *see* McIntyre JF
Fritsche HA, *see* Murray JL
Fritsche HA Jr, *see* Lee JS
Frontini L, *see* Gasparini G

Frost J, *see* Weinthal J
Frost JD, *see* Weinthal J
Frost P, *see* Abbruzzese JL
Frühauf S, *see* Haas R
Fryatt I, *see* Taylor AE
Frye D, *see* Buzdar AU
Frytak S, *see* Liengswangwong V
Fuchs N, *see* Graf N
Fuks Z, *see* Rabinovitch RA
Fukuoka M, *see* Kubota K
— *see* Masuda N
Fulton D, *see* Cairncross G
Fuqua SAW, *see* Ravdin PM
Furman W, *see* Pratt CB
Furman WL, *see* Pui C-H
Furuse K, *see* Kubota K
Fyles G, *see* Lowsky R

Gabka C, *see* Heiss MM
Gadner H, *see* Reiter A
Gajewski J, *see* Giralt SA
Gajjar A, Mulhern RK, Heideman RL, Sanford RA, Douglass EC, Kovnar EH, Langston JA, Jenkins JJ, Kun LE. Medulloblastoma in very young children: Outcome of definitive craniospinal irradiation following incomplete response to chemotherapy, 1212
Galicich J, *see* Armstrong JG
Gandola L, *see* Gianni AM
Gano J, *see* Vadhan-Raj S
García-Conde J, *see* Martín M
Garcia-Prats MD, *see* Mayordomo JI
Gardembas M, *see* Michel G
Garin-Chesa P, *see* Welt S
Garrigue MA, *see* Colombat P
Garrison L, *see* Vadhan-Raj S
Garwood D, *see* Crossen JR
Gasché C, *see* Reinisch W
Gaspard M-H, *see* Le Chevalier T
Gaspard MH, *see* Thyss A
Gasparini G. Tamoxifen and chemotherapy in the treatment of metastatic melanoma: Are there other possible mechanisms explaining their potentiation? (letter), 1994
—, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, Ambrosini G. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study, 2094
—, Weidner N, Bevilacqua P, Maluta S, Palma PD, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma, 454
Gastaut JA, *see* Poizot-Martin I
Gaulard P, *see* Haioun C
Gaynes L, *see* Seiden MV
Gaynor JJ, *see* Pisters PWT
— *see* Rabinovitch RA
Gazdar AF, *see* Ihde DC
Gebhardt MC, *see* McIntyre JF
Gelber RD, *see* Schorin MA
Geller NL, *see* Feuer EJ
Gelman R, *see* Bennett JM
— *see* Falkson G
— *see* Harris JR
— *see* Nixon AJ
Gelmon K, *see* Shenkier T
Genre D, *see* Poizot-Martin I
Gentet JC, *see* Pein F
— *see* Rousseau P
George R, *see* Ornadel D
Gerald WL, *see* Kushner BH
Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expression tumor cells in bone marrow aspirates by polymerase chain reaction, 725
Germain JS, *see* Welt S
Gershenson DM, *see* Lehman E
Gerstner JB, *see* Buroker TR
— *see* Jett JR
— *see* Loprinzi CL
Gesme DH Jr, *see* Buroker TR
— *see* Loprinzi CL
Geyer JR, Zeltzer PM, Boyett JM, Rorke LB, Stanley P, Albright AL, Wisoff JH, Milstein JM, Allen JC, Finlay JL, Ayers GD, Shurin SB, Stevens KR, Bleyer WA. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: A report from the Childrens Cancer Group, 1607
Ghalie R, Richman CM, Adler SS, Cobleigh MA, Korenblit AD, Manson SD, McLeod BC, Taylor SG IV, Valentino LA, Wolter J, Kaizer H. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation, 342
Ghosh BC, *see* Foss FM
Ghosh C, *see* Loprinzi CL
Giaccone G, *see* Linn SC
Gianni AM, Tarella C, Bregni M, Siena S, Lombardi F, Gandola L, Caracciolo D, Stern A, Bonadonna G, Boccadoro M, Pileri A. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma, 503
Gianni L, *see* Eisenhauer EA
Giannotti B, *see* Bajetta E
Gibbon DG, *see* Goldberg GL
Gilbert C, Meisenberg B, Vredenburgh J, Ross M, Hussein A, Perfect J, Peters WP. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support, 1005
Gilbert CJ, Peters WP. In reply (letter), 2518
Gilchrist GS, Tubergen DG, Sather HN, Coccia PF, O'Brien RT, Waskerwitz MJ, Hammond GD. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: A Childrens Cancer Group report, 2594

— *see* Tubergen DG
Gilli G, *see* Cocconi G
Gillings D, *see* Johnson TP
Giner V, *see* Sculier JP
Ginsberg R, *see* Rusch V
Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AB III. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois Cancer Center study, 2447
Giovannini M, *see* Poizot-Martin I
Giralt SA, LeMaistre CF, Vriesendorp HM, Andersson BS, Dimopoulos M, Gajewski J, Van Besien K, Mehra R, Przepiorka D, Khouri I, Yau J, Kantarjian H, Deisseroth AB, Champlin RE. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies, 1923
— *see* Khouri IF
Gisselbrecht C, *see* Haioun C
Giuliani L, *see* Boccardo F
Glantz M, *see* Choy H
Glatstein E, *see* Crossen JR
Glick J, *see* Falkson G
Glisson B, *see* Fossella FV
Gluckman E, *see* Michel G
— *see* Sebban C
Gödde A, *see* Rossi R.
Goedhals L, *see* Abratt RP
Goker E, *see* Conti JA
— *see* Tan CTC
Goldberg GL, Gibbon DG, Smith HO, DeVictoria C, Runowicz CD, Burns ER. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer, 2317
Goldberg RM, Loprinzi CL, O'Fallon JR, Veeder MH, Miser AW, Mailliard JA, Michalak JC, Dose AM, Rowland KM Jr, Burnham NL. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes, 155
— *see* Jett JR
— *see* Loprinzi CL
Goldhirsch A, *see* Borner M
Goldschmidt H, *see* Haas R
Goldsmith GH Jr. Gallium scans for residual Hodgkin's disease (letter), 1336
Goldspiel BR, *see* Wilson WH
Goldstone AH, *see* Jones HM
— *see* Sweetenham JW
— *see* Williams CD
Göller V, *see* Hertenstein B
Gonin R, *see* Ayash LJ
— *see* Einhorn LH
Goodman PJ, *see* Rajagopal S
Goodwin PJ, *see* Davis AM
Gooley T, *see* Weaver CH
Gordon B, Spadinger A, Hodges E, Ruby E, Stanley R, Coccia P. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation, 1917
Gordon LI, *see* Hoffman M
Gore ME, *see* Cunningham D
— *see* Taylor AE
Gore SD, *see* Rowinsky EK
Gospodarowicz MK, *see* Sutcliffe SB
Goss PE, Gwyn KMEH. Current perspectives on aromatase inhibitors in breast cancer, 2460
Gottfried M, *see* Le Chevalier T
Goupille P, *see* Delain M
Gouvernet J, *see* Michel G
Gower N, *see* Souhami RL
Grace C, *see* Remick SC
Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma, 1443
Graham M, *see* Welt S
Gralla RJ, *see* Kris MG
— *see* Navari RM
Gratecos N, *see* Michel G
Grayson J, *see* Ihde DC
Green AA, *see* Castleberry RP
Green DM, Beckwith JB, Berslow NE, Faria P, Moksness J, Finklestein JZ, Grundy P, Thomas PRM, Kim T, Shochat S, Haase G, Ritchey M, Kelalis P, D'Angio GJ. Treatment of children with stages II to IV anaplastic Wilms' tumor: A report from the National Wilms' Tumor Study Group, 2126
—, Breslow NE, Beckwith JB, Moksness J, Finklestein JZ, D'Angio GJ. Treatment of children with clear-cell sarcoma of the kidney: A report from the National Wilms' Tumor Study Group, 2132
Green ES, *see* Williams CD
Green MD, *see* Basser RL
Green MR, *see* Kosty MP
— *see* Vogelzang NJ
Green RL, *see* Mitchell MS
Green S, *see* Rivkin SE
Greggi S, *see* Scambia G
Gregory W, *see* Clark PI
Gregory WM, *see* Miles DW
Greiner R, *see* Borner M
Grem JL, McAtee N, Murphy RF, Hamilton JM, Balis F, Steinberg S, Arbuck SG, Setser A, Jordan E, Chen A, Kohler DR, Kotite B, Allegra CJ. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma, 560
Greven KM, *see* Corn BW
Gribben JG. Attainment of molecular remission: A worthwhile goal? (editorial), 1532
Griem KL, *see* Taylor SG IV
Grieve RJ, *see* Cullen MH
Griffin A-M, *see* Tattersall MHN
Griffin TW, *see* Phillips MH
Grill JP, *see* Hartmann LC
Grochow LB, *see* Rowinsky EK
Grogan TM, *see* Salmon SE
Grønbæk K, *see* d'Amore F
Groshen S, *see* Mitchell MS
Grossman SA, Piantadosi S, Covahey C. Are informed consent forms that describe clinical oncology research

protocols readable by most patients and their families? 2211
Grunberg SM, *see* Kris MG
— *see* Navari RM
Grundy P, *see* Green DM
Grygiel JJ, *see* Raghavan D
Guana AL, Cohen PR. Transient acantholytic dermatosis in oncology patients, 1703
Guarino L, *see* Tan CTC
Guarneri D, *see* Boccardo F
Guerry D IV, *see* Halpern AC
Guglielmi RB, *see* Gasparini G
Guiguet M, *see* Nordlinger B
Guillem JG, *see* Zeng Z-S
Gulati SC. Did we focus on the most important issues in the use of growth factors and stem-cell transplantation? (editorial), 650
Gulavita S, *see* Foote RL
Guleria A, *see* Yang JC
Guleria AS, Yang JC, Topalian SL, Weber JS, Parkinson DR, MacFarlane MP, White RL, Steinberg SM, White DE, Einhorn JH, Seipp CA, Austin HA III, Rosenberg SA, Schwartzentruber DJ. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma, 2714
Gunderson L, *see* Coia L
Gunderson LL, Mailliard JA, McKenna PJ, Martenson JA Jr, Burch PA, Cha SS, the North Central Cancer Treatment Group. Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable residual, or recurrent gastrointestinal carcinoma, 21
Guyotat D, *see* Archimbaud E
Gwyn KMEH, *see* Goss PE

Haas N, *see* Krigel RL
Haas R, Moos M, Karcher A, Möhle R, Witt B, Goldschmidt H, Frühauf S, Flentje M, Wannenmacher M, Hunstein W. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma, 1685
— *see* Pfreundschuh MG
Haase G, *see* Green DM
Haase GM, *see* Matthay KK
Habeshaw T, *see* Wishart GC
Hacker N, *see* Segelov E
Hacking D, *see* Abratt RP
Hackman R, *see* Weaver CH
Haddock MG, *see* Rasp GM
Hagemeister FB, *see* McLaughlin P
— *see* Velasquez WS
Hagenbeek A, *see* Somers R
— *see* van Leeuwen FE
Hahn R, *see* Loehrer PJ Sr
Hahne WF, *see* Kris MG
Hainsworth JD, *see* Hesketh PJ
Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly H, Morel P, Nouvel C, Herbrecht R, D'Agay MF, Gaulard P, Reyes F. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients, 2543
Hakes T, *see* Francis P
Hakimian D, Tallman MS, Hogan DK, Rademaker AW, Rose E, Nemcek AA Jr. Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemia, 268
— *see* Hoffman M
Haley B, *see* Hesketh PJ
Hallagan J, *see* Shpall EJ
Haller D, *see* Coia L
Halpern AC, Schuchter LM, Elder DE, Guerry D IV, Elenitsas R, Trock B, Matozzo I. Effects of topical tretinoin on dysplastic nevi, 1028
Halpern J, *see* Bartlett NL
Halsey J, *see* Bartlett NL
Haltom E, *see* Seiden MV
Hami L, *see* Shpall EJ
Hamilton JM, *see* Grem JL
Hamilton P, *see* Kwan W
Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, Kaiser G. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma, 2667
Hammack J, *see* Au E
Hammond GD, *see* Gilchrist GS
— *see* Nesbit ME Jr
Hanchett C, *see* Robbins KT
Hancock ML, *see* Pui C-H
Hanjani P, *see* Williams S
Hanks G, *see* Coia L
Hanks GE, *see* Corn BW
Hanlon A, *see* Coia L
Hanlon C, *see* Livingston PO
Hann IM, *see* Liesner RJ
Hann L, *see* Francis P
Hanna J, *see* Ravikumar TS
Hänseler T, *see* Weidmann B
Hansen HH, *see* Anderson H
Hansen JA, *see* Weaver CH
Hanson J, *see* Tang SC
Haq R, Sawka CA, Franssen E, Berinstein NL. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: A literature review, 1074
Haraf DJ, *see* Vokes EE
Harder F, *see* Borner M
Harel W, *see* Mitchell MS
Hargis JB, *see* Miller AA
Harker WG, *see* Hesketh PJ
Harnett A, *see* Wishart GC
Harper G, *see* Remick SC
Harper PG, *see* Miles DW
— *see* Souhami RL
Harris J, *see* Falkson G
Harris JR, Gelman R. What have we learned about risk factors for local recurrence after breast-conserving surgery and irradiation? (editorial), 647
Harris JR, *see* Nixon AJ

Harris MB, *see* Land VJ
Harris NL. Mantle cell lymphoma (letter), 876
Harris RE, *see* Matthay KK
Harrison LB, *see* Pisters PWT
Hart A, *see* Borger J
Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC. Prognostic significance of p53 immunostaining in epithelial ovarian cancer, 64
Hartsell WF, *see* Taylor SG IV
Harvey WH, *see* Hesketh PJ
Hasenclever D, *see* Pfreundschuh MG
Hassanein RES, *see* Townsend PW
Hayashi T, *see* Shimono T
Hayes DF, *see* Nixon AJ
Hayes FA, *see* Castleberry RP
Hays C, *see* Vadhan-Raj S
Hazuka MB, Crowley JJ, Bunn PA Jr, O'Rourke M, Braun TJ, Livingston RB. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non–small-cell lung cancer: Results of a phase II Southwest Oncology Group study, 1814
Head DR, *see* Pui C-H
Heelan RT, *see* Francis PA
Heideman R, *see* Pratt CB
Heideman RL, *see* Gajjar A
— *see* Stewart CF
Heimfeld S, *see* Shpall EJ
Heimpel H, *see* Hertenstein B
Heiss MM, Mempel W, Delanoff C, Jauch K-W, Gabka C, Mempel M, Dieterich H-J, Eissner H-J, Schildberg F-W. Blood transfusion-modulated tumor recurrence: First results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery, 1859
Heller G, *see* Kushner BH
Helling F, *see* Livingston PO
Hellman S. Natural history of small breast cancers, 2229
Hendler R, *see* Ravikumar TS
Henry-Amar M, *see* Somers R
Hepperle B, *see* Tang SC
Herbert V. Three stakes in hydrazine sulfate's heart, but questionable cancer remedies, like vampires, always rise again (editorial), 1107
Herbrecht R, *see* Haioun C
Herdt J, *see* Wilson WH
Herman D, *see* Remick SC
Hermans J, Bonenkamp H. In reply (letter), 879
— *see* Bunt AMG
Herndon JE II, *see* Kosty MP
—*see* Vogelzang NJ
Herr HW, Scher HI. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer, 975
— *see* Schultz PK
Hertenstein B, Stefanic M, Schmeiser T, Scholz M, Göller V, Clausen M, Bunjes D, Wiesneth M, Novotny J, Kochs M, Adam W-E, Heimpel H, Arnold R. Cardiac toxicity of bone marrow transplantation: Predictive value of cardiologic evaluation before transplant, 998
Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B, Plagge P, Flack NE. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis, 596
Hess AD, *see* Kennedy MJ
Hess KR, *see* Abbruzzese JL
Hickish T, *see* Cunningham D
Hiemenz JW, *see* Fields KK
Hilgarth M, *see* Reinisch W
Hill JM, *see* Butler RW
Hilsenbeck SH, *see* Ravdin PM
Hirashima T, *see* Masuda N
Hittelman WN, *see* Vadhan-Raj S
Ho D, *see* Buzdar AU
Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, Blum RH. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen, 553
Hock K, *see* Budman DR
Hodges E, *see* Gordon B
Hodson DI, *see* Browman GP
Hofbauer F, *see* Sautner T
Hoffman J, *see* Coia L
Hoffman M, Tallman MS, Hakimian D, Janson D, Hogan D, Variakogis D, Kuzel T, Gordon LI, Rai K. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma, 788
Hogan D, *see* Hoffman M
Hogan DK, *see* Hakimian D
Hohneker JA, *see* Rowinsky EK
Holmberg L, *see* Omne-Pontén M
Holmegaard SN, *see* Kristensen B
Holmes EC, *see* Ward WG
Holmes FA, *see* Buzdar AU
Hom SS, *see* Schwartzentruber DJ
Honegger H, *see* Stahel RA
Hong R-L, *see* Cheng A-L
Hong WK, *see* Fossella FV
— *see* Lee JS
— *see* Lippman SM
— *see* Perez-Soler R
Hoppe RT, *see* Horning SJ
Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA. Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study, 297
—, Negrin RS, Chao NJ, Long GD, Hoppe RT, Blume KG. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma, 2552
— *see* Bartlett NL
Hortobagyi GN, *see* Buzdar AU
Horton J, *see* Remick SC
Hoskins P, *see* Kaizer L
Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer, 60
Hossfeld DK, *see* Mross K
Host H, *see* Cuzick J

Houghton J, *see* Cuzick J
Howell SB, *see* Robbins KT
Huang Y, *see* Kemeny N
Hubbard SM, *see* Longo DL
Huber M, *see* Fossella FV
Hübner K, *see* Schumacher M
Hudes GR, *see* Roth BJ
Hudson BV, *see* Bates NP
Hudson GV, *see* Bates NP
Huelskamp AM, *see* Kennedy MJ
Hughes WT, *see* Pui C-H
Huguet F, *see* Attal M
Huh YO, *see* Khouri IF
Huhn D, *see* Siegert W
Hulstaert F, Van Belle S, Bleiberg H, Canon JL, Dewitte M, Buyse M, De Keyser P, Westelinck KJ. Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting, 2439
Hummel SJ, *see* Thigpen JT
Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: The Stanford experience, 2160
Hunstein W, *see* Haas R
Hupkes PE, *see* Lambrechts AC
Hurd DD. In reply (letter), 1101
Hürny C, Bernhard J. Lessons learned from measuring health-related quality of life in oncology (letter), 1994
Hurwitz C, *see* Pappo AS
Hurwitz CA, *see* Sonnichsen DS
Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report, 1868
— *see* Pienta KJ
Hussein A, *see* Gilbert C
Hutchinson JC, *see* Taylor SG IV
Hutchison RE, *see* Sandlund JT
Hutter HS, *see* Motzer RJ

Igwemezie LN, *see* Budman DR
Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, Grayson J, Minna JD, Johnson BE. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer, 2022
— *see* Foss FM
Ippoliti C, *see* Khouri IF
Ironside P, *see* Cooper IA
Irvin R, *see* Adkins DR
Ispizua A, Baroja A, de la Hoz C. Correlation of DNA content of laryngeal epithelial lesions to degree of malignancy, 1600
Ito J, *see* O'Donnell MR
Itoh K, *see* Murray JL
Izbicki JR, *see* Passlick B
Izzo J, *see* Toussaint C

Jackson DV Jr, *see* Muss HB
Jacky E, *see* Stahel RA
Jaeck D, *see* Nordlinger B
Jaffe ES, *see* Longo DL
Jaffe N, *see* Murray JL
Jakesz R, *see* Sautner T
Jakowatz J, *see* Mitchell MS
Jalkanen S, *see* Joensuu H
James L, *see* Souhami RL
Jänicke F, *see* Foekens JA
Janson D, *see* Hoffman M
Janssen DA, *see* Manian FA
Jaubert J, *see* Archimbaud E
Jauch K-W, *see* Heiss MM
Jeha S, *see* Lockhart S
Jenkins JJ, *see* Gajjar A
Jensen MK, *see* d'Amore F
Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, Kardinal CG, Twito DI, Levitt R, Gerstner JB. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer, 2321
—, Su JQ, Krook JE, Goldberg RM, Kugler JW. Measurable or assessable disease in lung cancer trials: Does it matter? 2677
Jett JR, *see* Liengswangwong V
— *see* Loprinzi CL
— *see* Maksymiuk AW
— *see* Shaw EG
Jewell WR, *see* Meyskens FL Jr
—*see* Rivkin SE
Jimenez C, *see* Weidmann B
Jodrell D, *see* Wishart GC
Jodrell DI, Reyno LM, Sridhara R, Eisenberger MA, Tkaczuk KH, Zuhowski EG, Sinibaldi VJ, Novak MJ, Egorin MJ. Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentrations in patients with prostate cancer, 166
Joel SP, *see* Clark PI
Joensuu H, Ristamäki R, Söderström K-O, Jalkanen S. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma, 2167
Johnson BE, *see* Ihde DC
Johnson D, *see* Loehrer PJ Sr
Johnson DH. In reply (letter), 643
— *see* Roth BJ
Johnson PWM. In reply (letter), 2516
—, Price CGA, Smith T, Cotter FE, Meerabux J, Rohatiner AZS, Young BD, Lister TA. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma, 798
— *see* Clark PI
— *see* Rohatiner AZS
— *see* Sweetenham JW
Johnson TP, Ford L, Warnecke RB, Nayfield SG, Kaluzny A, Cutter G, Gillings D, Sondik E, Ozer H. Effect of a National Cancer Institute Clinical Alert on breast cancer practice patterns, 1783
Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark

N, Drake JC, Chabner BA, Allegra CJ. The role of thymidylate synthase expression in prognosis and outcome to adjuvant chemotherapy in patients with rectal cancer, 2640
Jones AL, Smith IE, O'Brien MER, Talbot D, Walsh G, Ramage F, Robertshaw H, Ashley S. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: An active new regimen, 1259
Jones D, *see* Patt YZ
— *see* Stewart CF
Jones DV Jr, *see* Pazdur R
Jones EL, *see* Cullen MH
Jones HM, Jones SA, Watts MJ, Khwaja A, Mills W, Fielding A, Goldstone AH, Linch DC. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma, 1693
Jones RB, *see* Shpall EJ
Jones RJ, *see* Kennedy MJ
— *see* Rowinsky EK
Jones SA, *see* Jones HM
Jordan E, *see* Grem JL
Joshi V, *see* Castleberry RP
Jost LM, *see* Stahel RA
Jouet JP, *see* Michel G
Jouve M, *see* Spielmann M
Juhl H, *see* Gerhard M
Julien J-P, *see* Clahsen PC
Jungi WF, *see* Borner M
Jürgens H, *see* Rossi R

Kadin ME. Ki-1+ anaplastic large-cell lymphoma: Maturation of a clinicopathologic entity with prospects of effective therapy (editorial), 884
Kaiser G, *see* Hamm J
Kaizer H, *see* Ghalie R
Kaizer L. In reply (letter), 2236
—, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, Palmer M, Zee B, Levy M, Pater J. Effect of schedule and maintenance on the antiemetic efficacy of ondanestron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group, 1050
Kalifa C, *see* Tabone M-D
Kalish L, *see* Lynch TJ Jr
Kalish LA, *see* Marcus KC
Kalthoff H, *see* Gerhard M
Kaluzny A, *see* Johnson TP
Kamel NA, *see* Hartmann LC
Kamen BA, *see* Camitta B
Kanis J, *see* O'Rourke N
Kan-Mitchell J, *see* Mitchell MS
Kannourakis G, *see* White L
Kantarjian H, *see* Dimopoulos MA
— *see* Estey E
— *see* Giralt SA
Kantarjian HM, *see* Preti A
Kantoff P, *see* Kilbridge KL
Kantoff PW, Talcott JA. The radical prostatectomy series: Apples are not oranges (editorial), 2243
— *see* Seiden MV
Kaplan HG, *see* Navari RM
Kaplan I, *see* Seiden MV
Kappler K, *see* Atkins MB
Karcher A, *see* Haas R
Kardinal CG, *see* Buroker TR
— *see* Jett JR
— *see* Maksymiuk AW
Kasi L, *see* Patt YZ
Kasi LP, *see* Murray JL
Kassell J, *see* McIntyre JF
Katzmann JA, *see* Hartmann LC
Kaufmann SH, *see* Rowinsky EK
Kaul S, *see* Budman DR
Kavanagh JJ, *see* Vadhan-Raj S
Kawahara M, *see* Kubota K
Kaye SB. Gemcitabine: Current status of phase I and II trials (editorial), 1527
— *see* Stoter G
— *see* Wishart GC
Keating M, *see* Dimopoulos MA
— *see* Estey E
— *see* McLaughlin P
Keating MJ, *see* Khouri IF
Keeney GL, *see* Hartmann LC
Kelalis P, *see* Green DM
Kelley MJ, Mulshine JL. Anticancer antibodies for lung cancer (letter), 2519
Kellie S, *see* White L
Kellie SJ, *see* Shaw PJ
Kelsen D, *see* Rusch V
Kemeny N, Conti JA, Cohen A, Campana P, Huang Y, Shi WJ, Botet J, Pulliam S, Bertino JR. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma, 2288
— *see* Conti JA
— *see* Welt S
Kemperman H, *see* Borger J
Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Altomonte V, Huelskamp AM, Davidson NE. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer, 249
Kerber C, *see* Robbins KT
Kerger J, *see* Tomiak E
Kerr DJ, *see* Wishart GC
Kerr I, *see* Eisenhauer EA
Kersey JH, *see* Nesbit ME Jr
Kessinger A, *see* Darrington DL
Kheradpour A, *see* Tan CTC
Khouri I, *see* Giralt SA
Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SA, Ippoliti C, Marshall M, Thomas MW, O'Brien S, Robertson LE, Deisseroth AB, Champlin RE. Autologous and allogeneic bone

marrow transplantation for chronic lymphocytic leukemia: Preliminary results, 748
Khwaja A, *see* Jones HM
Kies MS, *see* Taylor SG IV
Kilbourn R, *see* Sella A
Kilbridge KL, Kantoff P. Intravesical therapy for superficial bladder cancer: Is it a wash? (editorial), 1
Kilpatrick D, *see* Krigel RL
Kim HI, *see* Yang JC
Kim K, *see* Loehrer PJ Sr
Kim T, *see* Green DM
— *see* Wells RJ
Kim TH, *see* Nesbit ME Jr
Kimura M, *see* Shimono T
King SC, Reiman RJ, Prosnitz LR. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease, 306
Kirchner H, *see* Pfreundschuh MG
Kirscher S, *see* Chauvet B
Kish JA, *see* Hesketh PJ
Klastersky J, *see* Sculier JP
— *see* Tomiak E
Klatt NE, *see* Loprinzi CL
Kleinebrand A, *see* Rossi R
Klijn JGM, *see* Foekens JA
Klimstra DS, *see* Zeng Z-S
Kline R, *see* Coia L
Klokman WJ, *see* van Leeuwen FE
Knepil J, *see* Wishart GC
Koc Y, *see* Foss FM
Koch P, *see* Pfreundschuh MG
Kochs M, *see* Hertenstein B
Kodama N, *see* Kubota K
Kohler DR, *see* Grem JL
Kolitz J, *see* Budman DR
Koller C, *see* Estey E
Korenblit AD, *see* Ghalie R
Kornblau S, *see* Estey E
Kornblith AB, *see* Kosty MP
Kosty MP, Fleishman SB, Herndon JE II, Coughlin K, Kornblith AB, Scalzo A, Morris JC, Mortimer J, Green MR. Cisplatin, vinblastine, and hydrazine sulfate in advanced non–small-cell lung cancer: A randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B, 1113
Kotite B, *see* Grem JL
Kovnar EH, *see* Gajjar A
Krakoff IH. Progress and prospects in cancer treatment: The Karnofsky legacy, 432
Kramer BS, *see* Feuer EJ
— *see* Ihde DC
Kramer MD, *see* Foekens JA
Krance RA, *see* Land VJ
Krigel RL, Palackdharry CS, Padavic K, Haas N, Kilpatrick D, Langer C, Comis R. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: A phase I study with apparent activity in non–small-cell lung cancer, 1251
Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, Tyson LB, Schmidt L, Hahne WF. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin, 1045
— *see* Francis PA
Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbøl I, Mouridsen HT. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study, 992
Krithivas K, *see* Seiden MV
Kronish LE, *see* Fields KK
Kronmueller N, *see* Spitzer G
Krook JE, *see* Buroker TR
— *see* Cullinan SA
— *see* Jett JR
— *see* Loprinzi CL
— *see* Maksymiuk AW
Krüger W, *see* Mross K
Kubo A, *see* Masuda N
Kubota K, Furuse K, Kawahara M, Kodama N, Yamamoto M, Ogawara M, Negoro S, Masuda N, Takada M, Matsui K, Takifuji N, Kudoh S, Kusunoki Y, Fukuoka M. Role of radiotherapy in combined modality treatment of locally advanced non–small-cell lung cancer, 1547
Kubuschok B, *see* Passlick B
Kudelka AP, *see* Vadhan-Raj S
Kudoh S, *see* Kubota K
— *see* Masuda N
Kugler JW, *see* Jett JR
— *see* Loprinzi CL
Kuhn J, *see* Adkins DR
Kuiper CM, *see* Linn SC
Kumar L. Leukemia: Management of relapse after allogeneic bone marrow transplantation, 1710
Kun LE, *see* Gajjar A
Kunitoh H, Watanabe K. Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non–small-cell lung cancer, 83
Kunka RL, *see* Spitzer TR
Kuo T-T, *see* Shih L-Y
Kurland LT, *see* Kyle RA
Kuross SA, *see* Loprinzi CL
Kusagawa M, *see* Shimono T
Kuse R, *see* Pfreundschuh MG
Kushner BH, La Quaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh S, Eddy J, Gerald WL, Heller G, Cheung N-KV. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age, 2607
Kusunoki Y, *see* Kubota K
— *see* Masuda N
Kuttesch JF, *see* Pratt CB
Kuzel T, *see* Hoffman M
Kwan W, Bjarnason GA, Hamilton P. Adjuvant therapy with fluorouracil and levamisole and liver ultrasound mimicking liver metastases (letter), 1335
Kyle RA, Beard CM, O'Fallon WM, Kurland LT. Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945, 1577
— *see* Bladé J

La Quaglia MP, *see* Kushner BH
Lacava JA, *see* Romero A
Lacombe D, *see* Spielmann M
— *see* Toussaint C
Lagrange JL, *see* Etienne MC
Lai G, *see* Giovanazzi-Bannon S
Lamagnere JP, *see* Colombat P
Lamagnère J-P, *see* Delain M
Lambrechts AC, Hupkes PE, Dorssers LCJ, van't Veer MB. Clinical significance of t(14;18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission, 1541
Lampkin B, *see* Nesbit ME Jr
Lampkin BC, *see* Wells RJ
Lanciano RM, *see* Corn BW
Land V, *see* Sadowitz PD
Land VJ, Shuster JJ, Crist WM, Ravindranath Y, Harris MB, Krance RA, Pinkel D, Pullen DJ. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study, 1939
Langer C, *see* Krigel RL
Langhi M, *see* Romero A
Langston JA, *see* Gajjar A
Larsen L, *see* Kristensen B
Larson SM, *see* Welt S
Lassere Y, *see* Pazdur R
Lathan B, *see* Pfreundschuh MG
Latreille J, *see* Kaizer L
Lauer SJ, *see* Camitta B
Lauper D, *see* Dorr RT
Laurent G, *see* Attal M
Laurie JA, *see* Loprinzi CL
Law M, *see* Loprinzi CL
Lawrence D, *see* Patt YZ
Lay J-D, *see* Cheng A-L
Le Bail N, *see* Tomiak E
Le Chevalier T, Brisgand D, Douillard J-Y, Pujol J-L, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard M-H, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non–small-cell lung cancer: Results of a European Multicenter Trial including 612 patients, 360
Leavitt P, *see* Stone RM
Lechner K, *see* Reinisch W
Ledermann JA, *see* Miles DW
Lee D, *see* Cairncross G
Lee DH, *see* Watling CJ
Lee JJ, *see* Lee JS
Lee JS, Lippman SM, Benner SE, Lee JJ, Ro JY, Lukeman JM, Morice RC, Peters EJ, Pang AC, Fritsche HA Jr, Hong WK. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia, 937
— *see* Fossella FV
— *see* Perez-Soler R
Legall E, *see* Pein F
Legha SS, *see* Murray JL
Lehman E, Gershenson DM, Burke TW, Levenback C, Silva EG, Morris M. Salvage surgery for chemorefractory gestational trophoblastic disease, 2737
Leibel SA, *see* Armstrong JG
Leiper AD, *see* Liesner RJ
LeMaistre CF, *see* Adkins DR
— *see* Giralt SA
Lemerle J, *see* Pein F
— *see* Tabone M-D
Lemerle S, *see* Michel G
Lenzi R, *see* Abbruzzese JL
Leonard RCF, *see* Wishart GC
Leone BA, *see* Romero A
Leone L, *see* Choy H
Lepage E, *see* Haioun C
— *see* Sebban C
LePajolec C, *see* Taylor SG IV
Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility, 843
Lesar M, *see* Ihde DC
Levenback C, *see* Lehman E
Leventhal B, *see* Camitta B
— *see* Castleberry RP
Levi J, *see* Stoter G
Levin B, *see* Patt YZ
— *see* Pazdur R
Levin R. "Salvage" therapy? (letter), 1997
— *see* Yang JC
Levine M, *see* Shepherd L
Levine MN, *see* Browman GP
Levitt R, *see* Buroker TR
— *see* Jett JR
— *see* Maksymiuk AW
Levy M, *see* Kaizer L
Lewis I, *see* Ornadel D
Leyvraz S, Pasche P, Bauer J, Bernasconi S, Monnier P. Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: Four-year results of a phase I/II study, 1876
— *see* Borner M
Li C-Y, *see* Tefferi A
Lianes P, *see* Le Chevalier T
— *see* Mayordomo JI
Liao S-Y, *see* Williams S
Liaw S-J, *see* Shih L-Y
Liberti G, *see* Sweetenham JW
Lichter AS, *see* Pierce LJ
Lichtman S, *see* Budman DR
Lieber MM, *see* Zincke H
Liebes L, *see* Hochster H
Liengswangwong V, Bonner JA, Shaw EG, Foote RL, Frytak S, Eagan RT, Jett JR, Richardson RL, Creagan ET, Su JQ. Limited-stage small-cell lung cancer: Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy, 496
Liesner RJ, Leiper AD, Hann IM, Chessells JM. Late effects

of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood, 916
Lifsey D, *see* Kris MG
Liggett PE, *see* Mitchell MS
Lilenbaum RC, *see* Miller AA
Lillington LM, *see* Chlebowski RT
Lin J-S, *see* Sandlund JT
Linassier C, *see* Colombat P
— *see* Delain M
Linch DC, *see* Jones HM
Lindsley K, *see* Kushner BH
Link MP, *see* Hunger SP
Linke KA, *see* Vadhan-Raj S
Linn SC, van Kalken CK, van Tellingen O, van der Valk P, van Groeningen CJ, Kuiper CM, Pinedo HM, Giaccone G. Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil, 812
Linnoila IR, *see* Foss FM
Linnoila RI, *see* Ihde DC
Lippman SM, Benner SE, Hong WK. Cancer chemoprevention, 851
— *see* Fossella FV
— *see* Lee JS
Lips S, *see* Tomiak E
Lipton J, *see* Lowsky R
Lister TA, *see* Johnson PWM
— *see* Rohatiner AZS
Liu PY, *see* Meyskens FL Jr
Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, Oettgen HF, Old LJ. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside, 1036
Livingston R, *see* Loehrer PJ Sr
Livingston RB, *see* Hazuka MB
Lluch A, *see* Martín M
Lockhart S, Plunkett W, Jeha S, Ramirez I, Zipf T, Cork A, Pinkel D. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia, 587
Lockwood L, *see* White L
Loeffler M, *see* Pfreundschuh MG
Loehnert T, *see* Borner M
Loehrer PJ, *see* Einhorn LH
— *see* Nichols CR
— *see* Roth BJ
Loehrer PJ Sr, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH. Escalated dosages of methotrexate vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial, 483
—, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, Blum R, the Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial, 1164
Lofters W, *see* Kaizer L
Logothetis CJ, *see* Sella A
Lokhorst HM, *see* Cornelissen JJ
Lombardi F, *see* Gianni AM
Long GD, *see* Horning SJ
Longo DL, Duffey PL, Jaffe ES, Raffeld M, Hubbard SM, Fisher RI, Wittes RE, DeVita VT Jr, Young RC. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: A high-grade lymphoma responsive to Pro-MACE-based combination chemotherapy, 2153
López-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the international index for aggressive lymphomas to patients with low-grade lymphoma, 1343
— *see* Montserrat E
López-Martín JA, *see* Martín M
Loprinzi CL. In reply (letter), 1997
— It is now the age to define the appropriate follow-up of primary breast cancer patients (editorial), 881
—, Goldberg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW, Kugler JW, Jett JR, Ghosh C, Pfeifle DM, Wender DB, Burch PA. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non–small-cell lung cancer, 1126
—, Kuross SA, O'Fallon JR, Gesme DH Jr, Gerstner JB, Rospond RM, Cobau CD, Goldberg RM. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer, 1121
—, Laurie JA, Wieand HS, Krook JE, Novotny PJ, Kugler JW, Bartel J, Law M, Bateman M, Klatt NE, Dose AM, Etzell PS, Nelimark RA, Mailliard JA, Moertel CG, the North Central Cancer Treatment Group. Prospective evaluation of prognostic variables from patient-completed questionnaires, 601
—, Ravdin PM, De Laurentiis M, Novotny P. Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? 1422
— *see* Au E
— *see* Foote RL
— *see* Goldberg RM
Lorenzi V, *see* Bukowski RM
Los G, *see* Robbins KT
Lossignol D, *see* Tomiak E
Lowenthal RM, *see* Cooper IA
Lowsky R, Lipton J, Fyles G, Minden M, Meharchand J, Tejpar I, Atkins H, Sutcliffe S, Messner H. Secondary malignancies after bone marrow transplantation in adults, 2187
Lu Z, *see* Diasio RB
Lubejko B, *see* Rowinsky EK
Lucas VS, *see* Rowinsky EK
Luckett R, *see* Dimopoulos MA
Ludwin S, *see* Cairncross G
Lukeman JM, *see* Lee JS
Lum BL, *see* Bartlett NL
Lund B, *see* Anderson H
Luo X, *see* Pappo AS
Luppi G, *see* Cocconi G
Lupsascka N, *see* Chauvet B
Lust JA, *see* Bladé J
Luthier F, *see* Delain M

Lütolf UM, *see* Ciernik IF
Lyn P, *see* Motzer RJ
Lynch C, *see* Ayash LJ
Lynch TJ Jr, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei E III. Phase II study of topotecan in metastatic non–small-cell lung cancer, 347
Lyons R, *see* Adkins DR
Lythgoe J, *see* Cuzick J

MacCallum PK, *see* Rohatiner AZS
Macdonald D, *see* Cairncross G
Macdonald DR, *see* Watling CJ
MacFarlane MP, *see* Guleria AS
— *see* Yang JC
Macham MA, *see* Wishart GC
Machiavelli M, *see* Romero A
MacLennan K, *see* Mercieca J
Madden T, *see* Rodman JH
Mader R, *see* Reinisch W
Mahmoud H, *see* Mathew P
— *see* Sandlund JT
Mahmoud HH, *see* Pui C-H
Mahoney D, *see* Camitta B
Mahoney DH, *see* Castleberry RP
Maillard JA, *see* Buroker TR
— *see* Cullinan SA
— *see* Goldberg RM
— *see* Gunderson LL
— *see* Jett JR
— *see* Loprinzi CL
— *see* Maksymiuk AW
Maksoud JG, *see* Maluf PT
Maksymiuk AW, Jett JR, Earle JD, Su JQ, Diegert FA, Mailliard JA, Kardinal CG, Krook JE, Veeder MH, Wiesenfeld M, Tschetter LK, Levitt R. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: Results of a North Central Cancer Treatment Group randomized clinical trial, 70
— *see* Jett JR
— *see* Loprinzi CL
— *see* Shaw EG
Malkin D, *see* McIntyre JF
Malpas J, *see* Cunningham D
Maluf PT, Filho VO, Cristofani LM, Britto JL, Almeida MT, Pontes E, Maksoud JG, Manissadjian A. Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood, 1963
Maluta S, *see* Gasparini G
Mancuso S, *see* Scambia G
Mangoni L, *see* Sertoli MR
Manian FA, Janssen DA. Use of parenteral antibiotics in neutropenic patients (letter), 2517
Manissadjian A, *see* Maluf PT
Mann G, *see* Reiter A
Mann RB, *see* DiGiuseppe JA
Manson SD, *see* Ghalie R
Mao L, *see* Sandlund JT
Maraninchi D, *see* Michel G
— *see* Sebban C
Marcus KC, Kalish LA, Coleman CN, Shulman LN, Rosenthal DS, Canellos GP, Mauch PM. Improved survival in patients with limited-stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy, 2567
Margolin KA, *see* Atkins MB
— *see* Nademanee A
Marina N, *see* Pratt CB
Markham D, *see* Bramwell V
Markman M, *see* Rusch V
Markowitz AB, *see* Pazdur R
Marks LB, *see* Prosnitz LR
Marsh J, *see* Ravikumar TS
Marshall E, *see* Hussain M
Marshall M, *see* Khouri IF
Martenson JA, *see* Rasp GM
Martenson JA Jr, *see* Gunderson LL
Martín M, Lluch A, Casado A, Santabárbara P, Adrover E, Valverde JJ, López-Martín JA, Rodriguez-Lescure A, Azagra P, García-Conde J, Diaz-Rubio E. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer, 986
Martin P, *see* Weaver CH
Martin SK, *see* Zincke H
Martinez A, *see* Le Chevalier T
Martorana G, *see* Boccardo F
Marubini E, *see* Gasparini G
Masny A, *see* Lerman C
Mason JR, *see* Shea TC
Masud T, *see* Clark PI
Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T, Yoshikawa A, Kubo A, Matsuura E, Nitta T, Takifuji N, Terakawa K, Negoro S. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer, 1833
—, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T, Negoro S, Takifuji N, Takada M. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non–small-cell lung cancer, 90
— *see* Kubota K
Mathew P, Ribeiro RC, Sonnichsen D, Relling M, Pratt C, Mahmoud H, Bowman L, Meyer W, Avery L, Crist W. Phase I study of oral etoposide in children with refractory solid tumors, 1452
Matozzo I, *see* Halpern AC
Matsui K, *see* Kubota K
— *see* Masuda N
Matsuura E, *see* Masuda N
Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary MC, Harris RE, Selch M, Atkinson JB, Haase GM, Ramsay NK. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the Childrens Cancer Group, 2382
Matthews J, *see* Cooper IA
— *see* Rohatiner AZS
Matthews JP, *see* Cooper IA
Matutes E, *see* Mercieca J

Mauch P, *see* Stone RM
Mauch PM, *see* Marcus KC
Mayberg MR, *see* Phillips MH
Maylevin F, *see* Spielmann M
May-Levin F, *see* Toussaint C
Mayordomo JI, Paz-Ares L, Diaz-Puente MT, Lianes P, Garcia-Prats MD, Cortes-Funes H. Prognostic factors for women with ovarian germ cell tumors (letter), 1737
Mazanet R, *see* Ayash LJ
Mazumdar M, *see* Mencel PJ
Mazumder A, *see* Uziely B
Mazzochhi B, *see* Cocconi G
McAtee N, *see* Grem JL
McCarthy W, *see* Raghavan D
McCauley DL, Calzone K, Wicha M. Neurotoxicity as a possible manifestation of paclitaxel hypersensitivity reactions (letter), 1102
McClay EF, McClay M-ET. In reply (letter), 1996
—, McClay MET. Tamoxifen: Is it useful in the treatment of patients with metastatic melanoma? 617
McClay M-ET, *see* McClay EF
McClay MET, *see* McClay EF
McCloskey E, *see* O'Rourke N
McCloskey T, *see* Stiff PJ
McCormack P, *see* Rusch V
McCowage G, *see* White L
McEvilly J-M, *see* Vokes EE
McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen A-L, Yan YX, Russo C, Sato J, Barbier N, Miser J, Malkin D, Gebhardt MC. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma, 925
McIntyre W, *see* Spitzer G
McKenna PJ, *see* Gunderson LL
McKenzie RS, *see* Stiff PJ
McLain D, *see* Bukowski RM
McLaughlin P, Hagemeister FB, Swan F Jr, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma, 575
— *see* Velasquez WS
McLaughlin PW, *see* Urba SG
McLeod BC, *see* Ghalie R
Mechinaud F, *see* Pein F
Meerabux J, *see* Johnson PWM
Meharchand J, *see* Lowsky R
Mehra R, *see* Giralt SA
Mehra RC, *see* Khouri IF
Meier U, *see* Ciernik IF
Meijer S, *see* Peters GJ
Meisenberg B. Etoposide for metastatic breast cancer (letter), 2235
— *see* Gilbert C
Meldrum M, *see* Cunningham D
Member Institutions of the Pediatric Oncology Group, *see* Castleberry RP
Mempel M, *see* Heiss MM
Mempel W, *see* Heiss MM
Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ. Advanced seminoma: Treatment results, survival, and prognostic factors in 142 patients, 120
Meneghini V, *see* Nadali G
Menestrina F, *see* Nadali G
Menichetti ET, *see* Bajetta E
Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. Role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype, 2588
Merle S, *see* Spielmann M
— *see* Toussaint C
Messner H, *see* Lowsky R
Metch B, *see* Rivkin SE
Metzger U, *see* Borner M
Meyer W, *see* Mathew P
Meyer WH, *see* Pratt CB
Meyers CA, Weitzner M, Byrne K, Valentine A, Champlin RE, Przepiorka D. Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation, 820
Meyers PA, *see* Butler RW
— *see* Tan CTC
Meyskens FL Jr, Liu PY, Tuthill RJ, Sondak VK, Fletcher WS, Jewell WR, Samlowski W, Balcerzak SP, Rector DJ, Noyes RD, Costanzi JJ. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: A Southwest Oncology Group study, 2060
Michalak JC, *see* Goldberg RM
Michallet M, *see* Archimbaud E
— *see* Reiffers J
— *see* Sebban C
Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Pico JL, Bordigoni P, Thuret I, Blaise D, Bernaudin F, Jouet JP, Lemerle S, Rubie H, Milpied N, Vannier JP, Demeocq F, Troussard X, Gratecos N, Plouvier E, Bergeron C, Gardembas M, Gouvernet J, Maraninchi D. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: Impact of conditioning regimen without total-body irradiation—A report from the Société Française de Greffe de Moelle, 1217
Mick R, *see* Vokes EE
Mier JW, *see* Atkins MB
Miglio LP, *see* Sertoli MR
Mignolet FY, *see* Clahsen PC
Mihaly G, *see* Basser RL
Mikaelian K, *see* Ward WG
Milan S, *see* Cunningham D
Milano G, Etienne MC, Renée N, Thyss A, Schneider M, Ramaioli A, Demard F. Relationship between fluorouracil systemic exposure and tumor response and patient survival, 1291
— *see* Etienne MC
Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CWL, Spiro SG, Gregory WM, Ledermann JA, Souhami RL, Harper PG. Received dose-intensity: A randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer, 77

Miles SA, Wang H, Elashoff R, Mitsuyasu RT. Improved survival for patients with AIDS-related Kaposi's sarcoma, 1910
Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A Cancer and Leukemia Group B study, 2743
Miller KB, *see* Schenkein DP
Mills W, *see* Jones HM
Milpied N, *see* Michel G
Milstein JM, *see* Geyer JR
Minden M, *see* Lowsky R
Minna JD, *see* Ihde DC
Minton JP, *see* Rivkin SE
Mirra JM, *see* Ward WG
Miser AW, *see* Goldberg RM
Miser J, *see* McIntyre JF
Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma, 402
—, Liggett PE, Green RL, Kan-Mitchell J, Murphree AL, Dean G, Spears L, Walonker F. Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine, 396
Mitsuyasu RT, *see* Miles SA
Mittal B, *see* Taylor SG IV
Moertel CG, *see* Cullinan SA
— *see* Loprinzi CL
Mohiuddin M, *see* Coia L
Möhle R, *see* Haas R
Moksness J, *see* Green DM
Molina A, *see* Nademanee A
Mommen P, *see* Sculier JP
Monconduit M, *see* Somers R
Mondzac AM. Tamoxifen dosage and bioequivalence: A correction (letter), 1993
Monnier A, *see* Le Chevalier T
Monnier P, *see* Leyvraz S
Montserrat E, López-Guillermo A, Rozman C. In reply (letter), 2767
— *see* López-Guillermo A
Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer, 689
Moos M, *see* Haas R
Morel P, *see* Haioun C
Morice RC, *see* Lee JS
Morris JC, *see* Kosty MP
Morris M, *see* Lehman E
Morris ME, *see* Darrington DL
Morris S, *see* Sandlund JT
Mortensen LS, *see* d'Amore F
Mortimer J, *see* Kosty MP
Mosteller F, *see* Eisenberg E
Motzer RJ, Bajorin DF, Schwartz LH, Hutter HS, Bosl GJ, Scher HI, Lyn P, Fischer P. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors, 2277
— *see* Mencel PJ
Mouridsen HT, *see* Kristensen B
Mross K, Bewermeier P, Krüger W, Stockschläder M, Zander A, Hossfeld DK. Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies, 1468
Mross KB. In reply (letter), 2768
Muggia FM, *see* Uziely B
Muh JP, *see* Colombat P
Mujoo K, *see* Murray JL
Mulcahy RT, *see* Bailey HH
Mulhern RK, *see* Gajjar A
Mullen M, *see* Shea TC
Mulshine JL, *see* Ihde DC
— *see* Kelley MJ
Munoz L, *see* Camitta B
Murad AM, Triginelli SA, Ribalta JCL. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer, 55
Murphree AL, *see* Mitchell MS
Murphy A, *see* Cullen MH
Murphy K, *see* Moore MJ
Murphy RF, *see* Grem JL
Murphy WK, *see* Fossella FV
— *see* Hesketh PJ
Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS, Legha SS, Ater JL, Jaffe N, Itoh K, Ross MI, Bucana CD, Thompson L, Cheung L, Rosenblum MG. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors, 184
— *see* Perez-Soler R
Murray N, Coppin C, Coldman A, Pater J, Rapp E. Drug delivery analysis of the Canadian multicenter trial in non–small-cell lung cancer, 2333
Murry DJ, *see* Rodman JH
Murthy AK, *see* Taylor SG IV
Muss HB, Case LD. In reply (letter), 2515
—, Case LD, Atkins JN, Bearden JD III, Cooper MR, Cruz JM, Jackson DV Jr, O'Rourke MA, Pavy MD, Powell BL, Richards F II, Spurr CL, Eagle K, White DR. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association study, 1630
Mustafa MM. In reply (letter), 1523
—, Pappo A, Cash J, Winick NJ, Buchanan GR. Aerosolized pentamidine for the prevention of *Pneumocystis carinii* pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole, 258
Myers RP, *see* Zincke H
Myers SE, *see* Shpall EJ
Myles J, *see* Eisenhauer EA
— *see* Shepherd L

Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, Perona G, Chilosi M, Menestrina F,

Fiacchini M, Stein H, Pizzolo G. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis, 793
Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G, Margolin KA, Woo D, Niland JC, Forman SJ. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells, 2176
— *see* O'Donnell MR
Nadler LM, *see* Stone RM
Nakagawa K, *see* Masuda N
Namikawa S, *see* Shimono T
Nathrath W, *see* Passlick B
Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin, 2204
Nayanar V, *see* White L
Nayfield SG, *see* Feuer EJ
— *see* Johnson TP
Neff JR, *see* Picci P
Negoro S, *see* Kubota K
— *see* Masuda N
Negrin RS, Pesando J. Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of *bcl-2* translocations, 1021
— *see* Horning SJ
Nelimark RA, *see* Loprinzi CL
Nelson K, Walsh D. In reply (letter), 1524
Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome, 213
Nelson T, *see* Au E
Nelson WG, *see* DiGiuseppe JA
Nemcek AA Jr, *see* Hakimian D
Nesbit ME, *see* Buckley J
Nesbit ME Jr, Buckley JD, Feig SA, Anderson JR, Lampkin B, Bernstein ID, Kim TH, Piomelli S, Kersey JH, Coccia PF, O'Reilly RC, August C, Thomas ED, Hammond GD. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: A report from the Childrens Cancer Group, 127
Neuberg D, *see* Nixon AJ
— *see* Roth BJ
— *see* Stone RM
Neumaier M, *see* Gerhard M
Neumann RLA, *see* Schumacher M
Neuwelt EA, *see* Crossen JR
Neville A, *see* Moore MJ
Ng M, *see* Segelov E
Ng P, *see* Taylor KM
Nguyen DT, *see* Foss FM
Nichols CR, Fox EP, Roth BJ, Williams SD, Loehrer PJ, Einhorn LH. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor, 1245
— *see* Loehrer PJ Sr
— *see* Saxman SB
Nicolson M, *see* Cunningham D
Niederle N, *see* Weidmann B
Niemeyer R, *see* Spitzer G
Nieuwenhuis HK, *see* Cornelissen JJ
Niland J, *see* O'Donnell MR
Niland JC, *see* Nademanee A
Nitta T, *see* Masuda N
Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer, 888
Noe DA, *see* Rowinsky EK
Nooy M, *see* Ornadel D
Nordlinger B, Vaillant J-C, Guiguet M, Balladur P, Paris F, Bachellier P, Jaeck D, the Association Francaise de Chirurgie. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases, 1491
Norman A, *see* Cunningham D
Northfelt DW. AIDS-related Kaposi's sarcoma: Still a problem, still an opportunity (editorial), 1109
Norton AJ, *see* Rohatiner AZS
Noumoff J, *see* Corn BW
Nouvel C, *see* Haioun C
Novak MJ, *see* Jodrell DI
Novotny J, *see* Hertenstein B
Novotny P, *see* Au E
— *see* Foote RL
— *see* Loprinzi CL
Novotny PJ, *see* Loprinzi CL
Noyes RD, *see* Meyskens FL Jr
Noyon R, *see* van Leeuwen FE

O'Boyle KR, *see* Atkins MB
Obrecht JP, *see* Borner M
O'Brien MC, *see* Foss FM
O'Brien MER, *see* Jones AL
O'Brien RT, *see* Gilchrist GS
— *see* Tubergen DG
O'Brien S, *see* Dimopoulos MA
— *see* Estey E
— *see* Khouri IF
Ochs J, *see* Pratt CB
O'Connell MJ. In memoriam: Charles G. Moertel (obituary), 2246
— *see* Buroker TR
— *see* Cullinan SA
Odom LF, *see* Wells RJ
O'Donnell MR, Schmidt GM, Tegtmeier BR, Faucett C, Fahey JL, Ito J, Nademanee A, Niland J, Parker P, Smith EP, Snyder DS, Stein AS, Blume KG, Forman SJ. Prediction of systemic fungal infection in allogeneic marrow recipients: Impact of amphotericin prophylaxis in high-risk patients, 827

— *see* Nademanee A
Oesterling JE, *see* Zincke H
Oettgen HF, *see* Livingston PO
— *see* Welt S
Oettle H, *see* Siegert W
O'Fallon J, *see* Au E
O'Fallon JR, *see* Foote RL
— *see* Goldberg RM
— *see* Loprinzi CL
O'Fallon WM, *see* Kyle RA
Offit K, Brown K. Quantitating familial cancer risk: A resource for clinical oncologists, 1724
Ogawara M, *see* Kubota K
Oken M, *see* Hamm J
Old LJ, *see* Livingston PO
— *see* Welt S
O'Leary MC, *see* Matthay KK
Olschewski M, *see* Schumacher M
Olshen RA, *see* Horning SJ
Omne-Pontén M, Holmberg L, Sjoden P-O. Psychosocial adjustment among women with breast cancer stages I and II: Six-year follow-up of consecutive patients, 1778
O'Neill K, *see* Budman DR
Onetto N, *see* Eisenhauer EA
Oratz R, *see* Hochster H
Orazem JP, *see* Francis PA
O'Reilly RC, *see* Nesbit ME Jr
Ornadel D, Souhami RL, Whelan J, Nooy M, de Elvira CR, Pringle J, Lewis I, Steward WP, George R, Bridgewater J, Wierzbicki R, Craft AW. Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: A phase II trial of the European Osteosarcoma Intergroup, 1842
O'Rourke M, *see* Hazuka MB
O'Rourke MA, *see* Muss HB
O'Rourke N, McCloskey E, Kanis J. WR-2721 and hypocalcemia (letter), 232
Osborne CK, *see* Ravdin PM
— *see* Rivkin SE
Osborne RJ, *see* Clark PI
O'Shaughnessy J, *see* Wilson WH
Osoba D. In reply (letter), 1994
— Lessons learned from measuring health-related quality of life in oncology, 608
— *see* Moore MJ
Ottaway J, *see* Shepherd L
Otto J, *see* Thyss A
Owen J, *see* Coia L
Oza AM, *see* Rohatiner AZS
Ozer H, *see* Johnson TP

Padavan M, *see* Livingston PO
Padavic K, *see* Krigel RL
Paesmans M, *see* Sculier JP
Palackdharry CS, *see* Krigel RL
Palli D, *see* Del Turco MR
Palma PD, *see* Gasparini G
Palmer M, *see* Kaizer L
Palmer R, *see* Navari RM
Palmeri S, *see* Bajetta E
Pandya KJ, *see* Taylor KM
Pang A, *see* Fossella FV
Pang AC, *see* Lee JS
Panici PB, *see* Scambia G
Panizo A, *see* Le Chevalier T
Pantel K, *see* Passlick B
Papa A, *see* Choy H
Papadopoulos NE, *see* Vadhan-Raj S
Pappo A, *see* Mustafa MM
Pappo AS, Fontanesi J, Luo X, Rao BN, Parham DM, Hurwitz C, Avery L, Pratt CB. Synovial sarcoma in children and adolescents: The St Jude Children's Research Hospital experience, 2360
Parente R, *see* Livingston PO
Parham DM, *see* Pappo AS
Paris F, *see* Nordlinger B
Parker P, *see* O'Donnell MR
Parker PM, *see* Nademanee A
Parkinson D, *see* Yang JC
Parkinson DR, *see* Guleria AS
Parmley RT, *see* Sadowitz PD
Partridge MR, *see* Souhami RL
Parwaresch R, *see* Reiter A
Pasche P, *see* Leyvraz S
Passlick B, Izbicki JR, Kubuschok B, Nathrath W, Thetter O, Pichlmeier U, Schweiberer L, Riethmüller G, Pantel K. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non–small-cell lung cancer, 1827
Pate O, *see* McLaughlin P
Patel SR, *see* Vadhan-Raj S
Pater J, *see* Kaizer L
— *see* Murray N
Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, Chuang V, Carrasco H, Roh M, Chase J, Fischer H, Jones D, Levin B. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: Effects of hepatitis B and C viral infection on drug toxicity and patient survival, 1204
—, Podoloff DA, Curley S, Kasi L, Smith R, Bhadkamkar V, Charnsangavej C. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels, 489
— *see* Pazdur R
Patterson WB, Emanuel EJ. Euthanasia and the care of cancer patients, 1516
Paul J, *see* Wishart GC
Pautard B, *see* Pein F
Pavy MD, *see* Muss HB
Payen C, *see* Attal M
Paz-Ares L, *see* Cunningham D
— *see* Mayordomo JI
Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B, Levin B. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regi-

men in the treatment of metastatic colorectal carcinoma, 2296
Pearce R, *see* Sweetenham JW
— *see* Williams CD
Pedersen M, *see* d'Amore F
Pedersen NT, *see* d'Amore F
Pegoraro C, *see* Boccardo F
Pein F, Tournade M-F, Zucker J-M, Brunat-Mentigny M, Deville A, Boutard P, Dusol F, Gentet JC, Legall E, Mechinaud F, Plouvier E, Plantaz D, Pautard B, Rubie H, Lemerle J. Etoposide and carboplatin: A highly effective combination in relapsed or refractory Wilms' tumor—A phase II study by the French Society of Pediatric Oncology, 931
Pereira C, *see* Atkins MB
Perez JE, *see* Romero A
Perez-Soler R, Donato NJ, Shin DM, Rosenblum MG, Zhang H-Z, Tornos C, Brewer H, Chan JC, Lee JS, Hong WK, Murray JL. Tumor epidermal growth factor receptor studies in patients with non–small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852, 730
— *see* Fossella FV
Perfect J, *see* Gilbert C
Perona G, *see* Nadali G
Perrotta A, *see* Sertoli MR
Pesando J, *see* Negrin RS
Peters EJ, *see* Lee JS
Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil, 2035
Peters HA, *see* Foekens JA
Peters WP, *see* Gilbert C
— *see* Gilbert CJ
Peterse H, *see* Borger J
Petersen FB, *see* Weaver CH
Peterson B. The role of transplantation in non-Hodgkin's lymphoma (editorial), 2524
Petitdidier C, *see* Delain M
Peto R, *see* Cuzick J
Petruska PJ, *see* Spitzer G
Pfeifle DM, *see* Loprinzi CL
Pfreundschuh MG, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, Haas R, Kirchner H, Koch P, Kuse R, Loeffler M, Diehl V. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group, 580
Phares JC, *see* Foss FM
— *see* Ihde DC
Phelps RM, *see* Ihde DC
Philip T, *see* Coiffier B
— *see* Williams CD
Phillips M, *see* Francis P
Phillips MH, Stelzer KJ, Griffin TW, Mayberg MR, Winn HR. Stereotactic radiosurgery: A review and comparison of methods, 1085
Piantadosi S, *see* Abeloff MD
— *see* Grossman SA
Piccart MJ, *see* Tomiak E
Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma, 2699
Pichert G, *see* Stahel RA
Pichlmeier U, *see* Passlick B
Pico JL, *see* Michel G
Piedbois P, Buyse M. Meta-analyses need time, collaboration, and funding (letter), 878
Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate, 2005
Pierce LJ, Lichter AS. Postmastectomy radiotherapy: More than locoregional control (editorial), 444
Pierce S, *see* Estey E
Pignon J-P, Ducreux M, Rougier P. Meta-analysis of adjuvant chemotherapy in gastric cancer: A critical reappraisal (letter), 877
Pileri A, *see* Gianni AM
Pinedo H, *see* Bramwell V
Pinedo HM, van Groeningen CJ. Vinorelbine: A horse of a different color? (editorial), 1745
— *see* Linn SC
— *see* Peters GJ
— *see* van Leeuwen FE
Pinkel D. Bone marrow transplant in acute myeloid leukemia (letter), 1737
— *see* Land VJ
— *see* Lockhart S
Pinkerton CR, *see* Cowie F
Pinkus GS, *see* Shivdasani RA
Piomelli S, *see* Nesbit ME Jr
Pisters KMW, *see* Francis PA
Pisters PWT, Harrison LB, Woodruff JM, Gaynor JJ, Brennan MF. A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk, 1150
Pizzolo G, *see* Nadali G
Pizzorno G, *see* Ravikumar TS
Plager C, *see* Vadhan-Raj S
Plagge P, *see* Hesketh PJ
Plagge PB, *see* Spitzer TR
Plantaz D, *see* Pein F
Platzer E, *see* Stahel RA
Plourde PV, *see* Buzdar AU
Plouvier E, *see* Michel G
— *see* Pein F
Plunkett W, *see* Lockhart S
Podoloff DA, *see* Murray JL
— *see* Patt YZ
Podratz KC, *see* Hartmann LC
Poizot-Martin I, Giovannini M, Rosello R, Viallat JR, Sauniere JF, Dalmas AM, Genre D, Dhiver C, Gastaut JA. Liposomal-doxorubicin in human immunodeficiency virus-associated Kaposi's sarcoma (letter), 645
Pollack J, *see* Ravikumar TS
Pollock BH, *see* Sadowitz PD

Pomplun M, *see* Bailey HH
Pontes E, *see* Maluf PT
Poon MA, *see* Cullinan SA
Poppema S, *see* Tang SC
Porcellini A, *see* Sertoli MR
Porkka K, Blomqvist C, Rissanen P, Elomaa I, Pyrhönen S. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer, 1639
Posner M, *see* Lynch TJ Jr
Pouillart P, *see* Spielmann M
Powell BL, *see* Muss HB
Powles R, *see* Cunningham D
Pozza F, *see* Gasparini G
Pozza LD, *see* Shaw PJ
Pratt C, *see* Mathew P
— *see* Sadowitz PD
Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, Avery L, Meyer WH. Phase I study of topotecan for pediatric patients with malignant solid tumors, 539
— *see* Pappo AS
— *see* Sonnichsen DS
— *see* Stewart CF
Press O, *see* Weaver CH
Preti A, Kantarjian HM. Management of adult acute lymphocytic leukemia: Present issues and key challenges, 1312
Priario J, *see* Bramwell V
Price CGA, *see* Johnson PWM
— *see* Rohatiner AZS
Pringle J, *see* Ornadel D
Pris J, *see* Attal M
Propert K, *see* Seiden MV
Prosnitz LR, Marks LB. Postmastectomy radiotherapy (letter), 1525
— *see* King SC
Przepiorka D, *see* Giralt SA
— *see* Khouri IF
— *see* Meyers CA
Pu Y-S, *see* Cheng A-L
Pugh RP, *see* Salmon SE
Puglia G, *see* Scambia G
Pui C-H, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC, Head DR, Mahmoud HH, Sandlund JT, Furman WL, Roberts WM, Crist WM, Raimondi SC. 11q23/*MLL* rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia, 909
—, Hughes WT, Evans WE, Crist WM. Prevention of *Pneumocystis carinii* pneumonia in children with cancer (letter), 1522
—, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH, Sandlund JT, Crist WM, Behm FG. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23;p13) or its derivative, 2601
— *see* Relling MV
— *see* Sandlund JT
Pujol J-L, *see* Le Chevalier T
Pullen DJ, *see* Land VJ
Pulliam S, *see* Kemeny N
Purdy M, *see* Shpall EJ
Puthawala Y, *see* Choy H
Pyrhönen S, *see* Porkka K

Queirolo P, *see* Bajetta E
Quintana E, *see* Rousseau P

Raaijmakers HGP, *see* Cornelissen JJ
Raber M, *see* Fossella FV
Raber MN, *see* Abbruzzese JL
Rabinovich MG, *see* Romero A
Rabinovitch RA, Zelfsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy, 206
Rabinowe SN, *see* Stone RM
Racadot E, *see* Sebban C
Rad N, *see* Stiff PJ
Rademaker A, *see* Giovanazzi-Bannon S
Rademaker AW, *see* Hakimian D
Raffeld M, *see* Longo DL
Raghavan D, Zalcberg JR, Grygiel JJ, Teriana N, Cox KM, McCarthy W, Flynn M. Multiple atypical nevi: A cutaneous marker of germ cell tumors, 2284
— *see* Stoter G
Ragusa K, *see* Conti JA
Rai K, *see* Hoffman M
Raimondi S, *see* Sandlund JT
Raimondi SC, *see* Pui C-H
— *see* Pui C-H
Rajagopal S, Goodman PJ, Tannock IF. Adjuvant chemotherapy for breast cancer: Discordance between physicians' perception of benefit and the results of clinical trials, 1296
Ramage F, *see* Jones AL
Ramaioli A, *see* Milano G
Ramirez I, *see* Lockhart S
Ramsay NK, *see* Matthay KK
Rao BN, *see* Pappo AS
Raphael B, *see* Hochster H
Rapp E, *see* Murray N
Raquin M, *see* Tabone M-D
Rasp GM, Haddock MG, Martenson JA. Clarification of entry criteria for the European Organization for Research and Treatment of Cancer H5-favorable trial of early-stage Hodgkin's disease (letter), 1739
Rauschecker HF, *see* Schumacher M
Ravaioli A, *see* Le Chevalier T
Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SAW, Hilsenbeck SH, Chamness GC, Osborne CK. Cathepsin D by Western blotting and immunohistochemistry: Failure to confirm correlations with prognosis in node-negative breast cancer, 467
— *see* Loprinzi CL
Ravikumar TS, Pizzorno G, Bodden W, Marsh J, Strair R, Pollack J, Hendler R, Hanna J, D'Andrea E. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors, 2723

Ravindranath Y, *see* Land VJ
Ravoet C, *see* Tomiak E
Raymond J, *see* Cunningham D
Reading CL, *see* Khouri IF
Rebischung J-L, *see* Taylor SG IV
Reboul F, *see* Chauvet B
Recht A, *see* Nixon AJ
Rector DJ, *see* Meyskens FL Jr
Reddy M, *see* Remick SC
Redman B, *see* Pienta KJ
Redman JR, *see* McLaughlin P
Redmond C, *see* Cuzick J
Reed EC, *see* Darrington DL
Rege V, *see* Choy H
Reich E, *see* Ayash LJ
Reid JM, *see* Tefferi A
Reiffers J, Stoppa AM, Attal M, Michallet M, the BGMT Group. Is there a place for blood stem-cell transplantation for the younger adult patient with acute myelogenous leukemia? (letter), 1100
— *see* Michel G
— *see* Sebban C
Reiman RJ, *see* King SC
Reinisch W, Willheim M, Hilgarth M, Gasché C, Mader R, Szepfalusi S, Steger G, Berger R, Lechner K, Boltz-Nitulescu G, Schwarzmeier JD. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia, 2146
Reisenleiter M, *see* Delain M
Reiter A, Schrappe M, Tiemann M, Parwaresch R, Zimmermann M, Yakisan E, Dopfer R, Bucsky P, Mann G, Gadner H, Riehm H. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster Group studies, 899
Relling M, *see* Mathew P
Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui C-H, Evans WE. Patient characteristics associated with high-risk methotrexate concentrations and toxicity, 1667
— *see* Sonnichsen DS
Remick SC, Reddy M, Herman D, Grace C, Harper G, Willis K, Candon B, Horton J, Ruckdeschel JC. Continuous infusion bleomycin in AIDS-related Kaposi's sarcoma, 1130
Renée N, *see* Etienne MC
— *see* Milano G
Rettig WJ, *see* Welt S
Reyes F, *see* Haioun C
Reyno LM, *see* Jodrell DI
Reynolds CP, *see* Matthay KK
Reznek R, *see* Clark PI
Rhodes V, *see* Pazdur R
Ribalta JCL, *see* Murad AM
Ribeiro G, *see* Cuzick J
Ribeiro R, *see* Sandlund JT
Ribeiro RC, *see* Mathew P
— *see* Pui C-H
Ricetti MM, *see* Nadali G
Richards EC, *see* Welt S
Richards F II, *see* Muss HB
Richardson GE, *see* Shapiro J
Richardson RL, *see* Liengswangwong V
Richman CM, *see* Ghalie R
Riehm H, *see* Reiter A
Rieker PP, *see* Talcott JA
Riepenhausen M, *see* Rossi R
Ries F, *see* Sculier JP
Riethmüller G, *see* Passlick B
Rigas JR, *see* Francis PA
Rissanen P, *see* Porkka K
Ristamäki R, *see* Joensuu H
Ritchey M, *see* Green DM
Ritter G, *see* Livingston PO
Ritter J, *see* Rossi R
Ritz J. Tumor immunity: Will new keys unlock the door? (editorial), 237
Rivera GK, *see* Pui C-H
Riviere A, *see* Le Chevalier T
Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study, 2078
Rizeq M, *see* Bartlett NL
Rizk N, *see* Horning SJ
Rizzoli V, *see* Sertoli MR
Ro JY, *see* Lee JS
Robbins KT, Storniolo AM, Kerber C, Vicario D, Seagren S, Shea M, Hanchett C, Los G, Howell SB. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer, 2113
Roberts WM, *see* Pui C-H
— *see* Sandlund JT
Robertshaw H, *see* Jones AL
Robertson LE, *see* Estey E
— *see* Khouri IF
Robertson TI, *see* Cooper IA
Roche PC, *see* Hartmann LC
Rockette HE, *see* Johnston PG
Rodary C, *see* Tabone M-D
Rodinò C, *see* Cocconi G
Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation, 2390
— *see* Relling MV
Rodriguez MA, *see* McLaughlin P
— *see* Velasquez WS
Rodriguez R, *see* Romero A
Rodriguez-Lescure A, *see* Martín M
Roh M, *see* Patt YZ
Rohatiner A. Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation (editorial), 2521
Rohatiner AZS, Johnson PWM, Price CGA, Arnott SJ, Amess JAL, Norton AJ, Dorey E, Adams K, Whelan JS, Matthews J, MacCallum PK, Oza AM, Lister TA. Myeloablative therapy with autologous bone marrow

transplantation as consolidation therapy for recurrent follicular lymphoma, 1177
— *see* Johnson PWM
Rolston K, *see* Rubenstein EB
Romaguera J, *see* Velasquez WS
Romaguera JE, *see* McLaughlin P
Rome R, *see* Segelov E
Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Acuña LR, Amato S, Barbieri R, Sabatini C, Leone BA. Vinorelbine as first-line chemotherapies for metastatic breast carcinoma, 336
Roodman GD, *see* Adkins DR
Rorke LB, *see* Geyer JR
Rose E, *see* Hakimian D
Rosello R, *see* Poizot-Martin I
Rosenberg SA, *see* Guleria AS
— *see* Schwartzentruber DJ
— *see* Yang JC
Rosenblum MG, *see* Murray JL
— *see* Perez-Soler R
Rosenfield N, *see* Kushner BH
Rosenthal DS, *see* Marcus KC
Rosenthal HG, *see* Townsend PW
Rosenthal MA, *see* Basser RL
Rosner GL, *see* Miller AA
Rospond RM, *see* Loprinzi CL
Ross M, *see* Gilbert C
Ross MI, *see* Murray JL
Rossi E, *see* Sertoli MR
Rossi R, Gödde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, Jürgens H. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: Analysis of 120 patients, 159
Rosso R, *see* Sertoli MR
Roth BJ. Combination chemotherapy in advanced prostate cancer: A silk purse? (editorial), 2001
—, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group, 2264
— *see* Einhorn LH
— *see* Nichols CR
Roth MS, *see* Datta YH
Rouesse J, *see* Bramwell V
— *see* Spielmann M
Rougier P, *see* Pignon J-P
Rougraff BT, *see* Picci P
Rousseau P, Flamant F, Quintana E, Voute PA, Gentet JC, the International Society of Pediatric Oncology Malignant Mesenchymal Tumor Committee. Primary chemotherapy in rhabdomyosarcomas and other malignant mesenchymal tumors of the orbit: Results of the International Society of Pediatric Oncology MMT 84 study, 516
Rowell G, *see* Shaw PJ
Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng Y-C, Grochow LB, Kaufmann SH. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia, 2193
—, Noe DA, Trump DL, Winer EP, Lucas VS, Wargin WA, Hohneker JA, Lubejko B, Sartorius SE, Ettinger DS, Donehower RC. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors, 1754
Rowland KM Jr, *see* Goldberg RM
Rowley S, *see* Weaver CH
Rozman C, *see* López-Guillermo A
— *see* Montserrat E
Rubagotti A, *see* Boccardo F
— *see* Sertoli MR
Rubenstein E, *see* Velasquez WS
Rubenstein EB, Rolston K, Elting L. Outpatient antibiotics therapy in febrile neutropenic patients undergoing high-dose chemotherapy and autologous bone marrow support (letter), 2516
Rubie H, *see* Michel G
— *see* Pein F
Ruby E, *see* Gordon B
Ruckdeschel JC, *see* Remick SC
Rudd R, *see* Souhami RL
Rudd RM, *see* Miles DW
Rueffer U, *see* Pfreundschuh MG
Ruffie P, *see* Le Chevalier T
Rugg TA, *see* Abratt RP
Ruka W, *see* Bramwell V
Runowicz CD, *see* Goldberg GL
Rusch V, Saltz L, Venkatraman E, Ginsberg R, McCormack P, Burt M, Markman M, Kelsen D. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma, 1156
Rushing D, *see* Bennett JM
Russell A, *see* Coia L
Russo A, *see* Bajetta E
Russo C, *see* McIntyre JF
Rutqvist L, *see* Cuzick J
Ruymann F, *see* Wells RJ
Ryan MA, *see* Foote RL
Ryan T, *see* Hesketh PJ

Sabatini C, *see* Romero A
Sadowitz PD, Dubowy R, Souid A, Pollock BH, Weinstein H, Parmley RT, Bowman WP, Land V, Vats T, Pratt C, Buchanan GR. Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: A Pediatric Oncology Group study, 1969
Safran H, *see* Choy H
Salerno G, *see* Scambia G
Sallan SE, *see* Schorin MA
Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study, 2405
Saltz L, *see* Rusch V
Salvagno L, *see* Sertoli MR
Salvia G, *see* Boccardo F

Salzman D, *see* Adkins DR
Samlowski W, *see* Meyskens FL Jr
Sanal SM, Flickinger FW, Caudell MJ, Sherry RM. Detection of bone marrow involvement in breast cancer with magnetic resonance imaging, 1415
Sandlund JT, Pui C-H, Santana VM, Mahmoud H, Roberts WM, Morris S, Raimondi S, Ribeiro R, Crist WM, Lin J-S, Mao L, Berard CW, Hutchison RE. Clinical features and treatment outcome for children with CD30$^+$ large-cell non-Hodgkin's lymphoma, 895
— *see* Pratt CB
— *see* Pui C-H
Sandmaier B, *see* Weaver CH
Sanford RA, *see* Gajjar A
Sanger WG, *see* Darrington DL
Sangiorgi L, *see* Picci P
Santabárbara P, *see* Eisenhauer EA
— *see* Martín M
Santana VM, *see* Pratt CB
— *see* Rodman JH
— *see* Sandlund JT
Santini G, *see* Sertoli MR
— *see* Sweetenham JW
Santoro A, *see* Bramwell V
Sanz GF, *see* Sanz MA
Sanz MA, Sanz GF, de la Rubia J. In reply (letter), 1101
Sarkis A, *see* Schultz PK
Sarkis AS, *see* Zeng Z-S
Sartorius SE, *see* Rowinsky EK
Sasako M, *see* Bunt AMG
Sassoon A, *see* Ward WG
Sather HN, *see* Gilchrist GS
Sathya J, *see* Browman GP
Sato J, *see* McIntyre JF
Saudes L, *see* Thyss A
Sauerbrei W, *see* Schumacher M
Sauniere JF, *see* Poizot-Martin I
Sausville EA, *see* Foss FM
Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer, 970
Sawka CA, *see* Haq R
Saxman SB, Nichols CR, Einhorn LH. Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: The Indiana University experience, 1390
Scalzo A, *see* Kosty MP
Scambia G, Panici PB, Foti E, Amoroso M, Salerno G, Ferrandina G, Battaglia F, Greggi S, De Gaetano A, Puglia G, Mancuso S. Squamous cell carcinoma antigen: Prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer, 2309
Schacter L, *see* Budman DR
Schaefer PL, *see* Buroker TR
Schantz SP, *see* Fisher SG
Schechter GP, *see* Foss FM
Schenkein DP, Dixon P, Desforges JF, Berkman E, Erban JK, Ascensao JL, Miller KB. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease, 2423
Scher HI, *see* Herr HW
— *see* Motzer RJ
— *see* Schultz PK
Scherr D, *see* Schultz PK
Scheurlen H, *see* Cuzick J
Schiessel R, *see* Sautner T
Schiffman K, *see* Weaver CH
Schildberg F-W, *see* Heiss MM
Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer, 241
— *see* Hamm J
Schilsky RL, *see* Miller AA
Schlaifer D, *see* Attal M
Schmeiser T, *see* Hertenstein B
Schmidt GM, *see* Nademanee A
— *see* O'Donnell MR
Schmidt L, *see* Kris MG
Schmitt M, *see* Foekens JA
Schmitz N, *see* Pfreundschuh MG
Schmoll H-J, *see* Siegert W
Schmoor C, *see* Schumacher M
Schneider J, *see* Francis P
Schneider M, *see* Etienne MC
— *see* Milano G
— *see* Thyss A
Schnipper L, *see* Ayash LJ
Schnitt S, *see* Nixon AJ
Schoester M, *see* Cornelissen JJ
— *see* Sonneveld P
Schold C Jr, *see* Cairncross G
Scholz M, *see* Hertenstein B
Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01, 740
Schraffordt-Koops H, *see* Bramwell V
Schrappe M, *see* Reiter A
Schreiber HW, *see* Gerhard M
Schuchter LM, *see* Halpern AC
Schulman P, *see* Budman DR
Schultz D, *see* Corn BW
Schultz PK, Herr HW, Zhang Z-F, Bajorin DF, Seidman A, Sarkis A, Fair WR, Scherr D, Bosl GJ, Scher HI. Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with 5-year follow-up, 1394
Schultz SM, *see* Roth BJ
Schumacher M, Bastert G, Bojar H, Hübner K, Olschewski M, Sauerbrei W, Schmoor C, Beyerle C, Neumann RLA, Rauschecker HF, the German Breast Cancer Study Group. Randomized 2 × 2 trial evaluating hor-

monal treatment and the duration of chemotherapy in node-positive breast cancer patients, 2086
Schwartz G, *see* Ayash LJ
Schwartz LH, *see* Motzer RJ
Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, Rosenberg SA, Topalian SL. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2, 1475
— *see* Guleria AS
— *see* Yang JC
Schwarzmeier JD, *see* Reinisch W
Schweiberer L, *see* Passlick B
Schwinghammer TL. Safety, pharmacokinetics, and pharmacodynamics of high-dose etoposide (letter), 2768
Scott AM, *see* Welt S
Sculier JP, Klastersky J, Giner V, Bureau G, Thiriaux J, Dabouis G, Efremidis A, Ries F, Berchier MC, Sergysels R, Mommen P, Paesmans M, the European Lung Cancer Working Party. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non–small-cell lung cancer, 353
— *see* Tomiak E
Seagren S, *see* Robbins KT
Sebban C, Lepage E, Vernant J-P, Gluckman E, Attal M, Reiffers J, Sutton L, Racadot E, Michallet M, Maraninchi D, Dreyfus F, Fiere D. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: A comparative study, 2580
Seeger RC, *see* Matthay KK
Segelov E, Campbell J, Ng M, Tattersall M, Rome R, Free K, Hacker N, Friedlander ML. Cisplatin-based chemotherapy for ovarian germ cell malignancies: The Australian experience, 378
—, Friedlander M. In reply (letter), 1738
Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W, Sklar J. Detection of circulating tumor cells in men with localized prostate cancer, 2634
Seidman A, *see* Schultz PK
Seidman AD, Barrett S, Canezo S. Photopsia during 3-hour paclitaxel administration at doses ≥ 250 mg/m^2 (letter), 1741
Seifter EJ, *see* DiGiuseppe JA
Seipp CA, *see* Guleria AS
— *see* Yang JC
Seiter K, *see* Conti JA
Selby P, *see* Cunningham D
Selby PJ, *see* Cunningham D
Selch M, *see* Matthay KK
Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer, 683
Selvaggi F, *see* Boccardo F
Senn HJ, *see* Borner M
Sergysels R, *see* Sculier JP
Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M, Capnist G, Rossi E, Mangoni L, Fabris P, Vinante O, Tedeschi L, Endrizzi L, Miglio LP, Perrotta A, Rosso R, Damasio E, Rizzoli V. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group, 1366
Sertoli MR, *see* Bajetta E
Seshadri R, *see* White L
Setser A, *see* Grem JL
Shapiro J, Richardson GE. Paclitaxel-induced "recall" soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb (letter), 2237
Shaw EG, Su JQ, Eagan RT, Jett JR, Maksymiuk AW, Deigert FA. Prophylactic cranial irradiation in complete responders with small-cell lung cancer: Analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases, 2327
— *see* Liengswangwong V
Shaw P, *see* White L
Shaw PJ, Bergin ME, Burgess MA, Pozza LD, Kellie SJ, Rowell G, Stevens MM, Webster BH, Bradstock KF. Childhood acute myeloid leukemia: Outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation, 2138
Shea M, *see* Robbins KT
Shea TC, Mason JR, Breslin M, Bissent E, Mullen M, Taetle R. Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy, 1012
Sheehan FA, *see* Nelson KA
Shellito PC, *see* Willett CG
Shen M-C, *see* Cheng A-L
Shenkier T, Gelmon K. Paclitaxel and radiation-recall dermatitis (letter), 439
Shepherd F, *see* Hamm J
Shepherd L, Ottaway J, Myles J, Levine M. Therapy-related leukemia associated with high-dose 4-epi-doxorubicin and cyclophosphamide used as adjuvant chemotherapy for breast cancer (letter), 2514
Sherry RM, *see* Sanal SM
Shi WJ, *see* Kemeny N
Shih L-Y, Liaw S-J, Dunn P, Kuo T-T. Primary small-intestinal lymphomas in Taiwan: Immunoproliferative small-intestinal disease and nonimmunoproliferative small-intestinal disease, 1375
Shimono T, Hayashi T, Kimura M, Yada I, Namikawa S, Yuasa H, Kusagawa M. Surgical treatment of primary lung cancer in patients less than 40 years of age, 981
Shin DM, *see* Fossella FV
— *see* Perez-Soler R
Shivdasani RA, Pinkus GS. In reply (letter), 877
Shochat S, *see* Green DM
Shott S, *see* Taylor SG IV
Showel JL, *see* Taylor SG IV
Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Curiel T, Bitter M, Claman HN, Stemmer SM, Purdy

M, Myers SE, Hami L, Taffs S, Heimfeld S, Hallagan J, Berenson RJ. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment, 28
Shulman LN, *see* Lynch TJ Jr
— *see* Marcus KC
Shurin SB, *see* Geyer JR
Shurtleff SA, *see* Pui C-H
Shuster JJ, *see* Camitta B
— *see* Castleberry RP
— *see* Land VJ
— *see* Sonnichsen DS
Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll H-J, Huhn D, the German Testicular Cancer Cooperative Study Group. High-dose treatment with carboplatin etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study, 1223
Siena S, *see* Gianni AM
Sikic BI, *see* Bartlett NL
— *see* Yuen AR
Silva EG, *see* Lehman E
Simons KJ, *see* Brandes LJ
Sinibaldi VJ, *see* Jodrell DI
Sjoden P-O, *see* Omne-Pontén M
Skarin A, *see* Lynch TJ Jr
Skeel RT, *see* Taylor KM
Sklar J, *see* Seiden MV
Slevin M, *see* Cunningham D
Slevin ML, *see* Clark PI
Smalley SR, *see* Townsend PW
Smid K, *see* Peters GJ
Smith EI, *see* Castleberry RP
Smith EP, *see* Nademanee A
— *see* O'Donnell MR
Smith HO, *see* Goldberg GL
Smith IE, *see* Jones AL
Smith JL, *see* Roth BJ
Smith L, *see* Adkins DR
Smith R, *see* Patt YZ
Smith T, *see* Johnson PWM
Smithson W, *see* Wells RJ
Smith-Sorensen B, *see* McIntyre JF
Sniecinski I, *see* Nademanee A
Snyder DS, *see* Nademanee A
— *see* O'Donnell MR
Sobol MM, *see* Basser RL
Soderberg C, *see* Choy H
Söderström K-O, *see* Joensuu H
Soiffer R, *see* Stone RM
Soldani M, *see* Cocconi G
Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, de Pauw BE, Breed WPM, Verdonck L, Burgers JMV, Eghbali H, Zittoun R. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial, 279
— *see* van Leeuwen FE
Somlo G, *see* Nademanee A
Sondak VK, *see* Meyskens FL Jr
Sondik E, *see* Johnson TP
Sonneveld P, Schoester M, de Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: Effect of cyclosporine on resistant tumor cells, 1584
— *see* Cornelissen JJ
Sonnichsen D, *see* Mathew P
Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors, 532
Sorensen JM, *see* Cheson BD
Sorich J, *see* Hochster H
Sosman JA, *see* Atkins MB
— *see* Stiff PJ
Souhami RL, Rudd R, de Elvira M-CR, James L, Gower N, Harper PG, Tobias JS, Partridge MR, Davison AG, Trask C, Spiro SG. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: A Cancer Research Campaign trial, 1806
— *see* Miles DW
— *see* Ornadel D
Souid A, *see* Sadowitz PD
Soukop M, *see* Wishart GC
Spadinger A, *see* Gordon B
Sparano JA, *see* Atkins MB
Spaulding MB, Fischer SG, Wolf GT, the Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma, 1592
Spears L, *see* Mitchell MS
Spencer V, *see* Spitzer G
Speyer J, *see* Hochster H
Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rouesse J, Pouillart P, Tursz T, Merle S. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer, 1764
— *see* Toussaint C
Spiro SG, *see* Miles DW
— *see* Souhami RL
— *see* Tobias JS
Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS, Bowers CE, Kronmueller N, Niemeyer R, McIntyre W. Randomized study of growth factors post–peripheral-blood stem-cell transplant: Neutrophil recovery is improved with modest clinical benefit, 661
Spitzer TR, Bryson JC, Cirenza E, Foelber R, Wallerstadt M, Stout C, Kunka RL, Plagge PB, Dubois A. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation, 2432
Spratt JS. Cost-effective follow-up of breast cancer patients (letter), 1996

Spriggs D, *see* Schiller JH
Spriggs DR, *see* Bailey HH
Spurr CL, *see* Muss HB
Sridhara R, *see* Jodrell DI
Srivastava A, *see* Wells RJ
Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A, Jacky E, Fey M, Platzer E. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies, 1931
Stanley P, *see* Geyer JR
Stanley R, *see* Gordon B
Stefanic M, *see* Hertenstein B
Steger G, *see* Reinisch W
Stein AS, *see* Nademanee A
— *see* O'Donnell MR
Stein H, *see* Nadali G
Steinberg S, *see* Grem JL
Steinberg SM, *see* Foss FM
— *see* Guleria AS
— *see* Ihde DC
— *see* Schwartzentruber DJ
— *see* Wilson WH
— *see* Yang JC
Steinherz PG, *see* Butler RW
Stelzer KJ, *see* Phillips MH
Stemmer SM, *see* Shpall EJ
Stepan DE, *see* Nademanee A
Stern A, *see* Gianni AM
Stetler-Stevenson MA, *see* Foss FM
Steuber P, *see* Camitta B
Stevens JA, *see* Figg WD
Stevens KR, *see* Geyer JR
Stevens MM, *see* Shaw PJ
Stevenson L, *see* Mitchell MS
Steward W, *see* Bramwell V
Steward WP, *see* Ornadel D
Stewart C, *see* Pratt CB
Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity, 1946
Stewart D, *see* Cairncross G
Stewart H, *see* Cuzick J
Stiff PJ, McKenzie RS, Alberts DS, Sosman JA, Dolan JR, Rad N, McCloskey T. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: High response rate for refractory ovarian carcinoma, 176
Stocker JL, *see* Foss FM
Stockschläder M, *see* Mross K
Stone JM, *see* Cooper IA
Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P, Freedman AS, Nadler LM. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma, 2535
Stoppa AM, *see* Reiffers J
Storb R, *see* Weaver CH
Storer B, *see* Schiller JH
Storniolo AM, *see* Robbins KT
Stoter G, Kaye SB, de Mulder PHM, Levi J, Raghavan D. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma (letter), 644
Stout C, *see* Spitzer TR
Strair R, *see* Ravikumar TS
Stram DO, *see* Matthay KK
Strauss G, *see* Lynch TJ Jr
Strohscheer I, *see* Siegert W
Strother D, *see* Camitta B
Stuart NSA, *see* Cullen MH
Su I-J, *see* Cheng A-L
Su JQ, *see* Hartmann LC
— *see* Jett JR
— *see* Liengswangwong V
— *see* Loprinzi CL
— *see* Maksymiuk AW
— *see* Shaw EG
Sugarman SM, *see* Pazdur R
Sullivan KM, *see* Weaver CH
Sunderland M, *see* Toussaint C
Sutcliffe S, *see* Lowsky R
Sutcliffe SB, Gospodarowicz MK, Fitzpatrick PJ. In memoriam: Vera Peters (obituary), 239
Sutton L, *see* Sebban C
Swan F, *see* Velasquez WS
Swan F Jr, *see* McLaughlin P
Sweetenham JW, Johnson PWM. ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma (letter), 2766
—, Liberti G, Pearce R, Taghipour G, Santini G, Goldstone AH. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: Results of the European Group for Bone Marrow Transplantation, 1358
Swenerton KD, *see* Eisenhauer EA
— *see* Hoskins PJ
Symann ML, *see* Coiffier B
Szepfalusi S, *see* Reinisch W

Tabone M-D, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy, 2614
Taetle R, *see* Shea TC
Taffs S, *see* Shpall EJ
Taghipour G, *see* Sweetenham JW
— *see* Williams CD
Takada M, *see* Kubota K
— *see* Masuda N
Takifuji N, *see* Kubota K
— *see* Masuda N
Takvorian T, *see* Stone RM
Talbot D, *see* Jones AL
Talbot DI, *see* Clark PI
Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule, 107

— *see* Kantoff PW
Tallman MS, *see* Hakimian D
— *see* Hoffman M
Tamanoi M, *see* Masuda N
Tan CTC, Wollner N, Trippett T, Goker E, Tong WPY, Kheradpour A, Meyers PA, VanSyckle KM, Guarino L, Elisseyeff Y, Bertino JR Jr. Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies, 1955
Tandon AK, *see* Ravdin PM
Tang SC, Visser L, Hepperle B, Hanson J, Poppema S. Clinical significance of *blc-2*-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases, 149
Tannock IF, *see* Moore MJ
— *see* Rajagopal S
Tannous R, *see* Wells RJ
Tao Y, *see* Livingston PO
Tarantolo SR, *see* Darrington DL
Tarayre M, *see* Somers R
Tarbell NJ, *see* Schorin MA
Tarella C, *see* Gianni AM
Tattersall M, *see* Segelov E
Tattersall MHN, Butow PN, Griffin A-M, Dunn SM. The take-home message: Patients prefer consultation audiotapes to summary letters, 1305
Taubes B, *see* Hochster H
Taylor AE, Wiltshaw E, Gore ME, Fryatt I, Fisher C. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer, 2066
Taylor KM, Feldstein ML, Skeel RT, Pandya KJ, Ng P, Carbone PP. Fundamental dilemmas of the randomized clinical trial process: Results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators, 1796
Taylor SG IV, Murthy AK, Vannetzel J-M, Colin P, Dray M, Caldarelli DD, Shott S, Vokes E, Showel JL, Hutchinson JC, Witt TR, Griem KL, Hartsell WF, Kies MS, Mittal B, Rebischung J-L, Coupez DJ, Desphieux J-L, Bobin S, LePajolec C. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer, 385
Taylor SG IV, *see* Ghalie R
Tedeschi L, *see* Sertoli MR
Tefferi A, Witzig TE, Reid JM, Li C-Y, Ames MM. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma, 569
Tegtmeier BR, *see* O'Donnell MR
Tejpar I, *see* Lowsky R
ten Bokkel Huinick WW, *see* Eisenhauer EA
Tepler I, *see* Ayash LJ
Tepper J, *see* Coia L
Terakawa K, *see* Masuda N
Teriana N, *see* Raghavan D
Terol MJ, *see* López-Gu'llermo A
Terry VH, *see* Datta YH
Testolin A, *see* Gasparini G
Tewfik HH, *see* Foote RL
Thall P, *see* Estey E
Thatcher N, *see* Anderson H
The Association Francaise de Chirurgie, *see* Nordlinger B
The Australian and New Zealand Lymphoma Group, *see* Cooper IA
The BGMT Group, *see* Reiffers J
The Central Lymphoma Group, *see* Cullen MH
The Danish Lymphoma Study Group, *see* d'Amore F
The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group, *see* Spaulding MB
The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group, *see* Loehrer PJ Sr
The German Breast Cancer Study Group, *see* Schumacher M
The German Testicular Cancer Cooperative Study Group, *see* Siegert W
The INSS-2 Conferees, *see* Brodeur GM
The International Society of Pediatric Oncology Malignant Mesenchymal Tumor Committee, *see* Rousseau P
The National Cancer Institute of Canada Clinical Trials Group, *see* Cairncross G
The National Research Council Project on Breast Cancer Follow-Up and the GIVIO Investigators, *see* Del Turco MR
The North Central Cancer Treatment Group, *see* Cullinan SA
— *see* Gunderson LL
— *see* Loprinzi CL
The Swiss Group for Clinical Cancer Research, *see* Borner M
Thetter O, *see* Passlick B
Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study, 1408
—, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study, 1748
Thiriaux J, *see* Sculier JP
Thomas D, *see* Bramwell V
Thomas ED, *see* Nesbit ME Jr
Thomas J, *see* Somers R
Thomas MW, *see* Khouri IF
Thomas PRM, *see* Green DM
Thomas X, *see* Archimbaud E
Thomassen MJ, *see* Bukowski RM
Thompson L, *see* Murray JL
Thorling K, *see* d'Amore F
Thornton AF, *see* Urba SG
Thuret I, *see* Michel G
Thürlimann B, *see* Borner M
Thyss A, Saudes L, Otto J, Creisson A, Gaspard MH, Dassonville O, Schneider M. Renal tolerance of cisplatin in patients more than 80 years old, 2121
— *see* Etienne MC
— *see* Milano G
Tiedemann K, *see* White L

Tiemann M, *see* Reiter A
Tien H-F, *see* Cheng A-L
Tilly H, *see* Haioun C
Tkaczuk KH, *see* Jodrell DI
Tobias JS, Spiro SG. Thoracic radiotherapy and chemotherapy for small-cell lung cancer: The discussion continues (letter), 643
— *see* Souhami RL
Tobler A, *see* Stahel RA
Todeschini G, *see* Nadali G
Tombes MB, *see* Bailey HH
Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Sculier JP, Auzannet V, Le Bail N, Bayssas M, Klastersky J. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis, 1458
Tong W, *see* Conti JA
Tong WPY, *see* Tan CTC
Toogood I, *see* White L
Topalian SL, *see* Guleria AS
— *see* Schwartzentruber DJ
— *see* Yang JC
Tormey DC, *see* Bennett JM
Tornos C, *see* Perez-Soler R
Tournade M-F, *see* Pein F
Toussaint C, Izzo J, Spielmann M, Merle S, May-Levin F, Armand JP, Lacombe D, Tursz T, Sunderland M, Chabot GG, Cvitkovic E. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer, 2102
Townsend PW, Rosenthal HG, Smalley SR, Cozad SC, Hassanein RES. Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease, 2345
Transbøl I, *see* Kristensen B
Trask C, *see* Souhami RL
Trask CWL, *see* Miles DW
Treleavan J, *see* Cunningham D
Tribbia G, *see* Bajetta E
Triginelli SA, *see* Murad AM
Trippett T, *see* Tan CTC
Trock B, *see* Halpern AC
Troncy J, *see* Archimbaud E
Troussard X, *see* Michel G
Troxel AB, *see* Bennett JM
Trump DL, *see* Rowinsky EK
Tschetter LK, *see* Cullinan SA
— *see* Jett JR
— *see* Maksymiuk AW
Tsukada H, *see* Masuda N
Tuason L, *see* Bukowski RM
Tubbs R, *see* Bukowski RM
Tubergen DG, Cullen JW, Boyett JM, Gilchrist GS, O'Brien RT, Coccia PF, Waskerwitz MJ. Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: A Childrens Cancer Group study, 273
— *see* Gilchrist GS
Tucker S, *see* Velasquez WS
Turner R, *see* Foss FM
Turpin F, *see* Spielmann M
Tursz T, *see* Le Chevalier T
— *see* Spielmann M
— *see* Toussaint C
Tuthill RJ, *see* Meyskens FL Jr
Tutsch K, *see* Schiller JH
Tutsch KD, *see* Bailey HH
Twito DI, *see* Jett JR
Tyson LB, *see* Kris MG

Unnik JV, *see* Bramwell V
Urba SG, Forastiere AA, Wolf GT, Esclamado RM, McLaughlin PW, Thornton AF. Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma, 946
Uziely B, Formenti SC, Watkins K, Mazumder A, Muggia FM. Calvert's formula and high-dose carboplatin (letter), 1740

Vadhan-Raj S, Kudelka AP, Garrison L, Gano J, Edwards CL, Freedman RS, Kavanagh JJ. Effects of interleukin-1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer, 707
Vadhan-Raj S, Papadopoulos NE, Burgess MA, Linke KA, Patel SR, Hays C, Arcenas A, Plager C, Kudelka AP, Hittelman WN, Broxmeyer HE, Williams DE, Garrison L, Benjamin RS. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma, 715
Vaillant J-C, *see* Nordlinger B
Valasquez WS. In reply (letter), 2766
Valentine A, *see* Meyers CA
Valentino LA, *see* Ghalie R
Valero V, *see* Buzdar AU
Vallejo CT, *see* Romero A
Valteau-Couanet D, *see* Tabone M-D
Valverde JJ, *see* Martín M
Van Belle S, *see* Hulstaert F
Van Besien K, *see* Giralt SA
van Besien KW, *see* Khouri IF
van de Velde CJH, *see* Bunt AMG
— *see* Clahsen PC
van den Belt-Dusebout AW, *see* van Leeuwen FE
van der Burg MEL, *see* Eisenhauer EA
van der Valk P, *see* Linn SC
van der Wilt CL, *see* Peters GJ
van Dongen J, *see* Borger J
van Glabbeke M, *see* Bramwell V
van Groeningen CJ, *see* Linn SC
— *see* Peters GJ
— *see* Pinedo HM
van Heerde P, *see* van Leeuwen FE
van Kalken CK, *see* Linn SC
van Kerkhoff EHM, *see* van Leeuwen FE
van Leeuwen FE, Chorus AMJ, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EHM, Pinedo HM, Somers R. Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating

agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage, 1063
—, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EHM, van Heerde P, Somers R. Second cancer risk following Hodgkin's disease: A 20-year follow-up study, 312
van Putten WLJ, *see* Foekens JA
van Tellingen O, *see* Linn SC
Vannetzel J-M, *see* Taylor SG IV
Vannier JP, *see* Michel G
VanSyckle KM, *see* Tan CTC
van't Veer MB, *see* Lambrechts AC
Variakogis D, *see* Hoffman M
Varini M, *see* Borner M
Vassanelli A, *see* Nadali G
Vats T, *see* Sadowitz PD
Veeder MH, *see* Goldberg RM
— *see* Maksymiuk AW
Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP—An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study, 1169
— *see* Spitzer G
Vena DA, *see* Cheson BD
Veneri D, *see* Nadali G
Venkatraman E, *see* Rusch V
Venner P, *see* Moore MJ
Venook AP. Treatment of hepatocellular carcinoma: Too many options? 1323
Verdonck L, *see* Somers R
Vermorken JB, *see* Eisenhauer EA
Vernant J-P, *see* Sebban C
Vespignani M, *see* Sertoli MR
Viallat JR, *see* Poizot-Martin I
Vicario D, *see* Robbins KT
Vicini F, *see* Nixon AJ
Vikram B. Predictors of response: New versus old? (letter), 1102
Vinante F, *see* Nadali G
Vinante O, *see* Sertoli MR
Vinci RZ, *see* Hochster H
Vinciguerra V, *see* Budman DR
Viner C, *see* Cunningham D
Visser L, *see* Tang SC
Vlamis V, *see* Mencel PJ
Vlock DR, *see* Fisher SG
Vogelsang GB, *see* Kennedy MJ
Vogelzang NJ, Weissman LB, Herndon JE II, Antman KH, Cooper MR, Corson JM, Green MR. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B phase II study, 1436
Vokes E, *see* Taylor SG IV
Vokes EE, Haraf DJ, Mick R, McEvilly J-M, Weichselbaum RR. Intensified concomitant chemotherapy with and without filgrastim for poor-prognosis head and neck cancer, 2351
—, Mick R, Weichselbaum RR. Reporting error corrected (letter), 643
Vose JM, *see* Darrington DL
Voute PA, *see* Rousseau P
Vredenburgh J, *see* Gilbert C
Vriesendorp HM, *see* Giralt SA
— *see* Khouri IF

Wagener C, *see* Gerhard M
Wagener T, *see* Bramwell V
Wainman N, *see* Cairncross G
Walker PR. Actions speak louder than words (letter), 2769
Wallerstadt M, *see* Spitzer TR
Walling J, *see* Anderson H
Walonker F, *see* Mitchell MS
Walsh D, *see* Nelson K
— *see* Nelson KA
Walsh G, *see* Jones AL
Wang C-H, *see* Cheng A-L
Wang H, *see* Miles SA
Wannenmacher M, *see* Haas R
Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC, Eilber FR, Eckardt JJ. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases, 1849
Wargin WA, *see* Rowinsky EK
Warland G, *see* Willett CG
Warnecke RB, *see* Johnson TP
Warr D, *see* Kaizer L
Warren D, *see* Ayash LJ
Warrington RC, *see* Brandes LJ
Waskerwitz MJ, *see* Gilchrist GS
— *see* Tubergen DG
Watanabe K, *see* Kunitoh H
Watkins K, *see* Uziely B
Watling CJ, Lee DH, Macdonald DR, Cairncross JG. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma, 1886
Watts MJ, *see* Jones HM
Weaver CH, Petersen FB, Appelbaum FR, Bensinger WI, Press O, Martin P, Sandmaier B, Deeg HJ, Hansen JA, Brunvand M, Rowley S, Benyunes K, Chauncey T, Fefer A, Hackman R, Gooley T, Schiffman K, Storb R, Sullivan KM, Weiden P, Witherspoon R, Buckner CD. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma, 2559
Weber D, *see* Dimopoulos MA
Weber JS, *see* Guleria AS
— *see* Yang JC
Webster BH, *see* Shaw PJ
Weichselbaum RR, *see* Vokes EE
Weiden P, *see* Weaver CH
Weidmann B, Hänseler T, Jimenez C, Niederle N. Tricuspid endocarditis induced by implantable venous access (letter), 1103
Weidner N, *see* Gasparini G
Weinstein H, *see* Sadowitz PD
Weinthal J, Frost J, Briones G, Cairo M. In reply (letter), 1523
—, Frost JD, Briones G, Cairo MS. Successful *Pneumocystis carinii* pneumonia prophylaxis using aeroso-

lized pentamidine in children with acute leukemia, 136
Weisenburger DD, *see* Darrington DL
Weiss GR, *see* Atkins MB
Weissman LB, *see* Vogelzang NJ
Weitzner M, *see* Meyers CA
Wells RJ, Woods WG, Buckley JD, Odom LF, Benjamin D, Bernstein I, Betcher D, Feig S, Kim T, Ruymann F, Smithson W, Srivastava A, Tannous R, Buckley CM, Whitt JK, Wolff L, Lampkin BC. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A Childrens Cancer Group study, 2367
Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF, Old LJ. Phase I/II study of iodine 131–labeled monoclonal antibody A33 in patients with advanced colon cancer, 1561
—, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, Carswell EA, Cohen A, Larson SM, Old LJ, Rettig WJ. Antibody targeting in metastatic colon cancer: A phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts, 1193
Wender DB, *see* Loprinzi CL
Wernz J, *see* Hochster H
Westelinck KJ, *see* Hulstaert F
Whalen A, *see* Talcott JA
Wheeler C, *see* Ayash LJ
Whelan J, *see* Ornadel D
Whelan JS, *see* Rohatiner AZS
Whelan M, *see* Stone RM
White DE, *see* Guleria AS
— *see* Schwartzentruber DJ
— *see* Yang JC
White DR, *see* Muss HB
White L, McCowage G, Kannourakis G, Nayanar V, Colnan L, Kellie S, Shaw P, Seshadri R, Lockwood L, Tiedemann K, Toogood I. Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: A phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group, 522
White RL, *see* Guleria AS
— *see* Yang JC
Whitt JK, *see* Wells RJ
Wicha M, *see* McCauley DL
Wieand HS, *see* Buroker TR
— *see* Cullinan SA
— *see* Loprinzi CL
Wierzbicki R, *see* Ornadel D
Wiesenfeld M, *see* Maksymiuk AW
Wiesneth M, *see* Hertenstein B
Wilding G, *see* Bailey HH
Willett CG, Warland G, Cheek R, Coen J, Efird J, Shellito PC, Compton CC. Proliferating cell nuclear antigen and mitotic activity in rectal cancer: Predictor of response to preoperative irradiation, 679
Willheim M, *see* Reinisch W
Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: Those transplanted with active CNS disease have a poor outcome—A report by the European Bone Marrow Transplant Lymphoma Registry, 2415
Williams DE, *see* Vadhan-Raj S
Williams MV, *see* Bates NP
Williams R, *see* Loehrer PJ Sr
Williams S, Blessing JA, Liao S-Y, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: A trial of the Gynecologic Oncology Group, 701
Williams SD, *see* Nichols CR
Willis K, *see* Remick SC
Wilson J, *see* Moore MJ
Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J, O'Shaughnessy J, Balis FM, Chabner BA. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion, 1621
Wiltshaw E, *see* Taylor AE
Winer EP, *see* Rowinsky EK
Winick NJ, *see* Mustafa MM
Winkler K, *see* Graf N
Winn HR, *see* Phillips MH
Winograd B, *see* Eisenhauer EA
Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J, Kaye SB. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial, 1771
Wisoff JH, *see* Geyer JR
Witherspoon R, *see* Weaver CH
Witt B, *see* Haas R
Witt TR, *see* Taylor SG IV
Wittes RE, *see* Longo DL
— *see* Wilson WH
Witzig TE, *see* Tefferi A
Wizenberg M, *see* Coia L
Wolf GT, *see* Fisher SG
— *see* Spaulding MB
— *see* Urba SG
Wolf M, *see* Hussain M
Wolf MM, *see* Cooper IA
Wolff L, *see* Wells RJ
Wollner N, *see* Tan CTC
Wolmark N, *see* Johnston PG
Wolter J, *see* Ghalie R
Wong GYC, *see* Livingston PO
Woo D, *see* Nademanee A
Woodroffe C, *see* Cullen MH
Woodruff JM, *see* Pisters PWT
Woods WG, *see* Wells RJ
Woolley KJ, *see* Francis PA
Wrigley PFM, *see* Clark PI
Wronski M, *see* Armstrong JG

Yada I, *see* Shimono T
Yakisan E, *see* Reiter A
Yamamoto M, *see* Kubota K
Yan YX, *see* McIntyre JF
Yana T, *see* Masuda N
Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ,

Weber JS, Ettinghausen SE, White DE, Steinberg SM, Cole DJ, Kim HI, Levin R, Guleria A, MacFarlane MP, White RL, Einhorn JH, Seipp CA, Rosenberg SA. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report, 1572
— *see* Guleria AS
Yannelli JR, *see* Schwartzentruber DJ
Yau J, *see* Giralt SA
— *see* Kaizer L
Yeh C, *see* Buzdar AU
Yeh K-H, Cheng A-L. An alternative method to overcome central venous portable external infusion pump blockage in patients receiving weekly 24-hour high-dose fluorouracil and leucovorin (letter), 875
Yeh S, *see* Kushner BH
Yoffe B, *see* Patt YZ
Yordan E, *see* Thigpen JT
Yoshikawa A, *see* Masuda N
Young BD, *see* Johnson PWM
Young RC, *see* Longo DL
Yuasa H, *see* Shimono T
Yuen AR, Sikic BI. Multidrug resistance in lymphomas, 2453

Zalcberg JR, *see* Raghavan D
Zampino MG, *see* Bajetta E
Zander A, *see* Mross K
Zanotti R, *see* Nadali G
Zaretsky SA, *see* Kris MG
Zee B, *see* Kaizer L
Zelfsky MJ, *see* Rabinovitch RA
Zeltzer PM, *see* Geyer JR
Zeng Z-S, Sarkis AS, Zhang Z-F, Klimstra DS, Charytonowicz E, Guillem JG, Cordon-Cardo C, Cohen AM. p53 nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients, 2043
Zhang H-Z, *see* Perez-Soler R
Zhang Z-F, *see* Schultz PK
— *see* Zeng Z-S
Zilembo N, *see* Bajetta E
Zimmermann M, *see* Reiter A
Zimmermann R, *see* Siegert W
Zincke H, Bergstralh EJ, Blute ML, Myers RP, Barrett DM, Lieber MM, Martin SK, Oesterling JE. Radical prostatectomy for clinically localized prostate cancer: Long-term results of 1,143 patients from a single institution, 2254
Zingsem J, *see* Siegert W
Zipf T, *see* Lockhart S
Zironi S, *see* Cocconi G
Zittoun R, *see* Somers R
Zorsky PE, *see* Fields KK
Zucker J-M, *see* Pein F
Zuhowski EG, *see* Jodrell DI
Zukiwski AA, *see* Murray JL
— *see* Sella A

SUBJECT INDEX

17-1a, in colorectal cancer, 1502
AB89, in B-cell lymphoma, 1499
Absolute lymphocyte count, in chronic lymphocytic leukemia, 1976
ABVD-MOPP regimen, low-dose involved-field radiotherapy plus
late effects of, 2164
in pediatric HD, 2160-2166
toxicity of, 2161-2162
Actinic keratoses, chemoprevention trials and, 865
Adenomatous polyps, chemoprevention trials and, 864
Adenopathy, internal, in hairy cell leukemia, 268-272
Adjuvant chemotherapy
cost-effectiveness of, physician perception of, 1300
cures following, 436
in early-stage breast cancer, 1783-1788
in osteosarcoma, 1842-1848
physician perception of, in breast cancer, 1296-1304
quality-adjusted life-year for, 1298, 1300
recommendation of, reasons for, 1298-1299
in soft tissue sarcoma, 1137-1149
withholding of, reasons for, 1298-1299
Afebrile patient, colony-stimulating factor in, 2472, 2486-2487
Age
in breast cancer follow-up, 881-883
breast cancer mortality and, 2232
in cancer treatment tolerance, 2447-2452
as prognostic factor
in breast conservation therapy, 653-660
in osteosarcoma, 427
young
breast cancer prognosis and, 888-894
breast cancer treatment outcome and, 890-892
primary lung cancer in, 981-985
Albumin, prognostic value of, in multiple myeloma, 118
Alcohol injection, percutaneous intratumoral, in hepatocellular carcinoma, 1328
Alizapride, tropisetron plus
adverse effects of, 2445
in chemotherapy-induced emesis, 2439-2446
Alpha-heavy chain protein, in immunoproliferative small-intestinal disease, 1378-1379
Alpha-tocopherol, in chemoprevention, 856
American Joint Commission on Cancer staging system, for colorectal cancer, 955
American Society of Clinical Oncology
activities of, health care reform and, 2510-2511
breast cancer reports of, impact of, 1789-1795
cancer research and, 2512-2513
founding of, 2510
Presidential Address to, 2510-2513
Amphotericin B
empiric, for neutropenia, 1007
fungal infection and, 827-834
for prophylaxis, and corticosteroid dosing, 829-831
Amsacrine, in combination chemotherapy, for acute myeloid leukemia, 2139

Androgen-deprivation therapy, effects of, on prostate cancer survival, 1868-1875
Anemia, cisplatin-associated, recombinant human erythropoietin treatment in, 1058-1062
Angiogenesis, tumor
  breast cancer and, 441-443
  in node-negative breast cancer, 454-466
Ann Arbor classification, in HD, 794
Anorexia-cachexia syndrome
  animal studies of, 213
  appetite in, 216
  biochemical abnormalities in, 213-218
  body composition in, 217-218
  of cancer, 213-225
  carbohydrate metabolism in, 213-214
  clinical features of, 215-216
  cytokines in, 215
  delta-9-tetrahydrocannabinol in, 220-221
  dexamethasone in, 220-221
  drug selection in, 221
  energy expenditure in, 215
  enteral nutrition in, 218-219
  fat metabolism in, 214-215
  food intake in, 216
  gastrointestinal function in, 216-217
  hormonal abnormalities in, 215
  management of, 218
  megestrol acetate in, 219-221
  metabolic abnormalities in, 213-218
  metoclopramide in, 219
  parenteral nutrition in, 218-219
  protein metabolism in, 214
  psychologic effects in, 216
  unproven drugs in, 219
  unproven treatments in, 218-219
Anti-carcinoembryonic antigen, in colorectal cancer, 1502
Anti-T-activated cell
  antibody, 1499
  in acute leukemia, 1498
Antibiotic(s)
  home intravenous therapy with, in low-risk patients, 107-114
  sequential prophylactic and empiric, for neutropenia, 1005-1011
Anticonvulsants, etoposide clearance and, 2393
Antigen
  free, passive monoclonal antibody therapy and, 1509
  see also specific types
Antigenic modulation, passive monoclonal antibody therapy and, 1509-1510
Antiidiotype monoclonal antibody, in B-cell lymphoma, 1499
Anxiety
  consultation audiotape *v* letter and, 1308
  following BMT, 822-823
Apheresis, single, in mobilization protocol, 1693-1702
Appetite
  in anorexia-cachexia syndrome, 216
  stimulation of, drugs for, 219-221
Ara-C triphosphate, 2221
Aromatase, in estrogen synthesis, 2460-2461
Aromatase cytochrome P-450 enzyme complex, inhibition of, in breast cancer, 2460-2470
Aromatase inhibitor
  classification of, 2461
  early, 2462
  new, 2462-2466
  structural formulae of, 2463
  in vitro preclinical evaluation of, 2461-2462
  in vivo preclinical evaluation of, 2462
Arteriovenous malformation, intracranial, radiosurgery for, 1087
Asparaginase
  cumulative dosing of, in acute lymphocytic leukemia, 1315
  in combination chemotherapy, for non-T, non-B acute lymphocytic leukemia, 1384
  in combined modality therapy, for acute lymphoblastic leukemia, 740-747
Asparaginase, ifosfamide, etoposide, cytarabine regimen, in NHL, 2542-2551
Aspirin, in chemoprevention, 857, 868
Astler-Coller staging system, modified, for colorectal cancer, 954-955
Audiotape, of consultation, for patients, 1305-1311
Autocrine effector, in Sézary syndrome, 326-335
Azacitidine, in maintenance regimen, for myeloid leukemia, 128

Bacille Calmette-Guèrin
  serologic response against, 1040
  in stage III melanoma, 1036-1044
Bacteremia, reduction of, in autologous BMT, 1005-1011
Basal metabolic rate, in anorexia-cachexia syndrome, 215
Bayesian analysis, for cancer risk, 1730
Bayesian priors, in suramin pharmacokinetic model, 169
BCG, *see* Bacille Calmette-Guèrin
Bepridil, vinblastine plus
  cardiac toxicity associated with, 816
  multidrug resistance reversal with, 812-819
  pharmacokinetics of, 813
Beta 2-microglobulin, prognostic value of, in multiple myeloma, 118
Beta-carotene, in chemoprevention, 856-858, 863
Biologic response modifiers, monoclonal antibodies as, 1505-1506
Bladder
  preservation of, in advanced bladder cancer, 975-980
  transurethral resection of, 1394-1395
Bladder cancer
  chemoprevention trials in, 867
  cystoscopic map for, 978
  invasive
    chemotherapy plus cystectomy in, 975-980
    neoadjuvant methotrexate, vinblastine, doxorubicin, cisplatin regimen for, 1394-1401
    survival prognostic factors in, 1399
  methotrexate, vinblastine, doxorubicin, cisplatin regimen in, 975-980
  paclitaxel in, 2264-2270
  superficial
    interferon alfa-2b prophylaxis in, 7-13
    intravesical therapy in, 1-4
    mitomycin in, 7-13
  transurethral resection in, 975-980
  vinblastine, ifosfamide, gallium regimen in, 2271-2276
Blast cell, in CSF, of leukemia in remission, 273-278
Bleeding, platelet count and, 2318-2319
Bleomycin
  in combination chemotherapy

dosing intensity of, 773
dosing schedule of, 771-772
for extragonadal germ cell tumors, 1390-1393
for NHL, 769-778, 1074-1084
for seminoma, 120-126
total dose of, 773
toxicity of, 773-774
in combined modality therapy, for HD, 779-787
continuous infusion
in Kaposi's sarcoma, 1130-1136
survival following, 1133
toxicity of, 1132-1134
in MACOP-B regimen, for NHL, 1366-1374
in MOPP-ABVD regimen, for HD, 279-287
Bleomycin, cisplatin, etoposide regimen
for ovarian germ cell tumor, 701-706
schedule of, 702
Bleomycin, cisplatin, vinblastine, cyclophosphamide, dactinomycin regimen
event-free survival following, 124
response to, 122
for seminoma, 120-126
survival following, 122-123
Bleomycin, ifosfamide, carboplatin regimen
in cervical cancer, 55-59
survival following, 57
toxicity of, 57
Bleomycin, vinblastine, methotrexate regimen
dosing modifications to, 290
pulmonary function following, 297-305
response to, 292
Bleomycin, vinblastine, methotrexate, radiotherapy regimen
compliance with, 291
in early HD, 288-296
hematologic toxicity of, 292
pulmonary toxicity of, 292-293
Blood transfusion, allogeneic, tumor recurrence following, 1859-1867
Body composition, in anorexia-cachexia syndrome, 217-218
Body-cell mass, in anorexia-cachexia syndrome, 217
Bone marrow
breast cancer metastasis to, MRI detection of, 1415-1421
chemoimmunologically purged bone marrow support in, 1006, 1008-1009
immunomagnetic purging of, 749
metastasis to
in stage II-III breast cancer, 1418
in stage III-IV breast cancer, 1419
occult breast cancer cells in, detection of, 478-479
polymerase chain reaction analysis of, 1023-1024
processing, 1360
purged, 1022
tumor cell detection in, 1021-1027
in vitro treatment of, 1179
Bone marrow harvesting, technique for, 250-251
Bone marrow transplantation
allogeneic
in acute lymphoblastic leukemia, 2580-2587
in acute lymphocytic leukemia, 1314-1316
in acute myeloblastic leukemia, 1217-1222
amphotericin B in, 827-834
conditioning regimen in, 1217-1222
etoposide, cyclophosphamide, TBI conditioning regimen for, 1923-1930
leukemic relapse following, 1710-1717
myelodysplastic syndrome following, 2538
systemic fungal infection in, 827-834
technique for, 128
allogeneic *v* autologous, in neuroblastoma, 2382-2389
autologous
in adult acute lymphocytic leukemia, 1316-1317
chemotherapy response and, 1080-1082
complications of, 2417
with cyclophosphamide, TBI regimen, 1177-1184
cyclosporine-induced GVHD following, interferon gamma in, 249-257
disease status at, 1359
G-CSF following, for lymphoma, 1931-1938
high-dose melphalan plus, 759-763
high-dose therapy regimens for, 1359-1360
in lymphoblastic lymphoma, 1358-1365
in metastatic breast cancer, 342-346
mitoxantrone, cyclophosphamide, carmustine, etoposide regimen and, 141-148
myelodysplastic syndrome following, 2535-2542
in NHL, 2415-2422
sequential chemotherapy *v*, in NHL, 2542-2551
t(14;18) studies following, 798-805
therapy regimen prior to, 1359
autologous *v* allogeneic, cardiac toxicity and, 1001-1002
busulfan, cyclophosphamide regimen for, 2138-2145
cardiac evaluation prior to, 1001
cardiac toxicity of, 998-1004
chemoradiotherapy and, myelodysplastic syndrome following, 2527-2534
chemotherapy *v*
in childhood acute myeloid leukemia, 127-135
for consolidation, 2372
in chronic lymphocytic leukemia, 748-758, 1983-1984
ciprofloxacin, rifampin, vancomycin, tobramycin regimen in, 1005-1011
clinical outcome following, 753-754
combination chemotherapy plus, for extragonadal germ cell tumors, 1390-1393
conditioning regimens for, 999
cyclophosphamide, TBI, methotrexate regimen following, 127-135
enriched CD34-positive autologous
in breast cancer, 28-36
treatment schema for, 29
GVHD following, 131
high-dose melphalan plus, in myeloma, 759-763
HLA-identical allogeneic, chemotherapy *v*, 262-267
immune recovery following, 755
late toxicity following, 753
neurobehavioral function following, 820-826
with peripheral-blood progenitor cells, 1007-1008
preparation for, 1023
second, 1711
secondary cancer following, 2187-2192
thiotepa, cisplatin, cyclophosphamide regimen plus, 342-346
toxicity of, 752-753

Bone marrow transplantation, cyclophosphamide, carmustine, etoposide regimen, in NHL, 2542-2551
Bone marrow transplantation, cyclophosphamide, TBI regimen, in lymphoma, 1177-1184
clinical toxicity of, 1179
hematopoietic recovery following, 1179
remission duration following, 1181
survival following, 1180, 1182
Bone marrow transplantation, cyclophosphamide, thiotepa, carboplatin regimen
in breast cancer, 37-44
response to, 41
toxicity of, 40-41
Bone marrow transplantation, cyclophosphamide, total-body irradiation regimen, in follicular NHL, 798-805
Bone marrow transplantation, etoposide, carboplatin regimen, in solid tumors, 2390-2397
Bone marrow transplantation, mitoxantrone, carboplatin, cyclophosphamide regimen
hematologic recovery following, 178
nonhematologic toxicity of, 178-179
in ovarian cancer, 176-183
response to, 180
Bone marrow transplantation, thiotepa, cisplatin, cyclophosphamide regimen
in breast cancer, 342-346
response to, 344
side effects of, 344
Bone marrow transplantation, total-body irradiation, etoposide, cyclophosphamide regimen, in NHL, 2552-2557
Bone metabolism
biochemical measurements of, 994-995
tamoxifen and, 992-997
Bone mineral density
measurements of, 994
tamoxifen and, 992-997
Brachytherapy
adjuvant
in low-grade soft tissue sarcoma, 1150-1155
outcome following, 1152
survival following, 1152
cranial irradiation *v*, 636-637
Brain metastasis, of lung cancer, postoperative radiation for, 2340-2344
Brain tumor
chemotherapy trials of, 2003-2004
corticosteroid-induced MRI changes of, 1886-1889
BRCA1 gene, testing for, attitudes about, 843-850
Breast cancer
adjuvant chemotherapy in, physician perception of, 1296-1304
adjuvant therapy in, clinical trial findings in, 1789-1795
advanced
clinical trial findings in, 1789-1795
continuous infusion vinorelbine in, 2102-2112
cyclosporine-induced GVHD in, 249-257
epirubicin drug resistance in, 1771-1777
epirubicin, quinidine, prednisolone regimen in, 1771-1777
metastatic sites of, 2105
vinorelbine plus doxorubicin in, 1764-1770
angiogenesis and, 441-443
aromatase inhibitors in, 2460-2470
bone marrow metastases of, MRI detection of, 1415-1421
breast conservation therapy in, *see* Breast conservation therapy
breast-conserving therapy *v* mastectomy in, long-term follow-up of, 1778-1782
chronic oral etoposide in, 986-991
circulating cells of, detection of, 478
clinical investigations in, impact of, 1789-1795
contralateral, chemoprevention trials and, 865-866
doxorubicin-refractory, paclitaxel in, 1621-1629
drug resistance in, quinidine for, 1771-1777
early-stage
adjuvant therapy in, 1786-1787
5-FU, doxorubicin, cyclophosphamide regimen in, 1266-1271
enriched CD34-positive autologous BMT in, 28-36
extensive in situ component in, 659
familial, Community Clinical Oncology Program, 1718-1723
genetic testing for, 843-850
Halsted model in, 2229
high-dose chemotherapy plus stem-cell transplantation in, 229-230
incomplete excision of, 659
integrating prognostic variables in, 1422-1426
local relapse in, systemic therapy for, 2071-2077
locally advanced, 5-FU, epirubicin, cisplatin regimen in, 1259-1265
lymph node involvement in, 2232-2233
mastectomy in, radiotherapy following, 444-446
mdr-1 expression in, 1627
metastatic
autologous BMT in, 342-346
double dose-intensive chemotherapy in, 37-44
multiple salvage regimens in, 1639-1647
reinduction in, 45-49
salvage regimens following, 1641
thiotepa, cisplatin, cyclophosphamide, BMT regimen in, 342-346
vinorelbine in, 336-341
mitoxantrone-refractory, paclitaxel in, 1621-1629
mortality in
age and, 2232
following radiotherapy, 447-453
National Cancer Institute Clinical Alert in, effect of, 1783-1788
96-hour paclitaxel infusion in, 1621-1629
node-negative, prognostic factors in, 454-466
node-positive, hormonal *v* chemotherapy in, 2086-2093
occult, polymerase chain reaction detection of, 475-482
passive monoclonal antibody therapy in, 1502
perioperative chemotherapy in, thromboembolic complications following, 1266-1271
postmenopausal low-risk, tamoxifen in, 992-997
practice patterns in, 1783-1788
pretreated advanced, vinorelbine in, 2094-2101
previously treated metastatic, etoposide for, 986-991
prognosis in
cathepsin D and, 467-474
plasminogen activator inhibitor-1 and, 1648-1658
young age and, 888-894
small, natural history of, 2229-2234
stage I-II
follow-up guidelines for, 881-883
psychosocial adjustment following, 1778-1782

stage II-III, bone marrow metastases of, 1418
stage III-IV, bone marrow metastases of, 1419
survival analysis in, 2231-2232
tamoxifen in, 2071-2077
once *v* twice-daily, 50-54
medroxyprogesterone acetate *v*, 1630-1638
time to relapse in, plasminogen activator inhibitor-1 level for, 1648-1658
treatment outcome in, young age and, 890-892
tumor angiogenesis in, 454-466
tumor size in, disease-free survival and, 2233
Breast conservation therapy
adjuvant systemic therapy in, 655
age in, 653-660
extensive in situ component in, 659
histologic subtypes in, 656
local recurrence risk factors following, 647-649
margin involvement in, by risk group, 656
mastectomy *v*, long-term follow-up of, 1778-1782
radiotherapy in, 654-655
local recurrence risk factors following, 647-649
surgery in, 654
vascular invasion in, incidence of, 656
Bronchial carcinogenesis, chemoprevention in, 938
Bronchial metaplasia, chemoprevention trials and, 862-863
Bronchus
dysplasia of, isotretinoin effects on, 941-942
squamous metaplasia of, isotretinoin chemoprevention in, 937-945
Busulfan, in BMT conditioning regimens, 999, 2419
Busulfan, cyclophosphamide regimen
in acute myeloblastic leukemia, 1217-1222
for BMT, in leukemia, 2138-2145
event-free survival following, 1220
GVHD following, 1220
high-dose, and autologous BMT, 1358-1360
relapse following, 1219-1220
TBI *v*, in acute myeloblastic leukemia, 1217-1222
transplant-related mortality following, 1219
Busulfan, etoposide regimen, prior to BMT, 1468-1474

C219, in p-glycoprotein assay, 2454
Cachexia
definition of, 213
in cancer, *see* Anorexia-cachexia syndrome
starvation *v* cancer, characteristics of, 214
Calcium, in chemoprevention, 856, 857, 864
CAMPATH
in acute leukemia, 1498
in B-cell lymphoma, 1499
in chronic leukemia, 1498-1500
Cancer
absolute risk for, 1728
advanced, cures in, 435
Bayesian risk analysis for, 1730
early detection of, 1732
familial, quantitating risk for, 1724-1736
incidence of, chemoprevention and, 868
Mendelian risk for, 1728-1730
metastatic, prognostic variables in, 601-607
predisposition to, selected syndromes of, 1726-1727
Cancer consultation, audiotapes *v* letters of, for patients, 1305-1311
Cancer treatment
adjuvant chemotherapy as, cures following, 436
cell differentiation in, 437
cell proliferation in, 437
cures following, 435
gene therapy as, 437
immunotoxins in, 437
progress in, 432-438
Carbohydrate metabolism, in anorexia-cachexia syndrome, 213-214
Carboplatin
cisplatin *v*
in ovarian cancer, 2066-2070
response to, 2068
in combination chemotherapy
for extragonadal germ cell tumors, 1390-1393
for seminoma, 120-126
etoposide plus
event-free survival following, 124
in relapsed or refractory Wilms' tumor, 931-936
response to, 122
for seminoma, 120-126
survival following, 122-123
toxicity of, 933-935
-induced thrombocytopenia, IL-1 alpha for, 707-714
peripheral-blood progenitor-cell mobilization by, 1012-1020
Carboplatin, bleomycin, ifosfamide regimen
in cervical cancer, 55-59
survival following, 57
toxicity of, 57
Carboplatin, cisplatin regimen
cisplatin *v*, in NSCLC, 353-359
response to, 355
toxicity of, 357
Carboplatin, cyclophosphamide, etoposide, stem-cell transplantation, interferon alfa-2b regimen
in lymphoma, 2423-2431
scheduled administration of, 2425
Carboplatin, cyclophosphamide, thiotepa, BMT regimen
in breast cancer, 37-44
response to, 41
toxicity of, 40-41
Carboplatin, etoposide regimen
antileukemic response to, 1971
continuous infusion, in leukemia, 1969-1973
extramedullary toxicity of, 1970-1971
gastrointestinal tract toxicity of, 1970
hematologic toxicity of, 1971
infections following, 1970
Carboplatin, etoposide, BMT regimen, in solid tumors, 2390-2397
Carboplatin, etoposide, ifosfamide, stem-cell transplantation regimen
dose escalation of, 1226
event-free survival following, 1229
in germ cell cancer, 1223-1231
hematologic toxicity of, 1226-1227
nonhematologic toxicity of, 1227
renal toxicity of, 1227
response to, 1227-1229
toxicity of, 1226
Carboplatin, ifosfamide, etoposide regimen
phase I-II evaluation of, 544-552

response to, 547
toxicity of, 547-548
Carboplatin, ifosfamide, etoposide, GM-CSF regimen
marrow toxicity following, 1256
in NSCLC, 1251-1258
platelet transfusions following, 1255
response to, 1254-1255
scheduling plan for, 1252
toxicity of, 1253-1254
Carboplatin, iproplatin, ifosfamide, epirubicin regimen, for neuroblastoma, in children, 1616-1620
Carboplatin, mitoxantrone, cyclophosphamide, BMT regimen
hematologic recovery following, 178
nonhematologic toxicity of, 178-179
in ovarian cancer, 176-183
response to, 180
Carcinoembryonic antigen
gene, human, schematic of, 726
polymerase chain reaction detection of, 725-729
radiolabeled-monoclonal antibody for, in occult colorectal cancer, 489-495
Carcinogenesis
field, 853-854
multistep, 852-853
premalignant epithelial, biology of, 852-854
Cardiac mortality, following radiotherapy, 451
Cardiotoxicity
of BMT, 998-1004
of vinorelbine plus doxorubicin, 1769
Carmustine
in BMT conditioning regimens, 999, 2419
in combination chemotherapy, for multiple myeloma, 2405-2414
in high-dose combination chemotherapy, and autologous BMT, 1358-1360
in maintenance regimen, for myeloid leukemia, 128
Carmustine, cyclophosphamide, etoposide, BMT regimen, in NHL, 2542-2551
Carmustine, dacarbazine, cisplatin, tamoxifen, IL-2, interferon alfa regimen, studies of, 620-621
Carmustine, dacarbazine, cisplatin, tamoxifen, interferon alfa regimen, studies of, 620
Carmustine, dacarbazine, cyclophosphamide, etoposide, stem-cell transplantation regimen
in lymphoma, 1890-1901
in multiple myeloma, 1890-1901
Carmustine, dexamethasone, etoposide, cytarabine, melphalan regimen
in HD, 580-586
survival following, 581
toxicity of, 583
Carmustine, etoposide, cytarabine, cyclophosphamide regimen, high-dose, and autologous BMT, 1358-1360
Carmustine, etoposide, cytarabine, melphalan regimen, high-dose, and autologous BMT, 1358-1360
Carmustine, mitoxantrone, cyclophosphamide, etoposide regimen, in refractory lymphoma, 141-148
Carmustine, prednisone, vindesine, cyclophosphamide regimen, in multiple myeloma, 2706-2714
Carmustine, vincristine, procarbazine, hydroxyurea, cisplatin, cytarabine, prednisone, cyclophosphamide regimen, for infants, 1607-1615
Cathepsin D
breast cancer prognosis and, 467-474
immunohistochemistry detection of, 470
prognostic significance of, clinical studies of, 473
Western blot measurement of, 467-474
Catheter
Delcath double balloon, 2725
hepatic artery, 2726
CD4 antigen, mortality and, in AIDS-related Kaposi's sarcoma, 1910-1916
CD5 antigen, in leukemia, 1498
CD10 antigen, in acute leukemia, 1498
CD13 antigen, in acute lymphocytic leukemia, 1318
CD14 antigen, in acute lymphocytic leukemia, 1318
CD19 antigen, in B-cell lymphoma, 1499
CD20 antigen, in B-cell lymphoma, 1499
CD23 antigen, soluble, in B-cell chronic lymphocytic leukemia, 2146-2152
CD25 antigen, in acute leukemia, 1498
CD30 antigen
assay for, 794
in childhood large-cell NHL, 895-898
in HD, 793-797
CD33 antigen
in acute leukemia, 1498
in acute lymphocytic leukemia, 1318
CD34 antigen
in acute lymphocytic leukemia, 1318
flow-cytometric analysis of, 1014
Cell-cycle analysis, in topotecan phase I trial, 2195
Cell proliferation, following IL-7, in cutaneous T-cell lymphoma, 328-329
Cervical cancer
metastatic, bleomycin, ifosfamide, carboplatin regimen in, 55-59
squamous cell carcinoma antigen in, 2309-2316
Cervical dysplasia, chemoprevention trials and, 867
CGS 16949A, 2464
CGS 20267, 2464-2465
Charged-particle irradiation, in stereotactic radiosurgery, 1091
Charlson comorbidity index, 2258-2259
Chemoembolization, in hepatocellular carcinoma, 1326
Chemohormonal therapy, in node-positive receptor-positive breast cancer, 2078-2085
Chemoimmunotherapy
of melanoma, 1553-1560
phase II trial of, in melanoma, 1553-1560
Chemoprevention
agents for, 853, 856-859
classification of, 858-859
efficacy of, 859
toxicity of, 859
in bladder trials, 867
in breast trials, 865-866
in cancer, 851-873
central concept in, 938
in cervical trials, 867
in colorectal trials, 864-865
completed trials for, agents in, 857-858
drug development in, 856
in esophageal trials, 866-867
future directions in, 868-869

in gastric trials, 866-867
in head and neck second primary tumors, 861-862
of isotretinoin, in bronchial squamous metaplasia, 937-945
in leukoplakia, 859
in lung cancer-associated second primary tumor, 863-864
in lung trials, 862-864
in oral premalignancy, 859-861
of overall cancer incidence, 868
phase I trials of, 854
phase II trials of, 854
phase III trials of, 855
in skin trials, 865
studies in, end points of, 855-856
study populations in, 856
trial results in, 859
in upper aerodigestive tract trials, 859-862
Chemoradiotherapy
concurrent, colony-stimulating factor in, 2473, 2494-2495
high-dose sequential, for multiple myeloma, 503-509
in neuroblastoma, 2382-2389
in pediatric HD, 2160-2166
sequential *v* concomitant, in head and neck cancer, 385-395
in stage IIIA HD, 2567-2572
stem-cell transplantation and, myelodysplastic syndrome following, 2527-2534
with G-CSF, in head and neck cancer, 2351-2359
Chemotherapy
adjuvant, *see* Adjuvant chemotherapy
allogeneic BMT *v*, in leukemia, 262-267
alternating radiotherapy with
acute toxicity of, 1878-1879
in head and neck cancer, 1876-1885
late toxicity following, 1880-1881
organ preservation following, 1881
recurrence following, 1879-1880
response to, 1879
surgery following, 1881
survival following, 1880
BMT *v*
for consolidation, 2372
in childhood acute myeloid leukemia, 127-135
combination, *see* Combination chemotherapy
conditioning regimen
in active CNS disease, 2419
for BMT, cardiotoxicity and, 998-1001
craniospinal irradiation following, for infant medulloblastoma, 1212-1216
curative, definition of, 2476
cystectomy plus, for invasive bladder cancer, 975-980
dose maintenance in, definition of, 2476
dose modification in, definition of, 2476
dose-intensity of
colony-stimulating factor for, 2472, 2488-2489
definition of, 2476
double dose-intensive, in metastatic breast cancer, 37-44
eight-in-1 day, for infants, 1607-1615
elderly patient tolerance of, 2447-2452
episodes of, leukemia risk and, 1063-1073
for hepatocellular carcinoma, 1325-1326
high-dose
antibiotic protocol following, 1006-1007
current status of, 5-6
hematopoietic recovery following, 664
infectious episodes following, 664-665
supportive care following, 663
high-dose melphalan, BMT regimen following, in myeloma, 759-763
infusional, in advanced breast cancer, 1259-1265
intensive induction, radiation following, in head and neck cancer, 946-953
intensive regimens of, graft-*v*-host disease and, 828
intraarterial, for hepatocellular carcinoma, 1326-1328
intrapleural
complications following, 1159
for malignant pleural mesothelioma, 1156-1163
pleurectomy-decortication plus, 1156-1163
relapse sites following, 1159
survival following, 1160
leukemia risk following, 1066-1068
multiple-cycle high-dose, carboplatin-mobilized peripheral-blood progenitor cells following, 1012-1020
neoadjuvant, for invasive bladder cancer, 1394-1401
palliative, definition of, 2476
palliative *v* curative-intent, 2477
primary response to, as prognostic factor, 1074-1084
response to, autologous BMT and, 1080-1082
short-pulse, for childhood Ki-1 anaplastic large-cell NHL, 899-908
standard regimens of, myelotoxicity of, 2477
standard-dose, definition of, 2476
stem-cell transplantation plus, 1993 Consensus Conference on, 226-231
total dose *v* dose-intensity of, 2333-2339
weekly, G-CSF plus, in SCLC, 77-82
weekly *v* 3-week
nonhematologic toxicity of, 1811
relapse site following, 1811-1812
response to, 1808
in SCLC, 1806-1813
survival following, 1809
toxicity of, 1810-1811
Child(ren)
colony-stimulating factor in, 2473, 2495-2496, 2497
continuous infusion topotecan in, 1946-1954
oral etoposide in, phase I trial of, 1452-1457
oral mucositis in, GM-CSF impact on, 1917-1922
sequential methotrexate, thioguanine regimen in, 1955-1962
synovial sarcoma in, 2360-2366
Chlorambucil
2-chlorodeoxyadenosine plus, phase I trial of, 569-574
in chronic lymphocytic leukemia, 1978
Chlorambucil, vincristine, procarbazine, prednisone-prednisolone, doxorubicin, bleomycin, vinblastine, etoposide, radiotherapy regimen
diagrammatic representation of, 781
dosing modifications in, 781
in HD, 779-787
response to, 781-782
survival following, 782-784
toxicity of, 784
Chlorhexidine mouthwash
for radiation-induced mucositis, 2630-2633

toxicity of, 2632
2-Chlorodeoxyadenosine
chlorambucil plus, phase I trial of, 569-574
in chronic lymphocytic leukemia, 1979-1980
in indolent NHL, 788-792
for macroglobulinemia, 2694-2698
nonhematologic toxicity of, 791
opportunistic infections following, 789-791
response to, 789
survival following, 2696-2697
toxicity of, 789, 2695-2696
see also Cladribine
CHOP, *see* Cyclophosphamide, doxorubicin, vincristine, prednisolone regimen
Ciprofloxacin, rifampin, vancomycin, tobramycin regimen
BMT and, 1005-1011
toxicity of, 1009
13-*cis*-retinoic acid
cellular differentiation induced by, in peripheral T-cell lymphoma, 1190
DNA internucleosomal fragmentation due to, 1191
for peripheral T-cell lymphoma, 1185-1192
Cisplatin
anemia associated with, recombinant human erythropoietin treatment for, 1058-1062
carboplatin *v*
in ovarian cancer, 2066-2070
response to, 2068
cisplatin, carboplatin regimen *v*, in NSCLC, 353-359
in combination chemotherapy
for extragonadal germ cell tumors, 1390-1393
for ovarian germ cell tumors, 378-384
for SCLC, 80-81
for seminoma, 120-126
daily low-dose, in NSCLC, 1814-1820
etoposide plus
dosing of, 2026
event-free survival following, 124
hematologic toxicities of, 2029
nonhematologic toxicities of, 2030
response to, 122, 2026-2027
in SCLC, 2022-2034
for seminoma, 120-126
survival following, 122-123, 2027-2028
toxicities of, 2028
high-dose, dolasetron mesylate following, 1045-1049
high-dose continuous infusion, in combination chemotherapy, 946-953
intraperitoneal, in advanced gastric cancer, 970-974
intrapleural, mitomycin plus, for malignant pleural mesothelioma, 1156-1163
nephrotoxicity associated with, 160
radiotherapy plus
in NSCLC, 1814-1820
randomized trials of, 1819
survival following, 1818
toxicity of, 1817
renal tolerance of, in elderly patients, 2121-2125
response to, 355
single-agent studies with, 2275
supradose infusion of
hematologic toxicity of, 2116
in head and neck cancer, 2113-2120
response to, 2114
survival following, 2114-2115
technical complications of, 2116
toxicity of, 2115-2116
tamoxifen synergy with, 622-623
topotecan plus
dosing of, 2744
phase I trial of, 2743-2750
toxicity of, 2747
toxicity of, 357
Cisplatin, carboplatin regimen
cisplatin *v*, in NSCLC, 353-359
response to, 355
toxicity of, 357
Cisplatin, cyclophosphamide, doxorubicin regimen
dose intensity of, 2338
in drug delivery analysis, 2333-2339
in NSCLC, 2333-2339
survival following, 2335
Cisplatin, cyclophosphamide, doxorubicin, vincristine, etoposide regimen, for neuroblastoma, 2607-2613
Cisplatin, dacarbazine, carmustine, tamoxifen, IL-2, interferon alfa regimen, studies of, 620-621
Cisplatin, dacarbazine, carmustine, tamoxifen, interferon alfa regimen, studies of, 620
Cisplatin, dacarbazine, IL-2, tamoxifen regimen, studies of, 622
Cisplatin, dacarbazine, tamoxifen regimen, studies of, 621
Cisplatin, dacarbazine, tamoxifen, IL-2 regimen
in melanoma, 1553-1560
response to, 1558
survival following, 1557
toxicity of, 1556-1557
Cisplatin, doxorubicin, cyclophosphamide regimen
for thymoma, 1164-1168
response to, 1166
survival following, 1167
toxicity of, 1165-1166
Cisplatin, doxorubicin, G-CSF regimen
neutrophil toxicity of, 1846
in osteosarcoma, 1842-1848
surgery following, 1846
toxicity of, 1844-1845
Cisplatin, epirubicin, 5-FU, folinic acid regimen
in gastric cancer, 2687-2693
response to, 2689-2690
toxicity of, 2688-2689
Cisplatin, etoposide regimen
scheduling of, 71-72
in SCLC, 70-76
toxicity of, 73-74
Cisplatin, etoposide, bleomycin regimen
for ovarian germ cell tumor, 701-706
schedule of, 702
Cisplatin, etoposide, ifosfamide, doxorubicin regimen, G-CSF plus
dose-intensity of, 79-80
in SCLC, 77-82
Cisplatin, etoposide, methylprednisolone, cytarabine regimen
adverse prognostic factors in, 1173
in refractory lymphoma, 1169-1176

response to, 1171
scheduling of, 1170
survival following, 1173
toxicity of, 1173-1174
Cisplatin, floxuridine, folinic acid, doxorubicin regimen
hepatic arterial infusion of, 1204-1211
hepatitis and, 1204-1211
in hepatocellular cancer, 1204-1211
toxicity of, 1209
Cisplatin, 5-FU, epirubicin regimen, continuous infusion
in breast cancer, 1259-1265
dosing of, 1263
hematologic toxicity of, 1262
nonhematologic toxicity of, 1262-1263
response to, 1261-1262
Cisplatin, 5-FU, mitoguazone regimen
in head and neck cancer, 946-953
response to, 949
toxicity of, 948
Cisplatin, 5-FU, radiotherapy regimen
death following, 392
in head and neck cancer, 385-395
histologic response to, 1594
in laryngeal cancer, 1592-1599
response to, 388-389, 1594-1595
survival following, 1595
toxicity of, 389-390, 1593-1594
Cisplatin, hydroxyurea, 5-FU, radiotherapy regimen, with G-CSF
acute toxicities of, 2354
cumulative toxicities of, 2355
dose-intensity of, 2355
for head and neck cancer, 2351-2359
response to, 2356
treatment regimen for, 2353
Cisplatin, irinotecan, G-CSF regimen
dose-escalation schedule of, 91
in NSCLC, 90-96
toxicity of, 92-94
Cisplatin, methotrexate, vinblastine, doxorubicin, G-CSF regimen
dose intensity of, 485-486
in urothelial cancer, 483-488
response to, 486
toxicity of, 485
Cisplatin, methotrexate, vinblastine, doxorubicin, regimen, in bladder cancer, 975-980
Cisplatin, thiotepa, cyclophosphamide, BMT regimen
in breast cancer, 342-346
response to, 344
side effects of, 344
Cisplatin, vinblastine, hydrazine sulfate regimen
in NSCLC, 1113-1120
response to, 1116
serum albumin level changes following, 1117
toxicity of, 1116
Cisplatin, vincristine, carmustine, procarbazine, hydroxyurea, cytarabine, prednisone, cyclophosphamide regimen, for infants, 1607-1615
Cisplatin, vindesine regimen
dose-intensity of, 2338
in drug delivery analysis, 2333-2339
in NSCLC, 360-367, 2333-2339
response to, 363
survival following, 363-364, 2335
toxicity of, 364
Cisplatin, vinorelbine regimen
in NSCLC, 360-367
response to, 363
survival following, 363-364
toxicity of, 364
Cisplatin, vinblastine, bleomycin, cyclophosphamide, dactinomycin regimen
event-free survival following, 124
response to, 122
for seminoma, 120-126
survival following, 122-123
Cisplatin. methotrexate, vinblastine, doxorubicin regimen, in bladder cancer, 1394-1401
Cladribine
high-dose, 2218
neurotoxicity of, 2216-2228
overview of, 2216-2219
standard-dose, 2219
structure of, 2217
see also 2-Chlorodeoxyadenosine
Clinical Alert
in early-stage breast cancer, 1783
of National Cancer Institute, effect of, 1783-1788
results of, 1784-1786
Clinical practice guidelines
for colony-stimulating factor, 2471-2508
colony-stimulating factors studied for, 2475-2476
conflicts of interest and, 2475
consensus development for, 2475
data collection for, 2474-2475
evidence for, grading of, 2475
literature review for, 2474-2475
outcomes assessed for, 2476-2477
panel composition for, 2474
process overview for, 2474
revisions to, 2475
term definitions for, 2476
Clinical trial(s)
in advanced breast cancer, findings in, 1789-1795
in breast cancer, impact of, 1789-1795
Community Clinical Oncology Program and, 1718-1723
definitive end points in, 855
intermediate end points in, 855-856
participating physicians in
patient accrual following, 1797-1798
profile of, 1800-1801
participation in
perceived benefits of, 1797, 1802
perceived drawbacks of, 1797, 1802
patient enrollment in, physician approach to, 1797, 1803
phase III, initiation of, 1794
randomized, dilemmas of, 1796-1805
Clonazepam, 2143
Clonidine, transdermal
efficacy of, in hot flash amelioration, 156-157
for tamoxifen-induced hot flash, 155-158
toxicity of, 157
CNS, active disease of

BMT and, 2415-2422
conditioning regimens for, 2419
Codon 175, mutation at, 928
Codon 209, mutation at, 928
Cognition
following BMT, 821-822
correlation of, and mood, 823-824
Colon cancer, *see* Colorectal cancer
Colony-forming assay, in topotecan phase I trial, 2195, 2198
Colony-forming unit granulocyte-macrophage
assay for, 663
clonogenic asssays for, 1022-1023
following high-dose chemotherapy, 661
Colony-stimulating factor
in acute myeloid leukemia, 2473, 2492-2494
as adjunct, to progenitor-cell transplantation, 2472-2473, 2489-2492
in afebrile patients, 2472, 2486-2487
administration duration of, 2473, 2498-2500
alternatives to, 2477
with chemoradiotherapy, for head and neck cancer, 2351-2359
in chemotherapy dose-intensity, 2472, 2488-2489
in children, 2473, 2495-2496, 2497
clinical guidelines for, 2471-2508
in concurrent chemoradiotherapy, 2473, 2494-2495
cost of, 2480
definition of, 2476
dosing of, 2473, 2496-2498
FDA approval of, 2474
in febrile patients, 2472, 2486-2487
G-CSF *v* GM-CSF type of, 2473, 2500
granulocyte, *see* Granulocyte colony-stimulating factor
granulocyte-macrophage, *see* Granulocyte-macrophage colony-stimulating factor
macrophage, *see* Macrophage colony-stimulating factor
in myelodysplastic syndromes, 2473, 2492-2494
pricing of, 2480
primary administration guidelines for, 2472, 2480-2484
primary adminstration of, definition of, 2476
secondary administration guidelines for, 2472, 2485-2486
secondary adminstration of, definition of, 2476
summary guidelines for, 2472-2473
toxicity comparisons among, 2479-2480
under development, in United States, 2476
Colorectal cancer
advanced
5-FU plus folinic acid in, 14-20
5-FU plus methotrexate *v* 5-FU in, 960-969
hydrazine sulfate in, 1121-1125
meta-analysis project in, 960-969
radiolabeled monoclonal antibody A33 in, 1561-1571
American Joint Commission on Cancer staging system for, 955
detection of, radiolabeled monoclonal antibody F19 for, 1197
Dukes' C, p53 in, 2043-2050
fibroblast activation protein in, 1193-1203
5-FU plus folinic acid in, 2035-2042
hepatic metastases of
floxuridine, folinic acid, dexamethasone regimen for, 2288-2295
repeat liver resections for, 1491-1496
lymph node-positive, p53 in, 2043-2050
metastatic
immunohistochemical analysis in, 1196, 1201
monoclonal antibody targeting in, 1193-1203
uracil, tegafur, folinic acid regimen for, 2296-2300
micrometastasis detection in, 725-729
modified Astler-Coller staging system for, 954-955
occult, radiolabeled IMMU-4 scintigraphy in, 489-495
passive monoclonal antibody therapy in, 1502-1504
radioimmunotherapy of, 1561-1571
radiolabeled monoclonal antibody F19 in, SPECT imaging of, 1195-1196, 1199
reactive stromal fibroblasts in, 1193-1203
recurrence in
following allogeneic blood transfusion, 1859-1867
risks for, 1864
staging systems for, 955
surgical procedures in, 956
survival in, p53 and, 2043-2050
trimetrexate, 5-FU, folinic acid regimen in, 695-700
tumor-node-metastasis staging system of, 955
vinblastine plus bepridil in, for multidrug resistance reversal, 812-819
Combination chemotherapy
for advanced prostate cancer, 2001-2002
for intravascular lymphomatosis, 2573-2579
neutropenic fever following, G-CSF for, 1245-1250
toxicities associated with, 2478
Combined modality therapy
in bladder cancer, 975-980
in head and neck cancer, 385-395
radiotherapy in, for stage III NSCLC, 1547-1552
in stage IIIA HD, 2567-2572
Common acute lymphoblastic leukemia antigen, 1498
Communication, physician-patient, audiotapes *v* letters for, 1305-1311
Community Clinical Oncology Program, 1718-1723
Composite Mucositis Score, 1918
grading criteria for, 1919
Computed tomography
for internal adenopathy, in hairy cell leukemia, 268-272
gallium scan *v*, in HD restaging, 309
of radiolabeled monoclonal antibody F19, 1195-1196, 1199
Consent form, oncology, readability of, 2211-2215
Consultation, audiotapes *v* letters of, for patients, 1305-1311
Convergent beam irradiation technique
stereotactic radiosurgery, 1085-1099
stereotactic radiotherapy, 1085
Corticosteroid(s)
in chronic lymphocytic leukemia, 1978
dosing of, and amphotericin prophylaxis, 829-831
-induced MRI changes, of glioma, 1886-1889
Cost
of G-CSF, for neutropenic fever, 1245-1250
oncologist perception of, 1298
Cost-effectiveness, of adjuvant chemotherapy, physician perception of, 1300
Cranial irradiation
brachytherapy *v*, 636
combination chemotherapy plus, in acute lymphoblastic leukemia, 740-747
complications following, frequency of, 628

injury following, treatment of, 628-631
methotrexate plus, in childhood cancer, 2621-2629
neurobehavioral sequelae of, 627-642
prophylactic
in SCLC, 2327-2332
neurotoxicity following, 632-633
survival following, 2330
radiosurgery *v*, 636-637
therapeutic
alternatives to, 636-637
neurotoxicity following, 629-631, 634-635
Craniospinal irradiation, for infant medulloblastoma, 1212-1216
Cross-linking assay, 327
Cryosurgery, for hepatocellular carcinoma, 1325
CSF
blast cells in
at acute lymphoblastic leukemia diagnosis, 2594-2600
of leukemia in remission, 273-278
occult breast cancer cells in, detection of, 479
Cutaneous marker, multiple atypical nevi as, in germ cell tumors, 2284-2287
Cyclophosphamide
in chemoradiotherapy regimen, for multiple myeloma, 503-509
in chronic lymphocytic leukemia, 1978
in combination chemotherapy
dosing intensity of, 773
dosing schedule of, 771-772
for multiple myeloma, 2405-2414
for NHL, 1074-1084, 769-778
for seminoma, 120-126
total dose of, 773
toxicity of, 773-774
in conditioning regimen, 2419
cumulative dosing of, in acute lymphocytic leukemia, 1315
divided-dose escalating, for pediatric tumors, 522-531
doxorubicin and, in combination chemotherapy, for lymphoma, 1349-1357
G-CSF following, in peripheral-blood progenitor-cell transplantation, 1693-1702
in high-dose combination chemotherapy, and autologous BMT, 1358-1360
leukemia risk following, 1063-1073
in MACOP-B regimen, for NHL, 1366-1374
in maintenance regimen, for myeloid leukemia, 128
N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl plus, 1285
in ProMACE-MOPP regimen, for NHL, 1366-1374
Cyclophosphamide, busulfan regimen
in acute myeloblastic leukemia, 1217-1222
for BMT, in leukemia, 2138-2145
event-free survival following, 1220
GVHD following, 1220
high-dose, and autologous BMT, 1358-1360
relapse following, 1219-1220
TBI *v*, in acute myeloblastic leukemia, 1217-1222
transplant-related mortality following, 1219
Cyclophosphamide, carboplatin, etoposide, stem-cell transplantation, interferon alfa-2b regimen
in lymphoma, 2423-2431
scheduled administration of, 2425
Cyclophosphamide, carmustine, etoposide, BMT regimen, 1358-1360
in NHL, 2542-2551
Cyclophosphamide, cisplatin, doxorubicin regimen
response to, 1166
survival following, 1167
for thymoma, 1164-1168
toxicity of, 1165-1166
Cyclophosphamide, cisplatin, vinblastine, bleomycin, dactinomycin regimen
event-free survival following, 124
response to, 122
for seminoma, 120-126
survival following, 122-123
Cyclophosphamide, dacarbazine, carmustine, etoposide, stem-cell transplantation regimen
in lymphoma, 1890-1901
in multiple myeloma, 1890-1901
Cyclophosphamide, doxorubicin regimen, in endometrial cancer
doxorubicin *v*, 1408-1414
response to, 1411
survival following, 1412
Cyclophosphamide, doxorubicin, cisplatin regimen
dose intensity of, 2338
in drug delivery analysis, 2333-2339
in NSCLC, 2333-2339
survival following, 2335
Cyclophosphamide, doxorubicin, dacarbazine regimen, PIXY321 plus
in sarcoma, 715-724
study design of, 716-717
Cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate, in NHL, 1074-1084
Cyclophosphamide, doxorubicin, etoposide, methotrexate, folinic acid, prednisone regimen, in non-Burkitt's lymphoma, 2153-2159
Cyclophosphamide, doxorubicin, vincristine, cisplatin, etoposide regimen, for neuroblastoma, 2607-2613
Cyclophosphamide, doxorubicin, vincristine, prednisolone regimen
dosing schedule of, 771-772
hospital admissions following, 774
MACOP-B *v*, in NHL, 769-778
in primary small-intestinal lymphoma, 1375-1382
response to, 772
survival following, 773
toxicity of, 773-774
Cyclophosphamide, doxorubicin, vincristine, prednisone regimen
impact of, on S-phase fraction, 2167-2175
in NHL, 1074-1084
Cyclophosphamide, epirubicin, 5-FU regimen, failure of, salvage therapy following, 1639-1647
Cyclophosphamide, etoposide regimen
mucositis following, 1920
scheduling of, 1918
Cyclophosphamide, etoposide, TBI regimen
for allogeneic BMT conditioning, 1923-1930
toxicity of, 1924-1925
Cyclophosphamide, 5-FU, doxorubicin regimen
in breast cancer, 1266-1271
thromboembolic complications following, 1266-1271
Cyclophosphamide, methotrexate, 5-FU regimen
compliance with, 2088
in node-positive breast cancer, 2086-2093
short-term toxicity of, 2091

Cyclophosphamide, methotrexate, 5-FU, tamoxifen regimen, in node-positive breast cancer, 2086-2093
Cyclophosphamide, methotrexate, 5-FU, vincristine, prednisone regimen
in breast cancer, 2078-2085
second primary tumor following, 2080-2081
survival following, 2080
tamoxifen concurrent with, 2078-2085
second primary tumor following, 2080-2081
survival following, 2080
toxicity of, 2081-2083
Cyclophosphamide, mitoxantrone, carboplatin, BMT regimen
hematologic recovery following, 178
nonhematologic toxicity of, 178-179
in ovarian cancer, 176-183
response to, 180
Cyclophosphamide, mitoxantrone, carmustine, etoposide regimen, in refractory lymphoma, 141-148
Cyclophosphamide, prednisone, vindesine, carmustine regimen, in multiple myeloma, 2706-2714
Cyclophosphamide, TBI, BMT regimen, 1358-1360
clinical toxicity of, 1179
hematopoietic recovery following, 1179
in lymphoma, 1177-1184
remission duration following, 1181
survival following, 1180, 1182
Cyclophosphamide, TBI, methotrexate regimen, BMT following, 127-135
Cyclophosphamide, thiotepa, carboplatin, BMT regimen
in breast cancer, 37-44
response to, 41
toxicity of, 40-41
Cyclophosphamide, thiotepa, cisplatin, BMT regimen
in breast cancer, 342-346
response to, 344
side effects of, 344
Cyclophosphamide, TBI, BMT regimen, in follicular NHL, 798-805
Cyclophosphamide, TBI, etoposide, BMT regimen, in NHL, 2552-2557
Cyclophosphamide, vincristine, carmustine, procarbazine, hydroxyurea, cisplatin, cytarabine, prednisone regimen, for infants, 1607-1615
Cyclophosphamide, vincristine, dactinomycin, doxorubicin regimen
in clear-cell renal sarcoma, 2132-2137
relapse sites following, 2135
in Wilms' tumor, 2126-2131
Cyclophosphamide, vincristine, doxorubicin, dacarbazine regimen
compliance with, 1142
mortality following, 1145
nonhematologic toxicity of, 1142
outcome following, 1141-1145
second malignancies following, 1145
in soft tissue sarcoma, 1137-1149
survival following, 1144
Cyclophosphamide, vincristine, doxorubicin, methylprednisolone regimen
extramedullary toxicity of, 762
in myeloma, 759-763
response to, 761
survival following, 761
toxicity of, 761-762
Cyclophosphamide, vincristine, etoposide regimen
for pediatric tumors, 522-531
toxicity of, 525-526
Cyclophosphamide, vincristine, prednisone regimen, impact of, on S-phase fraction, 2167-2175
Cyclophosphamide, vincristine, prednisone, radiotherapy regimen, impact of, on S-phase fraction, 2167-2175
Cyclosporine
administration of, and GVHD, 251
with doxorubicin
hematologic toxicity of, 837
nonhematologic toxicity of, 838
pharmacodynamics of, 836-837
pharmacokinetics of, 836-837
phase I trial of, 835-842
in drug resistance modulation, 1584-1591
GVHD induced by, interferon gamma in, 249-257
for multidrug resistance, 835-842
Cyclosporine, doxorubicin, vincristine, dexamethasone regimen
clinical response to, 1586
in mutiple myeloma, 1584-1591
Cystectomy
following combination chemotherapy, for invasive bladder cancer, 975-980
for invasive bladder cancer, 1397
map in, 978
Cytarabine
in BMT conditioning regimens, 999, 2419
in combination chemotherapy
for acute myeloid leukemia, 2139
for NHL, 1074-1084
for non-T, non-B acute lymphocytic leukemia, 1384
in combined modality therapy, for acute lymphoblastic leukemia, 740-747
cumulative dosing of, in acute lymphocytic leukemia, 1315
in high-dose combination chemotherapy, and autologous BMT, 1358-1360
in maintenance regimen, for myeloid leukemia, 128
mercaptopurine plus
administration of, 588
in relapsed acute leukemia, 587-595
toxic effects of, 590
teniposide plus
as intensification therapy, 1963-1968
in NHL, 1963-1968
Cytarabine, dexamethasone, carmustine, etoposide, melphalan regimen
in HD, 580-586
survival following, 581
toxicity of, 583
Cytarabine, etoposide, methylprednisolone, cisplatin regimen
adverse prognostic factors in, 1173
prognostic factors in, 1173
in refractory lymphoma, 1169-1176
response to, 1171
scheduling of, 1170
survival following, 1173
toxicity of, 1173-1174
Cytarabine, etoposide, thioguanine, dexamethasone, daunorubicin regimen, in acute myeloid leukemia, 2367-2377
Cytarabine, fludarabine, G-CSF regimen

in acute myelogenous leukemia, 671-678
complete remission following, 673
infection risk following, 677
in myelodysplastic syndromes, 671-678
survival probability following, 674
Cytarabine, ifosfamide, etoposide, asparaginase regimen, in NHL, 2542-2551
Cytarabine, methotrexate regimen
for acute lymphoblastic leukemia, 1939-1945
scheduling of, 1940
toxicity profile of, 1942
Cytarabine, mitoxantrone, peripheral-blood progenitor-cell support regimen, in NHL, 1685-1692
Cytarabine, vincristine, carmustine, procarbazine, hydroxyurea, cisplatin, prednisone, cyclophosphamide regimen, for infants, 1607-1615
Cytogenetics, in peripheral T-cell lymphoma, 1189
Cytokine(s)
in anorexia-cachexia syndrome, 215
in cutaneous T-cell lymphoma proliferation, 329
production of, by peripheral-blood monocytes, 103
Cytopenia
autoimmune, 1981
hypersplenic, 1981-1982
in chronic lymphocytic leukemia, 1981-1982
Cytotoxicity
antibody-dependent cell-mediated, 1497
complement-mediated, 1497

Dacarbazine
in malignant melanoma, 806-811
in MOPP-ABVD regimen, for HD, 279-287
side effects of, 809-810
tamoxifen synergy with, 623-624
Dacarbazine, carmustine, cisplatin, tamoxifen, interferon alfa regimen, studies of, 620
Dacarbazine, carmustine, cisplatin, tamoxifen, interleukin-2, interferon alfa regimen, studies of, 620-621
Dacarbazine, cisplatin, IL-2, tamoxifen regimen, studies of, 622
Dacarbazine, cisplatin, tamoxifen regimen, studies of, 621
Dacarbazine, cisplatin, tamoxifen, IL-2 regimen
in melanoma, 1553-1560
response to, 1558
survival following, 1557
toxicity of, 1556-1557
Dacarbazine, cyclophosphamide, carmustine, etoposide, stem-cell transplantation regimen
hematologic toxicity of, 1893
hemorrhage following, 1893
hypocalcemia following, 1894-1895
hypotension following, 1893-1895
infection following, 1893
in lymphoma, 1890-1901
metabolic toxicity following, 1893-1895
mortality associated with, 1896
in multiple myeloma, 1890-1901
nonhematologic toxicity following, 1895-1896
Dacarbazine, cyclophosphamide, doxorubicin, regimen, PIXY321 plus
in sarcoma, 715-724
study design of, 716-717
Dacarbazine, cyclophosphamide, vincristine, doxorubicin regimen
compliance with, 1142
mortality following, 1145
nonhematologic toxicity of, 1142
outcome following, 1141-1145
second malignancies following, 1145
in soft tissue sarcoma, 1137-1149
survival following, 1144
Dacarbazine, tamoxifen regimen, studies of, 621-622
Dactinomycin, in combination chemotherapy, for clear-cell sarcoma, 2134
in combination chemotherapy, for seminoma, 120-126
Dactinomycin, cisplatin, vinblastine, bleomycin, cyclophosphamide regimen
event-free survival following, 124
for seminoma, 120-126
response to, 122
survival following, 122-123
Dactinomycin, ifosfamide, vincristine regimen
in orbital rhabdomyosarcoma, 516-521
response to, 518
tolerance to, 519
Dactinomycin, vincristine, doxorubicin regimen, in Wilms' tumor, 2126-2131
Dactinomycin, vincristine, doxorubicin, cyclophosphamide regimen
in clear-cell renal sarcoma, 2132-2137
relapse sites following, 2135
in Wilms' tumor, 2126-2131
Daunorubicin
in combination chemotherapy
for acute myeloid leukemia, 2139
for non-T, non-B acute lymphocytic leukemia, 1384
cumulative dosing of, in acute lymphocytic leukemia, 1315
N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl plus, 1285
Daunorubicin, etoposide, thioguanine, dexamethasone, cytarabine regimen, in acute myeloid leukemia, 2367-2377
Delcath double balloon catheter, 2725
Delta-9-tetrahydrocannabinol, in anorexia-cachexia syndrome, 220-221
Dementia Rating Scale, 821
2′-Deoxycoformycin
in chronic lymphocytic leukemia, 1979-1980
see also Pentostatin
Depression
consultation audiotape *v* letter and, 1308
following BMT, 822-823
Dermatosis, transient acantholytic, in cancer, 1703-1709
Dexamethasone
in anorexia-cachexia syndrome, 220-221
in combination chemotherapy
for multiple myeloma, 2405-2414
for NHL, 1074-1084
ondansetron plus, 1050-1057
antiemetic efficacy of, 598
in cisplatin-induced emesis, 596-600
safety of, 599
tropisetron plus
adverse effects of, 2445
in chemotherapy-induced emesis, 2439-2446
Dexamethasone, carmustine, etoposide, cytarabine, melphalan regimen

in HD, 580-586
survival following, 581
toxicity of, 583
Dexamethasone, doxorubicin, vincristine, cyclosporine regimen
clinical response to, 1586
in mutiple myeloma, 1584-1591
Dexamethasone, etoposide, thioguanine, daunorubicin, cytarabine regimen, in acute myeloid leukemia, 2367-2377
Dexamethasone, floxuridine, folinic acid regimen
bilirubin elevation following, 2292
for hepatic metastases, 2288-2295
Dexamethasone, fludarabine, mitoxantrone regimen
dose escalation of, 576
in lymphoma, 575-579
nonhematologic toxicity of, 577
phase I trial of, 575-579
response to, 577
toxicity of, 576-577
Dexamethasone, vincristine, doxorubicin regimen
chemoradiotherapy plus, 503-509
in multiple myeloma, 115-119, 2706-2714
response to, 116
Dexrazoxane, epirubicin regimen, toxicity of, 1659-1666
Dibromodulcitol, doxorubicin, vincristine, tamoxifen, fluoxymeterone regimen, in breast cancer, 45-49
Dihydropyrimidine dehydrogenase
activity, determination of, 2249
deficiency of, 2248-2253
5-FU chemotherapy and, 2239-2242
DNA
internucleosomal fragmentation of, retinoic acid-induced, 1191
in laryngeal lesions, 1600-1606
testing, for Mendelian cancer risk, 1728-1730
DNA index, in NHL, 2168-2169
DNA ploidy, in NHL, 2169-2170
Docetaxel
hematologic toxicity of, 1241, 1460
hypersensitivity reaction to, 1461-1462
in metastatic NSCLC, 1238-1244
neurologic toxicity of, 1464
nonhematologic toxicity of, 1241, 1460-1461
peripheral edema following, 1464-1465
phase I trial of, 1458-1467
in platinum-refractory ovarian cancer, 2301-2308
in recurrent NSCLC, 1238-1244
response to, 1234, 1240
skin toxicity of, 1462-1464
in stage III-IV NSCLC, 1232-1237
toxicity of, 1234-1235, 1241-1242, 2304-2306
weekly 1-hour intravenous infusion of, 1458-1467
weight gain following, 1464-1465
Dolasetron mesylate
antiemetic effects of, 1047
antiemetic trial of, 1045-1049
dosing of, 1048
side effects of, 1046-1047
structure of, 1046
Dose-intensity, of chemotherapy, colony-stimulating factor for, 2472, 2488-2489
Dot-blot immune staining, in GM2 antibody detection, 1038
Doxorubicin
clearance of, 839
in combination chemotherapy
dosing intensity of, 773
dosing schedule of, 771-772
for multiple myeloma, 2405-2414
for NHL, 769-778, 1074-1084
for SCLC, 80-81
S-phase fraction and, 2167-2175
total dose of, 773
toxicity of, 773-774
in combined modality therapy
for acute lymphoblastic leukemia, 740-747
for HD, 779-787
cumulative dosing of, in acute lymphocytic leukemia, 1315
cyclophosphamide and, in combination chemotherapy, for lymphoma, 1349-1357
cyclosporine with
hematologic toxicity of, 837
for multidrug resistance, 835-842
nonhematologic toxicity of, 838
pharmacokinetics of, 836-837
phase I trial of, 835-842
in endometrial cancer, 1408-1414
ketoconazole plus, in prostate cancer, 683-688
in MACOP-B regimen, for NHL, 1366-1374
in maintenance regimen, for myeloid leukemia, 128
in MOPP-ABVD regimen, for HD, 279-287
pharmacodynamics of, 838-839
pharmacokinetics of, 838
in hepatic arterial infusion, 2730
in ProMACE-MOPP regimen, for NHL, 1366-1374
response to, in endometrial cancer, 1411
survival following, in endometrial cancer, 1412
vinorelbine plus
in breast cancer, 1764-1770
hematologic toxicity of, 1767
nonhematologic toxicity of, 1768
response duration for, 1769
response to, 1767-1768
scheduling of, 1766
tolerance to, 1766-1767
Doxorubicin, bleomycin, vinblastine, dacarbazine regimen, in pediatric HD, 2160-2166
Doxorubicin, cisplatin, cyclophosphamide regimen
for thymoma, 1164-1168
response to, 1166
survival following, 1167
toxicity of, 1165-1166
Doxorubicin, cisplatin, etoposide, ifosfamide regimen, G-CSF plus
dose-intensity of, 79-80
in SCLC, 77-82
Doxorubicin, cisplatin, G-CSF regimen
neutrophil toxicity of, 1846
in osteosarcoma, 1842-1848
surgery following, 1846
toxicity of, 1844-1845
Doxorubicin, cyclophosphamide regimen, in endometrial cancer
doxorubicin *v*, 1408-1414
response to, 1411
survival following, 1412
Doxorubicin, cyclophosphamide, cisplatin regimen
dose intensity of, 2338

in drug delivery analysis, 2333-2339
in NSCLC, 2333-2339
survival following, 2335
Doxorubicin, cyclophosphamide, dacarbazine regimen, PIXY321 plus
in sarcoma, 715-724
study design of, 716-717
Doxorubicin, cyclophosphamide, etoposide, methotrexate, folinic acid, prednisone regimen, in non-Burkitt's lymphoma, 2153-2159
Doxorubicin, cyclophosphamide, vincristine, cisplatin, etoposide regimen, for neuroblastoma, 2607-2613
Doxorubicin, cyclophosphamide, vincristine, dacarbazine regimen
compliance with, 1142
mortality following, 1145
nonhematologic toxicity of, 1142
outcome following, 1141-1145
second malignancies following, 1145
in soft tissue sarcoma, 1137-1149
survival following, 1144
Doxorubicin, dibromodulcitol, vincristine, tamoxifen, fluoxymesterone regimen, in breast cancer, 45-49
Doxorubicin, floxuridine, folinic acid, cisplatin regimen
hepatic arterial infusion of, 1204
hepatitis and, 1204-1211
in hepatocellular cancer, 1204-1211
toxicity of, 1209
Doxorubicin, 5-FU, cyclophosphamide regimen
in breast cancer, 1266-1271
thromboembolic complications following, 1266
Doxorubicin, 5-FU, mitomycin regimen
in gastric cancer, 2687-2693
response to, 2689-2690
toxicity of, 2688-2689
Doxorubicin, methotrexate, vinblastine, cisplatin regimen
in bladder cancer, 975-980, 1394-1401
Doxorubicin, methotrexate, vinblastine, cisplatin, G-CSF regimen
dose-intensity of, 485-486
response to, 486
toxicity of, 485
in urothelial cancer, 483-488
Doxorubicin, vincristine, dactinomycin regimen, in Wilms' tumor, 2126-2131
Doxorubicin, vincristine, dactinomycin, cyclophosphamide regimen
in clear-cell renal sarcoma, 2132-2137
relapse sites following, 2135
in Wilms' tumor, 2126-2131
Doxorubicin, vincristine, dexamethasone regimen
chemoradiotherapy plus, 503-509
in multiple myeloma, 115-119, 2706-2714
response to, 116
Doxorubicin, vincristine, dexamethasone, cyclosporine regimen
clinical response to, 1586
in mutiple myeloma, 1584-1591
Doxorubicin, vincristine, methylprednisolone regimen
extramedullary toxicity of, 762
in myeloma, 759-763
response to, 761
survival following, 761
toxicity of, 761-762
Doxorubicinol, clearance of, 839
Drug resistance
cyclosporine modulation of, 1584-1591
epirubicin, quinidine for, 1771-1777
multi-, *see* Multidrug resistance
overview of, 1771
reversal of, vinblastine plus bepridil for, 812-819
Dysplastic nevi
clinical evaluation of, 1030
clinical photography of, 1031
definition of, 1028
diagnostic criteria for, 1028-1029
epidemiologic settings of, 1032
gross morphologic response of, 1029
histologic evaluation of, 1032
histologic response of, 1029
histopathology of, 1033
therapy of, 1029
topical tretinoin and, 1028-1035

Edema, following docetaxel, 1464-1465
Ejection fraction, before BMT, cardiotoxicity and, 998-1004
Elderly patient(s)
cisplatin in, renal tolerance and, 2121-2125
treatment tolerance of, 2447-2452
Embolization, in hepatocellular carcinoma, 1326
Emesis
alizapride plus tropisetron for, 2439-2446
delayed, ondansetron scheduling for, 1053-1054
dexamethasone plus tropisetron for, 2439-2446
dolasetron mesylate for, 1045-1049
oral ondansetron for, 2432-2438
quality of life and, 1054-1055
TBI-associated, oral ondansetron for, 2432-2438
tropisetron for, 2439-2446
End point(s)
definitive, in chemoprevention studies, 855
intermediate, in chemoprevention studies, 855-856
Endometrial cancer
doxorubicin *v* doxorubicin, cyclophosphamide regimen in, 1408-1414
radiotherapy technique in, 510-515
Enteral nutrition, in anorexia-cachexia syndrome, 218-219
Ependymoma, in infants, eight-in-1 day therapy for, 1607-1615
Epidermal growth factor receptor, description of, 730-731
Epirubicin
dexrazoxane plus, toxicity of, 1659-1666
dosing of, 1661
high-dose, toxicity of, 1659-1666
pharmacokinetic studies of, 1663-1664
resistance to, quinidine for, 1771-1777
Epirubicin, carboplatin, iproplatin, ifosfamide regimen, for neuroblastoma, in children, 1616-1620
Epirubicin, 5-FU, cisplatin regimen, continuous infusion
in breast cancer, 1259-1265
dosing of, 1263
hematologic toxicity of, 1262
nonhematologic toxicity of, 1262-1263
response to, 1261-1262
Epirubicin, 5-FU, cyclophosphamide regimen, failure of, salvage therapy following, 1639-1647
Epirubicin, quinidine, prednisolone regimen

in breast cancer, 1771-1777
progression-free survival following, 1775
response to, 1774
survival following, 1774-1775
toxicity of, 1773-1774
toxicity pattern following, 1774
Erythropoietin, recombinant human, *see* Recombinant human erythropoietin
Esophagus, chemoprevention trials of, 866-867
Estramustine, etoposide plus
in hormone-refractory prostate cancer, 2005-2012
survival following, 2008
therapeutic activity of, 2008
toxicities of, 2007
Estrogen, synthesis of, aromatase and, 2460-2461
Etoposide
in BMT conditioning regimens, 999
in chemoradiotherapy regimen, for multiple myeloma, 503-509
carboplatin plus
event-free survival following, 124
for seminoma, 120-126
in relapsed or refractory Wilms' tumor, 931-936
response to, 122
survival following, 122-123
toxicity of, 933-935
chronic oral
in breast cancer, 986-991
toxicity of, 988
cisplatin plus
dosing of, 2026
event-free survival following, 124
hematologic toxicities of, 2029
nonhematologic toxicities of, 2030
response to, 122, 2026-2027
in SCLC, 2022-2034
for seminoma, 120-126
survival following, 122-123, 2027-2028
toxicities of, 2028
clearance of, anticonvulsants and, 2393
in combination chemotherapy
for acute myeloid leukemia, 2139
for extragonadal germ cell tumors, 1390-1393
for NHL, 1074-1084
for SCLC, 80-81
for seminoma, 120-126
in combined modality therapy, for HD, 779-787
in conditioning regimen, 2419
continuous infusion
in NSCLC, 83-89
toxicity of, 85
estramustine plus
in hormone-refractory prostate cancer, 2005-2012
survival following, 2008
therapeutic activity of, 2008
toxicities of, 2007
5-day *v* 8-day schedules of, 1430, 1431
high-dose
in leukemia, 1468-1474
pharmacokinetics of, 2390-2397
in high-dose combination chemotherapy, and autologous BMT, 1358-1360
in metastatic breast cancer, phase II trials of, 990
oral
clinical toxicities of, 1454-1455
in pediatric solid tumors, 1452-1457
in platinum-resistant ovarian cancer, 60-63
response to, 62
pharmacokinetic studies of, 1430-1431
pharmacokinetics of, 1468-1474, 1907
phase I trial of, 1902-1909
plasma disposition curve of, 1907
in ProMACE-MOPP regimen, for NHL, 1366-1374
response to, pharmacokinetic predictors of, 1431-1432
in SCLC, 1427-1435
SCLC response to, 1430
stability of, 1903-1904
toxicity of, 1432
Etoposide, cyclophosphamide, TBI, BMT regimen, in NHL, 2552-2557
Etoposide, bleomycin, cisplatin regimen
for ovarian germ cell tumor, 701-706
schedule of, 702
Etoposide, busulfan regimen, before BMT, 1468-1474
Etoposide, carboplatin regimen
antileukemic response to, 1971
continuous infusion, in leukemia, 1969-1973
extramedullary toxicity of, 1970-1971
gastrointestinal tract toxicity of, 1970
hematologic toxicity of, 1971
infections following, 1970
Etoposide, carboplatin, BMT regimen, in solid tumors, 2390-2397
Etoposide, carboplatin, ifosfamide, stem-cell transplantation regimen, 1223-1231
dose escalation of, 1226
event-free survival following, 1229
in germ cell cancer, 1223-1231
hematologic toxicity of, 1226-1227
nonhematologic toxicity of, 1227
renal toxicity of, 1227
response to, 1227-1229
toxicity of, 1226
Etoposide, cisplatin regimen
scheduling of, 71-72
in SCLC, 70-76
toxicity of, 73-74
Etoposide, cisplatin, ifosfamide, doxorubicin regimen, G-CSF plus
dose-intensity of, 79-80
in SCLC, 77-82
Etoposide, cyclophosphamide regimen
mucositis following, 1920
scheduling of, 1918
Etoposide, cyclophosphamide, carboplatin, stem-cell transplantation, interferon alfa-2b regimen
in lymphoma, 2423-2431
scheduled administration of, 2425
Etoposide, cyclophosphamide, carmustine, BMT regimen, in NHL, 2542-2551
Etoposide, cyclophosphamide, doxorubicin, methotrexate, folinic acid, prednisone regimen, in non-Burkitt's lymphoma, 2153-2159
Etoposide, cyclophosphamide, doxorubicin, vincristine, cisplatin regimen, for neuroblastoma, 2607-2613

Etoposide, cyclophosphamide, TBI regimen
for allogeneic BMT conditioning, 1923-1930
toxicity of, 1924-1925
Etoposide, dacarbazine, cyclophosphamide, carmustine, etoposide, stem-cell transplantation regimen, in lymphoma, 1890-1901
Etoposide, dacarbazine, cyclophosphamide, carmustine, stem-cell transplantation regimen, in multiple myeloma, 1890-1901
Etoposide, dexamethasone, carmustine, cytarabine, melphalan regimen
in HD, 580-586
survival following, 581
toxicity of, 583
Etoposide, ifosfamide, asparaginase, cytarabine regimen, in NHL, 2542-2551
Etoposide, ifosfamide, carboplatin regimen
phase I-II evaluation of, 544-552
response to, 547
toxicity of, 547-548
Etoposide, ifosfamide, carboplatin, GM-CSF regimen
marrow toxicity following, 1256
in NSCLC, 1251-1258
platelet transfusions following, 1255
response to, 1254-1255
scheduling plan for, 1252
toxicity of, 1253-1254
Etoposide, irinotecan, G-CSF regimen, in lung cancer, 1833-1841
Etoposide, methylprednisolone, cytarabine, cisplatin regimen
adverse prognostic factors in, 1173
in refractory lymphoma, 1169-1176
prognostic factors in, 1173
response to, 1171
scheduling of, 1170
survival following, 1173
toxicity of, 1173-1174
Etoposide, mitoxantrone, cyclophosphamide, carmustine regimen, in refractory lymphoma, 141-148
Etoposide, thioguanine, dexamethasone, daunorubicin, cytarabine regimen, in acute myeloid leukemia, 2367-2377
Etoposide, thiotepa, TBI regimen
mucositis following, 1920
scheduling of, 1918
Etoposide, vincristine, cyclophosphamide regimen
for pediatric tumors, 522-531
toxicity of, 525-526
Etretinate, in chemoprevention, 857-858
Euthanasia
in cancer, 1516-1521
definitions related to, 1518
double effect principle in, 1518-1519
ethics of, 1518
involuntary active, 1518
legalizing, 1519
legitimating, 1519
narcotics in, 1520-1521
passive, 1518, 1520
voluntary active, 1518
Exon 5, sequence of, 928
Exon 6, sequence of, 928
Extensive in situ component, definition of, 659
Extracellular mass, in anorexia-cachexia syndrome, 217
Extremity, osteosarcoma of, pulmonary metastases of, 1849-1858

1F5, in B-cell lymphoma, 1499
3F8, in melanoma, 1502
Factor VIII-related antigen, in node-negative breast cancer, 455
Fanconi's syndrome, renal, treatment associated with, 161
Fat, in chemoprevention, 857
Fat metabolism, in anorexia-cachexia syndrome, 214-215
FCE 24304, 2465
Febrile patient, colony-stimulating factor in, 2472, 2486-2487
Fenretinide, in chemoprevention, 857, 865
Fever, neutropenia with, home antibiotic therapy for, 107-114
Fibroblast, reactive stromal, of metastatic colorectal cancer, 1193-1203
Fibroblast activation protein, monoclonal antibody F19 targeting of, 1193-1203
Filgrastim, 2477, 2479
see also Granulocyte-colony stimulating factor
Finasteride, in chemoprevention, 856
Flesch Reading Ease Score, 2212, 2214
Flesch-Kincaid, grade level, 2212, 2214
Floxuridine, folinic acid, dexamethasone regimen
bilirubin elevation following, 2292
for hepatic metastases, 2288-2295
Floxuridine, folinic acid, doxorubicin, cisplatin regimen
hepatic arterial infusion of, 1204
hepatitis and, 1204-1211
in hepatocellular cancer, 1204-1211
toxicity of, 1209
Fludarabine
adverse drug reactions of, 2222
in chronic lymphocytic leukemia, 1979-1980
in combination therapy, 2221
high-dose, neurotoxicity of, 2218
interferon alfa-2a plus
immune function following, 2055
in mycosis fungoides, 2051-2059
in Sézary syndrome, 2051-2059
toxicity of, 2055
neurotoxicity of, 2216-2228
overview of, 2219-2221
standard-dose, 2219
structure of, 2217
Fludarabine, cytarabine, G-CSF regimen
in acute myelogenous leukemia, 671-678
complete remission following, 673
infection risk following, 677
in myelodysplastic syndromes, 671-678
survival probability following, 674
Fludarabine, mitoxantrone, dexamethasone regimen
dose escalation of, 576
in lymphoma, 575-579
nonhematologic toxicity of, 577
phase I trial of, 575-579
response to, 577
toxicity of, 576-577
Fluorouracil
in advanced colorectal cancer, 960-969
survival following, 964-965
tumor response following, 964
in cancer chemotherapy, overview of, 1291
cytotoxicity of, phosphoribosylpyrophosphate levels and, 695-700
dihydropyrimidine dehydrogenase activity and, 2239-2242

dose intensity of, 564
folinic acid plus
in colorectal cancer, 14-20, 2035-2042
toxicity of, 17-18
in gastric cancer, 412-416
methotrexate plus, in advanced colorectal cancer, 960-969
N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl plus, 1285
pharmacokinetic studies of, 1292, 2249
pharmacokinetics of, 561, 564-565
in hepatic arterial infusion, 2729
plantar-palmar syndrome following, 1260
response to, 1293
survival following, 1293
toxic reactions to, 415
Fluorouracil, cisplatin, epirubicin, folinic acid regimen
in gastric cancer, 2687-2693
response to, 2689-2690
toxicity of, 2688-2689
Fluorouracil, cisplatin, mitoguazone regimen
in head and neck cancer, 946-953
response to, 949
toxicity of, 948
Fluorouracil, cisplatin, radiotherapy regimen
death following, 392
histologic response to, 1594
in head and neck cancer, 385-395
in laryngeal cancer, 1592-1599
response to, 1594-1595, 388-389
survival following, 1595
toxicity of, 1593-1594, 389-390
Fluorouracil, cyclophosphamide, methotrexate regimen
compliance with, 2088
in node-positive breast cancer, 2086-2093
short-term toxicity of, 2091
Fluorouracil, cyclophosphamide, methotrexate, tamoxifen regimen, in node-positive breast cancer, 2086-2093
Fluorouracil, cyclophosphamide, methotrexate, vincristine, prednisone regimen
in breast cancer, 2078-2085
second primary tumor following, 2080-2081
survival following, 2080
toxicity of, 2081-2083
Fluorouracil, doxorubicin, cisplatin regimen
in gastric cancer, 412-416
toxic reactions to, 415
Fluorouracil, doxorubicin, cyclophosphamide regimen
in breast cancer, 1266-1271
thromboembolic complications following, 1266-1271
Fluorouracil, doxorubicin, methyl lomustine regimen
in gastric cancer, 412-416
toxic reactions to, 415
Fluorouracil, doxorubicin, mitomycin C regimen
in gastric cancer, 2687-2693
response to, 2689-2690
toxicity of, 2688-2689
Fluorouracil, epirubicin, cisplatin regimen, continuous-infusion
in breast cancer, 1259-1265
dosing of, 1263
hematologic toxicity of, 1262
nonhematologic toxicity of, 1262-1263
response to, 1261-1262
Fluorouracil, epirubicin, cyclophosphamide regimen, failure of, salvage therapy following, 1639-1647
Fluorouracil, folinic acid, GM-CSF regimen
clinical response to, 565
in gastrointestinal adenocarcinoma, 560-568
toxicity of, 562-563
Fluorouracil, folinic acid, radiotherapy regimen
in gastrointestinal cancer, 21-27
toxicity of, 24-25
Fluorouracil, folinic acid, trimetrexate regimen
dosing of, 698
in gastrointestinal cancer, 695-700
response to, 697
survival following, 697
toxicity of, 696-697
Fluorouracil, hydroxyurea, radiotherapy regimen, with G-CSF
acute toxicities of, 2354
cumulative toxicities of, 2355
for head and neck cancer, 2351-2359
response to, 2356
Fluorouracil, hydroxyurea, radiotherapy, cisplatin regimen, with G-CSF
acute toxicities of, 2354
dose intensity of, 2355
for head and neck cancer, 2351-2359
treatment regimen for, 2353
Fluorouracil, radiotherapy plus, in head and neck cancer, 2648-2653
Fluoxymesterone, dibromodulcitol, doxorubicin, vincristine, tamoxifen regimen, in breast cancer, 45-49
Folinic acid
in chemoprevention, 857, 862
in chemoradiotherapy regimen, for multiple myeloma, 503-509
in combination chemotherapy
for NHL, 1074-1084
for non-T, non-B acute lymphocytic leukemia, 1384
5-FU plus
in colorectal cancer, 14-20, 2035-2042
toxicity of, 17-18
in MACOP-B regimen, for NHL, 1366-1374
in ProMACE-MOPP regimen, for NHL, 1366-1374
Folinic acid, cyclophosphamide, doxorubicin, etoposide, methotrexate, prednisone regimen, in non-Burkitt's lymphoma, 2153-2159
Folinic acid, floxuridine, dexamethasone regimen
bilirubin elevation following, 2292
for hepatic metastases, 2288-2295
Folinic acid, floxuridine, doxorubicin, cisplatin regimen
hepatic arterial infusion of, 1204
hepatitis and, 1204-1211
in hepatocellular cancer, 1204-1211
toxicity of, 1209
Folinic acid, 5-FU, cisplatin, epirubicin regimen
in gastric cancer, 2687-2693
response to, 2689-2690
toxicity of, 2688-2689
Folinic acid, 5-FU, GM-CSF regimen
clinical response to, 565
in gastrointestinal adenocarcinoma, 560-568
toxicity of, 562
Folinic acid, 5-FU, radiotherapy regimen
in gastrointestinal cancer, 21-27

toxicity of, 24-25
Folinic acid, 5-FU, trimetrexate regimen
dosing of, 698
in gastrointestinal cancer, 695-700
response to, 697
survival following, 697
toxicity of, 696-697
Folinic acid, uracil, tegafur regimen, for colorectal cancer, 2296-2300
Fracture, metastatic-associated
postoperative radiotherapy of, 2345-2350
second orthopedic procedures for, 2347
5-FU, *see* Fluorouracil
Functional Assessment of Cancer Therapy Scale, 614
Fungal infection(s)
amphotericin B and, 827-834
risk factors for, 830

14G2a, in melanoma, 1502
G-CSF, *see* Granulocyte colony-stimulating factor
Gallium scan
CT *v*, in HD restaging, 309
intensity scoring scale for, 307
restaging of, in HD, prognostic importance of, 306-311
Gallium, vinblastine, ifosfamide regimen
results with, 2274
survival following, 2273-2274
toxicity of, 2273
in urothelial carcinoma, 2271-2276
Gamma camera scan, in occult colorectal cancer, 490
Gamma Knife, in stereotactic radiosurgery, 1090-1091
Ganglioside
definition of, 1036, 1041
GM2, in stage III melanoma, 1036-1044
reagents, 1037
Gastric cancer
advanced
5-FU in, 412-416
intraperitoneal cisplatin chemotherapy for, 970-974
surgery, intraperitoneal cisplatin regimen in, 970-974
5-FU, cisplatin, epirubicin, folinic acid regimen in, 2687-2693
5-FU, doxorubicin, mitomycin regimen in, 2687-2693
lymphadenectomy in, 417-422
passive monoclonal antibody therapy in, 1505
Gastrin-releasing peptide, 1502
Gastrointestinal cancer
5-FU, folinic acid, radiotherapy regimen in, 21-27
trimetrexate, 5-FU, folinic acid regimen in, 695-700
Gastrointestinal function, in anorexia-cachexia syndrome, 216-217
Gemcitabine
as monotherapy, 1535-1540
development of, 1527
dosing of, 1823
leukocyte toxicity following, 1537
nonhematologic toxicity of, 1537
in NSCLC, 1528, 1535-1540
once-weekly schedule of, 1527
phase I-II trials of, current status of, 1527-1531
phase II trial of, 1535-1540, 1821-1826
platelet toxicity following, 1537
response to, 1823
survival following, 1529, 1539
symptomatic toxicity of, 1825
toxicity of, 1824-1825
weekly, in NSCLC, 1821-1826
Gene therapy, advances in, 437
Genetic counseling, quantitating familial cancer risk in, 1724-1736
Genetic testing
attitudes about, 843-850
for breast cancer susceptibility, 843-850
impact of, expectations about, 847
interest in, factors associated with, 845-847
negative impact of, 847
for ovarian cancer susceptibility, 843-850
Gentamicin, nephrotoxicity associated with, 160
Germ cell cancer
carboplatin, etoposide, ifosfamide, stem-cell transplantation regimen in, 1223-1231
multiple atypical nevi and, 2284-2287
nonseminomatous, high-dose chemotherapy plus stem-cell transplantation in, 230
ovarian, cisplatin-based chemotherapy for, 378-384
paclitaxel for, 2277-2283
relapsed extragonadal, salvage chemotherapy in, 1390-1393
Gestational trophoblastic disease, chemorefractory, surgery for, 2737-2742
Gleason score, in prostate cancer, 1402-1404
Glioma
procarbazine, lomustine, vincristine regimen for, 2013-2021
recurrent malignant, corticosteroid-induced MRI changes of, 1886-1889
Glucocorticoids, combination chemotherapy plus, in multiple myeloma, 2405-2414
Glutathione
activity of, 196, 200
modulation of, 194-205
overview of, 194-195
serum levels of, 196
GM-CSF, *see* Granulocyte-macrophage colony-stimulating factor
GM2 antibody
delayed-type hypersensitivity response to, 1040
detection of, by dot-blot immune staining, 1038
serologic response against, 1039-1040
GM2 ganglioside, vaccination with, in stage III melanoma, 1036-1044
GM2-BCG vaccine
immunoglobulin M antibody response to, 1039
production of, 1037
in stage III melanoma, 1036-1044
Goldie-Coldman hypothesis, 2607-2613
Graft-*v*-host disease
cyclosporine-induced, in breast cancer, 249-257
following busulfan, cyclophosphamide regimen, 1220
induction of, cyclosporine and, 252
regimens for, 828
Granisetron
adverse effects of, 2208
antiemetic efficacy of, 2206
for cisplatin-induced nausea, 2204-2210
dosing of, and efficacy, 2207
safety of, 2206-2208
Granulocyte colony-stimulating factor

administration of, 1932
combination chemotherapy plus, in SCLC, 77-82
cost impact of, 1245-1250
following BMT, for lymphoma, 1931-1938
following stem-cell transplantation, 661-670
hematopoietic recovery following, 664
important issues for, 650-652
infectious episodes following, 664-665
in peripheral-blood stem-cell transplantation, 1693-1702, 2176-2186
results of, 1247
safety of, 1935-1936
supportive care following, 663
toxicity of, 2477, 2479
utilization of, models for, 1247
weekly chemotherapy plus, in SCLC, 77-82
with 3-hour paclitaxel infusion, 241-248
Granulocyte colony-stimulating factor, doxorubicin, cisplatin regimen
neutrophil toxicity of, 1846
in osteosarcoma, 1842-1848
surgery following, 1846
toxicity of, 1844-1845
Granulocyte colony-stimulating factor, fludarabine, cytarabine regimen
in acute myelogenous leukemia, 671-678
complete remission following, 673
infection risk following, 677
in myelodysplastic syndromes, 671-678
survival probability following, 674
Granulocyte colony-stimulating factor, irinotecan, cisplatin regimen
dose-escalation schedule of, 91
in NSCLC, 90-96
toxicity of, 92-94
Granulocyte colony-stimulating factor, irinotecan, etoposide regimen, in lung cancer, 1833-1841
Granulocyte colony-stimulating factor, methotrexate, vinblastine, doxorubicin, cisplatin regimen
dose-intensity of, 485-486
response to, 486
toxicity of, 485
in urothelial cancer, 483-488
Granulocyte-macrophage, colony-forming unit, clonogenic asssays for, 1022-1023
Granulocyte-macrophage colony-stimulating factor
carboplatin-mobilized peripheral-blood progenitor cells and, 1012-1020
chemoradiotherapy plus, in multiple myeloma, 503-509
effect of, on oral mucositis, 1917-1922
following stem-cell transplantation, 661-670
hematopoietic recovery following, 664
IL-3 fusion with, *see* PIXY321
important issues for, 650-652
infectious episodes following, 664-665
safety of, 2671-2672
in SCLC, 2667-2677
supportive care following, 663
toxicity of, 2479, 564
Granulocyte-macrophage colony-stimulating factor, ifosfamide, carboplatin, etoposide regimen
marrow toxicity following, 1256
in NSCLC, 1251-1258
platelet transfusions following, 1255
response to, 1254-1255
scheduling plan for, 1252
toxicity of, 1253-1254
Granulocyte-macrophage colony-stimulating factor, 5-FU, folinic acid regimen
clinical response to, 565
in gastrointestinal adenocarcinoma, 560-568
toxicity of, 562
Growth factor
hematopoietic, important issues in, 650-652
see also specific type
Gunning Fog Index, for consent forms, 2212, 2214
GVHD, *see* Graft-versus-host disease

Halsted model
in breast cancer, 2229
mastectomy in, 2229-2230
HAMA response
following radiolabeled monoclonal antibody A33, 1565-1566
passive monoclonal antibody therapy and, 1510
HD, *see* Hodgkin's disease
Head and neck cancer
alternating chemotherapy with radiotherapy in, 1876-1885
chemoradiotherapy in
intensive, 946-953
with G-CSF, 2351-2359
sequential *v* concomitant, 385-395
cisplatin, 5-FU, radiotherapy regimen in, 385-395
failure sites in, 391
5-FU plus radiotherapy in, 2648-2653
organ preservation in, 946-953
supradose cisplatin infusion in, 2113-2120
Hepatectomy, for colorectal metastases, repeat resections following, 1491-1496
Hepatic arterial infusion
complications associated with, 2728
of floxuridine, folinic acid, dexamethasone regimen, 2288-2295
of floxuridine, folinic acid, doxorubicin, cisplatin regimen, 1204-1211
technical aspects of, 2728-2729
for unresectable liver tumors, 2723-2736
Hepatic metastasis, floxuridine, folinic acid, dexamethasone regimen for, 2288-2295
Hepatitis B, floxuridine, folinic acid, doxorubicin, cisplatin regimen and, 1204-1211
Hepatitis C, floxuridine, folinic acid, doxorubicin, cisplatin regimen and, 1204-1211
Hepatocellular cancer
chemoembolization in, 1326
chemotherapy for, 1325-1326
cryosurgery for, 1325
embolization in, 1326
floxuridine, folinic acid, doxorubicin, cisplatin regimen in, 1204-1211
hepatic arterial infusion in, 1204-1211
incidence of, 1323
intraarterial chemotherapy in, 1326-1328
isolated hepatic perfusion in, 1327-1328
lipiodol in, 1326-1327
new approaches in, 1330

novel therapies for, 1324
orthotopic liver transplantation in, 1329-1330
percutaneous intratumoral alcohol injection in, 1328
radiation in, 1328
radioimmunotherapy in, 1328
styrene-maleic acid-neocarzinostatin in, 1327
surgery for, 1323-1325
treatment of, 1323-1334
HLA-DR antigen, in breast cancer, following interferon gamma, 252
Hodgkin's disease
adult, chemotherapy plus stem-cell transplantation in, 228-229
advanced
chlorambucil, vincristine, procarbazine, prednisone-prednisolone, doxorubicin, bleomycin, vinblastine, etoposide, radiotherapy regimen in, 779-787
restaging gallium scans in, 306-311
Ann Arbor classification in, 794
cyclophosphamide in, leukemia risk following, 1066-1068
cyclophosphamide, carboplatin, etoposide, stem-cell transplantation, interferon alfa-2b regimen in, 2423-2431
dexamethasone, carmustine, etoposide, cytarabine, melphalan regimen in, 580-586
leukemia risk following, 1063-1073
limited stage IIIA, improved survival in, 2567-2572
lomustine in, leukemia risk following, 1066-1068
low platelet count in, 1066-1068
mechlorethamine in, leukemia risk following, 1066-1068
pediatric, chemoradiotherapy in, 2160-2166
procarbazine in, leukemia risk following, 1066-1068
radiotherapy in, leukemia risk following, 1066-1068
second cancers following, 312-325
soluble CD30 in, 793-797
stage IA-IIa, vinblastine, bleomycin, methotrexate, radiotherapy regimen in, 288-296
stage IIIA, chemoradiotherapy in, 2567-2572
stage IIIB-IV, MOPP *v* MOPP-ABVD regimen in, 279-287
stage of, leukemia risk and, 1070
teniposide in, leukemia risk following, 1066-1068
therapy of, pulmonary function following, 297-305
TBI, etoposide, cyclophosphamide, BMT regimen in, 2552-2557
Home therapy, with antibiotics
duration of, 112
economic outcomes of, 111-112
in low-risk patients, 107-114
medical complications following, 110-111
patient attitude and, 111
regimens for, 111
Hormonal therapy, in node-positive receptor-positive breast cancer, 2078-2085
Hormone abnormality, in anorexia-cachexia syndrome, 215
Hot flash, tamoxifen-induced, transdermal clonidine for, 155-158
Human anti-mouse antibody response
following radiolabeled monoclonal antibody A33, 1565-1566
passive monoclonal abtibody therapy and, 1510
Human T-cell leukemia virus I, 1975
Human T-cell leukemia virus II, 1975
Hydrazine sulfate
in cancer therapy, 1107-1108
in colorectal cancer, 1121-1125
in NSCLC, 1126-1129
response to, 1127
survival following, 1123, 1128
toxicities of, 1123
Hydrazine sulfate, cisplatin, vinblastine regimen
in NSCLC, 1113-1120
response to, 1116
serum albumin level changes following, 1117
toxicity of, 1116
Hydrocortisone, in combination chemotherapy, for non-T, non-B acute lymphocytic leukemia, 1384
Hydroxyurea, 5-FU, radiotherapy regimen, with G-CSF
acute toxicities of, 2354
cumulative toxicities of, 2355
dose intensity of, 2355
for head and neck cancer, 2351-2359
response to, 2356
treatment regimen for, 2353
Hydroxyurea, vincristine, carmustine, procarbazine, cisplatin, cytarabine, prednisone, cyclophosphamide regimen, for infants, 1607-1615

ICI-D1033, 2465
Ifosfamide
in combination chemotherapy
for extragonadal germ cell tumors, 1390-1393
for SCLC, 80-81
nephrotoxicity associated with, 160
risk factors for, 159-165
Ifosfamide, bleomycin, carboplatin regimen
in cervical cancer, 55-59
survival following, 57
toxicity of, 57
Ifosfamide, carboplatin, etoposide regimen
high-dose, stem-cell transplantation following, 1223-1231
phase I-II evaluation of, 544-552
response to, 547
toxicity of, 547-548
Ifosfamide, carboplatin, etoposide, GM-CSF regimen
marrow toxicity following, 1256
in NSCLC, 1251-1258
platelet transfusions following, 1255
response to, 1254-1255
scheduling plan for, 1252
toxicity of, 1253-1254
Ifosfamide, carboplatin, etoposide, stem-cell transplantation regimen
dose escalation of, 1226
event-free survival following, 1229
in germ cell cancer, 1223-1231
hematologic toxicity of, 1226-1227
nonhematologic toxicity of, 1227
renal toxicity of, 1227
response to, 1227-1229
toxicity of, 1226
Ifosfamide, cisplatin, etoposide, doxorubicin regimen, G-CSF plus
dose-intensity of, 79-80
in SCLC, 77-82
Ifosfamide, etoposide, asparaginase, cytarabine regimen, in NHL, 2542-2551
Ifosfamide, mesna, carboplatin, iproplatin, epirubicin regimen, for neuroblastoma, in children, 1616-1620
Ifosfamide, vinblastine, gallium regimen
results with, 2274

survival following, 2273-2274
toxicity of, 2273
in urothelial carcinoma, 2271-2276
Ifosfamide, vincristine, dactinomycin regimen
in orbital rhabdomyosarcoma, 516-521
response to, 518
tolerance to, 519
IL-1 alpha, *see* Interleukin-1 alpha
IL-3, *see* Interleukin-3
IMMU-4, radiolabeled-, in occult colorectal cancer, 489-495
Immune complex, passive monoclonal antibody therapy and, 1510-1511
Immunization
in stage III melanoma, 1036-1044
survival and, 1040-1041
Immunocytometry, of peripheral-blood lymphocytes, 99
Immunoglobulin M antibodies, GM2-BCG-induced, in stage III melanoma, 1036-1044
Immunohistochemical assay
for *mdr*1 levels, 2455
in metastatic colorectal cancer, 1196, 1201
of micrometastasis, in NSCLC, 1827-1832
for p-glycoprotein levels, 2454
of p53 protein, 2045
of peripheral T-cell lymphoma, 1189
Immunology, in cancer therapy, 237-238
Immunoperoxidase staining, in topotecan phase I trial, 2195
Immunophenotypic studies, in acute lymphocytic leukemia, 1318
Immunoproliferative small-intestinal disease, 1378-1379
in Taiwan, 1375-1382
Immunoselection, passive monoclonal antibody therapy and, 1509-1510
Immunotherapy
active specific, of melanoma, interferon alfa-2b following, 402-411
IL-2 in, 1553-1560
in metastatic melanoma, 1475-1483
predicting response to, 1482
of primary choroidal melanoma, 396-401
Immunotoxin, in chronic lymphocytic leukemia, 1983
Indiana classification, for testicular cancer, 370
Infection
definition of, 1007
in chronic lymphocytic leukemia, 1980-1981
reduction of, in autologous BMT, 1005-1011
Informed consent, forms for, readability of, 2211-2215
Interferon, for maintenance, in myeloma, 2413
Interferon alfa
combination chemotherapy plus, in multiple myeloma, 2405-2414
for post BMT leukemic relapse, 1713-1714
Interferon alfa, dacarbazine, carmustine, cisplatin, tamoxifen regimen, studies of, 620
Interferon alfa, dacarbazine, carmustine, cisplatin, tamoxifen, IL-2 regimen, studies of, 620-621
Interferon alfa-2a
dacarbazine plus
in malignant melanoma, 806-811
side effects of, 809-810
fludarabine plus
immune function following, 2055
in mycosis fungoides, 2051-2059
in Sézary syndrome, 2051-2059
toxicity of, 2055
Interferon alfa-2b
in bladder cancer prophylaxis, 7-13
in chronic lymphocytic leukemia, 1982-1983
clinical efficacy of, 2426-2427
clinical toxicity of, 2426
disease-free survival following, 2429
following active specific immunotherapy, of melanoma, 402-411
major toxicity of, 2428
toxicity of, 11
treatment with, 404
Interferon alfa-2b, cyclophosphamide, carboplatin, etoposide, stem-cell transplantation regimen
in lymphoma, 2423-2431
scheduled administration of, 2425
Interferon gamma
administration of, 251
compliance with, 2322
in cyclosporine-induced GVHD, following BMT, 249-257
phase I trial of, 249-257
results with, 2323-2324
in SCLC, 2321-2326
toxicity of, 252-253, 2323
Interleukin-1 alpha
for carboplatin-induced thrombocytopenia, 707-714
in cumulative myelosuppression, 713
in myelosuppression, 709-710
side effects of, 710
tumor response following, 710-711
Interleukin-1-beta, production of, 103
Interleukin-2
cell proliferation following, 329
in chronic lymphocytic leukemia, 1982-1983
high- *v* low-dose, for renal cancer, 1572-1576
high-dose, renal dysfunction associated with, 2714-2722
IL-7 and, in cutaneous T-cell lymphoma, 326-335
toxicity of, 1556-1574
tumor-infiltrating lymphocytes plus, in melanoma, 1475-1483
Interleukin-2, cisplatin, dacarbazine, tamoxifen regimen
in melanoma, 1553-1560
response to, 1558
survival following, 1557
toxicity of, 1556-1557
Interleukin-2, dacarbazine, carmustine, cisplatin, tamoxifen, interferon alfa regimen, studies of, 620-621
Interleukin-2, dacarbazine, cisplatin, tamoxifen regimen, studies of, 622
Interleukin-3, GM-CSF fusion with, *see* PIXY321
Interleukin-6, production of, 103
Interleukin-7
cell proliferation following, 329
IL-2 and, in cutaneous T-cell lymphoma, 326-335
polymerase chain reaction for, 327-328
radioiodination of, 327
Internal-External Locus of Control Scale, 822
International Prognostic Index
for aggressive lymphoma, 1340-1342
calculation for, 1347-1348
for low-grade lymphoma, 1343-1348
International Staging System, for neuroblastoma, 2379

Intrahepatic bile duct cancer, staging of, 1324
Intraperitoneal chemotherapy, cisplatin, in advanced gastric cancer, 970-974
Intravascular lymphomatosis, combination chemotherapy in, 2573-2579
Iproplatin, carboplatin, ifosfamide, epirubicin regimen, for neuroblastoma, in children, 1616-1620
Irinotecan, overview of, 1833-1834
Irinotecan, cisplatin, G-CSF regimen
  dose-escalation schedule of, 91
  in NSCLC, 90-96
  toxicity of, 92-94
Irinotecan, etoposide, G-CSF regimen
  hematologic toxicity of, 1835-1837
  in lung cancer, 1833-1841
  nonhematologic toxicity of, 1836-1837
  pharmacokinetics of, 1837
  phase II trial of, 1833-1841
  response to, 1837-1838
  toxicity of, 1835-1837
Isolated hepatic perfusion, in hepatocellular carcinoma, 1327-1328
Isotretinoin
  adherence with, 939
  bronchial metaplasia index following, 942
  in chemoprevention, 857, 862, 865
    bronchial squamous metaplasia and, 937-945
  effects of
    on bronchial dysplasia, 941-942
    on bronchial squamous metaplasia, 939-940
  toxic effects of, 942

J-5, in acute leukemia, 1498

Kaposi's sarcoma, AIDS-related
  bleomycin in, 1130-1136
  improved survival in, 1910-1916
  overview of, 1109-1110
Karnofsky, David, 432-438
Keratin 19 transcript, reverse-transcriptase polymerase chain reaction assay for, 479
Ketoconazole, doxorubicin plus, in prostate cancer, 683-688
Kidney, childhood clear-cell sarcoma of, 2132-2137

Labeling index, plasma cell, prognostic value of, in multiple myeloma, 118
Lactate dehydrogenase, prognostic value of, in multiple myeloma, 118
Laryngeal cancer, neoadjuvant organ-preserving chemotherapy in, 1592-1599
Larynx, epithelial lesions of, DNA in, 1600-1606
L-Buthionine sulfoximine
  administration of, 195-196
  antitumor effect of, 198
  dose escalation of, 195-196
  formulation of, 195
  glutathione activity following, 200
  impact of, on glutathione, 198-200
  melphalan plus, phase I trial of, 194-205
  plasma concentration of, 201
  serum levels of, 200-201
  toxicity of, 197-198

Leu-1
  in acute leukemia, 1498
  in T-cell lymphoma, 1499
Leu-3a, in T-cell lymphoma, 1499
Leukemia
  acute, passive monoclonal antibody therapy in, 1498
  acute lymphoblastic
    CSF blasts in, 2594-2600
    in remission, spinal fluid blasts in, 273-278
  acute lymphocytic, blast-colony assay for, 1318-1319
  acute myelocytic, passive monoclonal antibody therapy in, 1499-1500
  acute myelogenous
    following chemoradiotherapy and stem-cell transplantation, 2527-2534
    fludarabine, cytarabine, G-CSF regimen in, 671-678
    myeloablative therapy with autologous stem-cell transplantation, 2521-2523
  acute myeloid
    chemotherapy *v* BMT in, 262-267
    colony-stimulating factor in, 2473, 2492-2494
  adult acute lymphoblastic, allogeneic BMT in, 2580-2587
  adult acute lymphocytic
    allogeneic BMT in, 1314-1316
    asparaginase cumulative dosing in, 1315
    autologous BMT in, 1316-1317
    B-cell, 1314
    best remission induction regimen in, 1313
    chemotherapy plus stem-cell transplantation in, 227-228
    CNS prophylaxis in, 1317-1318
    consolidation-intensification therapy in, 1313-1314
    cure in, 1312-1313
    cyclophosphamide cumulative dosing in, 1315
    cytarabine cumulative dosing in, 1315
    doxorubicin-daunorubicin cumulative dosing in, 1315
    first remission in, approaches following, 1316
    immunophenotypic studies in, 1318
    karyotype-associated molecular abnormalities in, 1319
    maintenance therapy in, 1314
    management of, 1312-1322
    mercaptopurine cumulative dosing in, 1315
    mercaptopurine maintenance therapy in, 1314
    methotrexate cumulative dosing in, 1315
    methotrexate maintenance therapy in, 1314
    minimal residual disease detection in, 1318-1319
    molecular abnormalities in, 1319
    multidrug resistance detection in, 1318
    short dose-intensive regimens in, 1314
    subset therapies in, 1314
    T-cell, 1314
    vincristine cumulative dosing in, 1315
  adult acute myelocytic, chemotherapy plus stem-cell transplantation in, 226-227
  B and pre-B acute lymphocytic, passive monoclonal antibody therapy in, 1498-1499
  B-cell chronic lymphocytic, soluble CD23 in, 2146-2152
  childhood acute
    aerolized pentamidine in, 136-140
    Pneumocystis carinii pneumonia prophylaxis in, 136-140
    sequential chemotherapy in, survival following, 435
  childhood acute lymphoblastic

asparaginase, doxorubicin, methotrexate, prednisone, cytarabine, mercaptopurine, cranial irradiation regimen in, 740-747
methotrexate, cytarabine consolidation regimen for, 1939-1945
childhood acute lymphoblastic
t(1;19)(q23;p13) in, 2601-2606
childhood acute myeloid
BMT in, busulfan, cyclophosphamide regimen for, 2138-2145
BMT *v* chemotherapy in, 127-135
etoposide, thioguanine, dexamethasone, daunorubicin, cytarabine regimen in, 2367-2377
intensive therapy of, late effects of, 916-924
chronic lymphocytic
absolute lymphocyte count in, 1976
autoimmune cytopenia in, 1981
biologic response modifiers in, 1982-1983
BMT in, 1983-1984
causative viruses in, 1975
chlorambucil in, 1978
2-chlorodeoxyadenosine in, 1979-1980
clinical presentation of, 1976
clonality in, 1977
combination chemotherapy in, 1978-1979
complications in, 1980-1982
corticosteroids in, 1978
cyclophosphamide in, 1978
cytogenetics in, 1975
2-deoxycoformycin in, 1979-1980
diagnosis of, 1976-1977
epidemiology of, 1974
etiology of, 1974-1976
fludarabine in, 1979-1980
hypersplenic cytopenia in, 1981-1982
immunotoxins in, 1983
infections in, 1980-1981
laboratory abnormalities in, 1976
monoclonal antibodies in, 1983
new patient therapy in, 1977-1978
oncogenes in, 1975-1976
passive monoclonal antibody therapy in, 1500
prednisone in, 1978
radioimmunoconjugates in, 1983
radiotherapy in, 1980
refractory, therapy of, 1982-1984
response criteria in, 1980
second malignancies following, 1982
single drugs in, 1978
staging of, 1977
therapy of, 1977-1980
transformation in, 1982
tumor-suppressor genes in, 1976
updated review of, 1974-1990
chronic lymphoid, 2-chlorodeoxyadenosine plus chlorambucil in, 569-574
following chemotherapy, 1066-1068
following cisplatin, etoposide, bleomycin regimen, 701-706
following cyclophosphamide, 1066-1068
following HD therapy, incidence of, 1063-1064
following lomustine, 1066-1068
following mechlorethamine, 1066-1068
following procarbazine, 1066-1068
following radiotherapy, 1066-1068
following teniposide, 1066-1068
hairy cell
adenopathy incidence in, 269
internal adenopathy in, 268-272
infant acute lymphoblastic
adrenal function in, 920
cardiac function in, 920-921
chromosome analysis in, 910-911
11q23-MLL rearrangement in, 909-915
endocrine function in, 919
eyes in, 921
gonadal function in, 918-920
growth in, 918
hearing in, 920, 921
molecular analysis in, 910-911
renal function in, 920
thyroid function in, 920
treatment outcome in, 912
large granular lymphocyte, pentostatin in, 2588-2593
non-T, non-B acute lymphocytic
methotrexate, mercaptopurine regimen in, 1383-1389
prognostic factors in, 1385-1386
pediatric acute myeloblastic
allogeneic BMT in, 1217-1222
busulfan, cyclophosphamide regimen *v* TBI in, 1217-1222
pediatric refractory, carboplatin, etoposide regimen in, 1969-1973
refractory acute, topotecan in, 2192-2203
relapse, following allogeneic BMT, 1710-1717
relapsed acute, mercaptopurine plus cytarabine in, 587-595
relapsed chronic lymphocytic, BMT in, 748-758
risk of
following HD, 1063-1073
HD stage and, 1070
as second cancer, relative risk of, 320
T-prolymphocytic, pentostatin in, 2588-2593
Leukoplakia, chemoprevention trials in, 859
Leventhal, Brigid, in memoriam, 1111-1112
Li-Fraumeni syndrome, germline p53 mutations in, 925-930
Linac method, of stereotactic radiosurgery, 1088-1089
Lipiodol, in hepatocellular carcinoma, 1326-1327
Liver, colorectal cancer metastases to, repeated resections for, 1491-1496
Liver cancer
staging of, 1324
unresectable, high-dose hepatic arterial infusion chemotherapy for, 2723-2736
Lobectomy, in lung cancer, 983
Lomustine, leukemia risk following, 1063-1073
Lomustine, procarbazine, vincristine regimen
dose-intensity of, 2018
for glioma, 2013-2021
response to, 2016-2017
Lung
osteosarcoma metastases to, 1849-1858
detection of, 1855
premalignancy of, chemoprevention trials and, 862-863
Lung cancer
additional therapy of, 2341
advanced, irinotecan, etoposide, G-CSF regimen in, 1833-1841
5-year survivors in, 985
histologic cell type in, 982

incidence of, 1238
limited-stage small-cell, thoracic failure in, 496-502
lobectomy in, 983
measurable disease in, 2677-2681
metastatic non–small-cell, docetaxel in, 1238-1244
non–small-cell
advanced, weekly gemcitabine in, 1821-1826
cisplatin *v* cisplatin, carboplatin regimen in, 353-359
cisplatin, vinblastine, hydrazine sulfate regimen in, 1113-1120
cisplatin, vinorelbine regimen in, 360-367
continuous infusion etoposide in, 83-89
cyclophosphamide, doxorubicin, cisplatin regimen in, 2333-2339
daily cisplatin plus radiotherapy in, 1814-1820
drug delivery analysis in, 2333-2339
hydrazine sulfate in, 1126-1129
irinotecan, cisplatin, G-CSF regimen in, 90-96
nodal micrometastases in, 1827-1832
relapse prognosis in, 1827-1832
topotecan for, 347-352
vindesine, cisplatin regimen in, 360-367, 2333-2339
vinorelbine in, 360-367
passive monoclonal antibody therapy in, 1504
pneumonectomy in, 983
primary, in younger patients, 981-985
probe-thoracotomy in, 983
recurrent non–small-cell, docetaxel in, 1238-1244
as second cancer, relative risk of, 319-320
small-cell
cisplatin, etoposide regimen in, 70-76
combination chemotherapy in, neutropenic fever following, 1245-1250
etoposide in, 1427-1435
etoposide plus cisplatin in, 2022-2034
GM-CSF in, 2667-2677
high-dose chemotherapy plus stem-cell transplantation in, 230
interferon gamma in, 2321-2326
irinotecan, etoposide, G-CSF regimen in, 1833-1841
metastatic sites in, 1429
prophylactic cranial irradiation in, 2327-2332
weekly chemotherapy in, 77-82
weekly *v* 3-week chemotherapy in, 1806-1813
stage III non–small-cell, radiotherapy in, 1547-1552
stage III-IV non–small-cell, docetaxel in, 1232-1237
surgery in, 983
disease stage of, 982
survival in, 982-983
therapy of, 982
wedge resection in, 983
LYM-1, in B-cell lymphoma, 1499
Lymph node, NSCLC micrometastasis in, 1827-1832
Lymphadenectomy, in gastric cancer, 417-422
Lymphokine-activated killer cell, assay for, 99
Lymphoma
adult diffuse small noncleaved-cell non-Burkitt's, combination chemotherapy in, 2153-2159
adult lymphoblastic, autologous BMT in, 1358-1365
aggressive, International Prognostic Index for, 1340-1342
B-cell, 1499
passive monoclonal antibody therapy in, 1500-1501
BMT for, G-CSF following, 1931-1938
cutaneous T-cell, IL-7 and IL-2 in, 326-335
cyclophosphamide, carboplatin, etoposide, stem-cell transplantation, interferon alfa-2b regimen in, 2423-2431
dacarbazine, cyclophosphamide, carmustine, etoposide, stem-cell transplantation regimen in, 1890-1901
follicular, cyclophosphamide, TBI, BMT regimen in, 1177-1184
follicular large-cell
cyclophosphamide and doxorubicin-based regimen in, 1349-1357
histologic characteristics in, 1351
histologic diagnosis in, 1352
as intermediate-grade, 1349-1357
International Prognostic Index in, 1354
overview of, 1349-1350
prognostic factors in, 1353
survival in, 1352-1353
low-grade
2-chlorodeoxyadenosine plus chlorambucil in, 569-574
fludarabine, mitoxantrone, dexamethasone regimen in, 575-579
International Prognostic Index for, 1343-1348
prognostic score calculation for, 1347-1348
malignant, TBI, etoposide, cyclophosphamide, stem-cell transplantation regimen in, 2559-2566
multidrug resistance in, 2453-2459
non-Burkitt's, prognostic factors in, 2157
peripheral T-cell
cytogenetic studies of, 1189
immunohistochemistry studies of, 1189
retinoic acid-induced cellular differentiation in, 1190
retinoic acids for, 1185-1192
primary small-intestinal
CHOP regimen in, 1375-1382
in Taiwan, 1375-1382
recurrent follicular, myeloablative therapy with BMT in, 1177-1184
refractory
etoposide, methylprednisolone, cytarabine, cisplatin regimen in, 1169-1176
mitoxantrone, cyclophosphamide, carmustine, etoposide regimen in, 141-148
prognostic factors in, with etoposide, methylprednisolone, cytarabine, cisplatin regimen, 1172-1173
residual, PCR detection of, 1532-1534
T-cell, passive monoclonal antibody therapy in, 1499, 1501

M195, in acute leukemia, 1498
MACOP-B, *see* Methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, bleomycin regimen
Macrophage colony-stimulating factor
phase I trial of, 97-106
serum concentrations of, 104
treatment plan for, 98
Magnetic resonance imaging
for bone marrow metastasis detection
in breast cancer, 1415-1421
in stage II-III breast cancer, 1418
in stage III-IV breast cancer, 1419
corticosteroid-induced changes in, of glioma, 1886-1889
Malignant melanoma
advanced, dacarbazine in, 806-811
incidence of, 1036

interferon alfa-2a plus dacarbazine in, 806-811
vitamin A *v* observation in, 2060-2065
Margin involvement, as prognostic factor, in breast conservation therapy, 653-660
Marrow harvesting, technique for, 250-251
Mastectomy
breast-conserving therapy *v*, long-term follow-up of, 1778-1782
in Halsted model, 2229
radiotherapy following, 444-446
radiotherapy plus, survival following, 447-453
M-CSF, *see* Macrophage colony-stimulating factor
Mechlorethamine, leukemia risk following, 1063-1073
Mechlorethamine, vincristine, procarbazine, prednisone regimen
death following, 283
in HD, 279-287
response to, 282
survival following, 283
see also MOPP regimen
Mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine regimen
death following, 283
in HD, 279-287
response to, 282
survival following, 283
Medroxyprogesterone acetate, tamoxifen *v*, in breast cancer, 1630-1638
Medulloblastoma, infant, craniospinal irradiation for, 1212-1216
Megestrol acetate, in anorexia-cachexia syndrome, 219-221
Melacine, 402-411
Melanoma
active specific immunotherapy of, interferon alfa-2b following, 402-411
immunization in, survival and, 1040-1041
malignant, *see* Malignant melanoma
metastatic
chemoimmunotherapy of, 1553-1560
cisplatin, dacarbazine, tamoxifen, IL-2 regimen in, 1553-1560
standard therapy for, 624-625
tamoxifen in, 617-626
passive monoclonal antibody therapy in, 1502, 1504-1505
primary choroidal, therapeutic vaccine for, 396-401
stage III, GM2 ganglioside in, 1036-1044
theraccine, interferon alfa-2b following, 402-411
tumor-infiltrating lymphocytes plus IL-2 in, 1475-1483
Melphalan
in chemoradiotherapy regimen, for multiple myeloma, 503-509
in combination chemotherapy, for multiple myeloma, 2405-2414
in conditioning regimen, 2419
high-dose
plus BMT, in myeloma, 759-763
long-term follow-up of, 764-768
with peripheral-blood progenitor-cell support, 40
quality of life following, 765
response to, 765
survival following, 765-766
toxicity of, 766
in high-dose combination chemotherapy, and autologous BMT, 1358-1360
L-buthionine sulfoximine plus, phase I trial of, 194-205
in metastatic breast cancer, 37-44
pharmacokinetics of, 202
serum levels of, 196-197, 201-202
Melphalan, dexamethasone, carmustine, etoposide, cytarabine regimen
in HD, 580-586
survival following, 581
toxicity of, 583
Melphalan, TBI regimen, high-dose, and autologous BMT, 1358-1360
Mendelian risk, for cancer, 1728-1730
Mercaptopurine
in combined modality therapy, for acute lymphoblastic leukemia, 740-747
cumulative dosing of, in acute lymphocytic leukemia, 1315
cytarabine plus
administration of, 588
in relapsed acute leukemia, 587-595
toxic effects of, 590
in maintenance regimen, for myeloid leukemia, 128
Mercaptopurine, methotrexate regimen
in non-T, non-B acute lymphocytic leukemia, 1383-1389
patient outcomes following, 1385
prognostic factors following, 1385
toxicity following, 1386-1387
treatment regimen with, 1384-1385
Mesna, nephrotoxicity associated with, 160
Mesothelioma
malignant
TNM staging for, 1158
trimetrexate for, 1436-1442
malignant pleural, pleurectomy-decortication plus intrapleural chemotherapy in, 1156-1163
Metaplasia, bronchial squamous
index for, following isotretinoin, 941-942
isotretinoin chemoprevention in, 937-945
smoking cessation impact on, 941
Metastasis
by site, in node-negative breast cancer, 463
clinical appearance of, in breast cancer, 2230
hypothesis of, in breast cancer, 2229-2230
tumor angiogenesis and, 441-442
Methotrexate
in chemoradiotherapy regimen, for multiple myeloma, 503-509
in combination chemotherapy
for acute myeloid leukemia, 2139
dosing intensity of, 773
dosing schedule of, 771-772
for NHL, 1074-1084, 769-778
total dose of, 773
toxicity of, 773-774
in combined modality therapy, for acute lymphoblastic leukemia, 740-747
cranial irradiation plus, in childhood cancer, 2621-2629
cumulative dosing of, in acute lymphocytic leukemia, 1315
delayed excretion of, toxicity of, 1667-1672
5-FU plus
in advanced colorectal cancer, 960-969
survival following, 964-965
tumor response following, 964
high-dose, toxicity of, 1667-1672
in maintenance regimen, for myeloid leukemia, 128
nephrotoxicity associated with, 160
in osteosarcoma, 1443-1451

pharmacokinetics of, 1443-1451
in ProMACE-MOPP regimen, for NHL, 1366-1374
Methotrexate, cyclophosphamide, 5-FU regimen
compliance with, 2088
in node-positive breast cancer, 2086-2093
short-term toxicity of, 2091
Methotrexate, cyclophosphamide, 5-FU, tamoxifen regimen, in node-positive breast cancer, 2086-2093
Methotrexate, cyclophosphamide, 5-FU, vincristine, prednisone regimen
in breast cancer, 2078-2085
second primary tumor following, 2080-2081
survival following, 2080
toxicity of, 2081-2083
Methotrexate, cyclophosphamide, doxorubicin, etoposide, folinic acid, prednisone regimen, in non-Burkitt's lymphoma, 2153-2159
Methotrexate, cyclophosphamide, TBI regimen, BMT following, 127-135
Methotrexate, cytarabine regimen
for acute lymphoblastic leukemia, 1939-1945
scheduling of, 1940
toxicity profile of, 1942
Methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, bleomycin regimen
CHOP *v*, in NHL, 769-778
dosing schedule of, 771-772
hospital admissions following, 774
response to, 772
survival following, 773
toxicity of, 773-774
Methotrexate, folinic acid, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, in NHL, 1074-1084
Methotrexate, folinic acid, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen
death following, 1371
in NHL, 1074-1084
ProMACE-MOPP *v*, in NHL, 1366-1374
survival following, 1370
toxicity of, 1371
Methotrexate, mercaptopurine regimen
in non-T, non-B acute lymphocytic leukemia, 1383-1389
patient outcomes following, 1385
prognostic factors following, 1385
toxicity following, 1386-1387
treatment regimen with, 1384-1385
Methotrexate, thioguanine regimen, sequential, in children, 1955-1962
Methotrexate, vinblastine, bleomycin, radiotherapy regimen, pulmonary toxicity of, 292-293
Methotrexate, vinblastine, bleomycin regimen
dosing modifications to, 290
pulmonary function following, 297-305
response to, 292
Methotrexate, vinblastine, bleomycin, radiotherapy regimen
compliance with, 291
in early HD, 288-296
hematologic toxicity of, 292
Methotrexate, vinblastine, doxorubicin, cisplatin regimen
in bladder cancer, 975-980, 1394-1401
relapse pattern following, 975-980
Methotrexate, vinblastine, doxorubicin, cisplatin, G-CSF regimen
dose-intensity of, 485-486
response to, 486
toxicity of, 485
in urothelial cancer, 483-488
Methylmethacrylate, 2348
Methylprednisolone, etoposide, cytarabine, cisplatin regimen
adverse prognostic factors in, 1173
in refractory lymphoma, 1169-1176
response to, 1171
scheduling of, 1170
survival following, 1173
toxicity of, 1173-1174
Methylprednisolone, vincristine, doxorubicin regimen
extramedullary toxicity of, 762
in myeloma, 759-763
response to, 761
survival following, 761
toxicity of, 761-762
Metoclopramide, in anorexia-cachexia syndrome, 219
Micrometastasis
immunohistochemical assessment of, in NSCLC, 1827-1832
in lymph nodes, of NSCLC, 1827-1832
polymerase chain reaction detection of, 725-729
Microvessel density, of tumor
as prognostic factor, 454-466
relationship of, to other prognostic variables, 458-459
Minimal residual disease, in acute lymphocytic leukemia, detection of, 1318-1319
Minnesota, Olmsted County in, multiple myeloma in, 1577-1583
Mitoguazone, rationale for, 947
Mitoguazone, 5-FU, cisplatin regimen
in head and neck cancer, 946-953
response to, 949
toxicity of, 948
Mitomycin
in superficial bladder cancer, 7-13
intrapleural cisplatin plus, for malignant pleural mesothelioma, 1156-1163
toxicity of, 11
Mitomycin, 5-FU, doxorubicin regimen
in gastric cancer, 2687-2693
response to, 2689-2690
toxicity of, 2688-2689
Mitotic activity, in rectal cancer, preoperative irradiation and, 679-682
Mitoxantrone
extramedullary toxicity of, 144-145
hematologic toxicity of, 143-144
high-dose
in combination chemotherapy, for ovarian cancer, 176-183
pharmacokinetics following, 180
pharmacokinetic characteristics of, 143
pharmacokinetic studies of, 177, 179-180
prednisone plus
hematologic toxicity of, 693
in prostate cancer, 689-694
phase II study of, 689-694
response to, 691-692
toxicity of, 692
response to, 145

Mitoxantrone, carboplatin, cyclophosphamide, BMT regimen
hematologic recovery following, 178
in ovarian cancer, 176-183
nonhematologic toxicity of, 178-179
response to, 180
Mitoxantrone, cyclophosphamide, carmustine, etoposide regimen, in refractory lymphoma, 141-148
Mitoxantrone, cytarabine, peripheral-blood progenitor-cell support regimen, in NHL, 1685-1692
Mitoxantrone, fludarabine, dexamethasone regimen
dose escalation of, 576
in lymphoma, 575-579
nonhematologic toxicity of, 577
phase I trial of, 575-579
response to, 577
toxicity of, 576-577
Moertel, Charles G., in memoriam, 2246-2247
Molgramostim, 2479
see also Granulocyte-macrophage colony-stimulating factor
Monoclonal antibody(ies)
in acute myelocytic leukemia, 1499-1500
antigenic heterogeneity and, 1511
antigenic modulation and, 1509-1510
in B and pre-B acute lymphocytic leukemia, 1498-1499
in B-cell lymphoma, 1499, 1500-1501
as biologic response modifiers, 1505-1506
in bone marrow purging, 1021-1027
in breast cancer, 1502
in chronic lymphocytic leukemia, 1500, 1983
class and, 1511
clinical efficacy of, 1506-1508
in colorectal cancer, 1502-1504
as cytotoxic therapy, 1497-1515
dosing of, 1508
free antigens and, 1509
with ganglioside specificity, 1036-1044
HAMA response and, 1510
immune complexes and, 1510-1511
immunoselection and, 1509-1510
infusion rates and, 1510
in lung cancer, 1504
in melanoma, 1502, 1504-1505
in multiple myeloma, 1501-1502
in neuroblastoma, 1505
in ovarian cancer, 1505
in pancreatic cancer, 1505
passive therapy with
in acute leukemia, 1498
side effects of, 1508
pharmacokinetics of, 1509
in prostate cancer, 1505
radiolabeled, in occult colorectal cancer, 489-495
serum levels of, 1509
in stomach cancer, 1505
subclass and, 1511
in T-cell lymphoma, 1499, 1501
toxicity of, 1508-1509
in vivo binding of, to malignant cells, 1506
Monoclonal antibody 14G2a
HAMA levels following, 189-190
immunohistochemistry of, 186
immunoscintigraphy of, 186-187
in neuroectodermal tumors, 184-193
pharmacokinetics of, 186
phase I trial of, 184-193
preparation of, 185
prolonged intravenous infusion of, 184-193
radiolabeling of, 185
response to, 188
serum sodium changes following, 188-189
toxicity of, 187-189
unlabeled, serum half-life of, 189-191
in vivo uptake of, 190
Monoclonal antibody A33
description of, 1562
HAMA response following, 1565-1566
iodine-labeled, dosing of, 1563
radiolabeled
in colon cancer, 1561
phase I-II trial of, 1561-1571
Monoclonal antibody F19
for fibroblast activation protein targeting, 1193-1203
radioiodination of
administration of, 1195
biodistribution of, 1200
for colorectal cancer detection, 1197, 1199
Monoclonal antibody M1G8, in cathepsin D detection, 467-474
Mononuclear phagocyte, assays for, 98-99
Mood, correlation of, and cognition, 823-824
MOPP-ABVD regimen
low-dose involved-field radiotherapy plus
in pediatric HD, 2160-2166
late effects of, 2164
toxicity of, 2161-2162
pulmonary function following, 297-305
Morbidity, PIXY321 effects on, 721-722
Mortality
cardiac, following radiotherapy, 451
CD4 cells and, in AIDS-related Kaposi's sarcoma, 1910-1916
following radiotherapy of breast cancer, 447-453
MRI, *see* Magnetic resonance imaging
MRK-16, in p-glycoprotein assay, 2454
Mucosal proliferation, in colon, chemoprevention trials and, 864
Mucositis
Composite Mucositis Score for, 1918-1919
grading criteria for, 2631
oral
assessment of, 1918
following stem-cell transplantation, 1917-1922
GM-CSF impact on, 1917-1922
standard care for, 1918
Oral Assessment Score for, 1918-1919
PIXY321 effects on, 721-722
radiation-induced, chlorhexidine mouthwash for, 2630-2633
Multidrug resistance
in acute lymphocytic leukemia, detection of, 1318
cyclosporine for, 835-842
future studies of, 2457-2458
in lymphomas, 2453-2459
modulation of, 2456-2457
P-glycoprotein-mediated, 813
as prognostic variable, 2456
quinidine for, 1771-1777

Multiple drug resistance-1 gene, 812-813
  prognostic value of, in multiple myeloma, 115-119
Multiple myeloma
  combination chemotherapy, glucocorticoids, interferon alfa regimen in, 2405-2414
  dacarbazine, cyclophosphamide, carmustine, etoposide, stem-cell transplantation regimen in, 1890-1901
  doxorubicin, vincristine, dexamethasone, cyclosporine regimen in, 1584-1591
  drug resistance in, cyclosporine modulation of, 1584-1591
  high-dose sequential chemoradiotherapy for, 503-509
  immunoglobulin D, 2398-2404
    survival following, 2401-2402
  incidence of, 1578-1580
  multiple drug resistance-1 gene in, prognostic value of, 115-119
  in Olmsted County, Minnesota, 1577-1583
  overview of, 503
  passive monoclonal antibody therapy in, 1501-1502
  prednisone, vindesine, carmustine, cyclophosphamide regimen in, 2706-2714
  survival in, 1580
  vincristine, doxorubicin, dexamethasone regimen in, 115-119, 2706-2714
Mycosis
  amphotericin B for, 827-834
  risk factors for, 830
Mycosis fungoides
  fludarabine plus interferon alfa-2a in, 2051-2059
  IL-7 and IL-2 in, 326-335
Myelodysplasia, myeloablative therapy, with autologous stem-cell transplantation, 2521-2523
Myelodysplastic syndrome(s)
  colony-stimulating factor in, 2473, 2492-2494
  fludarabine, cytarabine, G-CSF regimen in, 671-678
  following allogeneic BMT, 2538
  following autologous BMT, in NHL, 2535-2542
  following chemoradiotherapy and stem-cell transplantation, 2527-2534
  risk for, classification-tree analysis of, 2540
Myeloma
  high-dose melphalan in, long-term follow-up of, 764-768
  high-dose melphalan plus BMT in, 759-763
  interferon maintenance in, 2413
  melphalan in, with no BMT, 764-768
  multiple, *see* Multiple myeloma
Myelosuppression
  chemotherapy-induced multilineage, PIXY321 in, 715-724
  cumulative
    Il-1 alpha in, 713
    PIXY321 effects on, 720-721
  IL-1 alpha in, 709-710
  peripheral-blood progenitor-cell reinfusion and, 1014-1016
  PIXY321 effects on, 718

N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl
  cyclophosphamide plus, 1285
  daunorubicin plus, 1285
  5-FU plus, 1285
  in refractory cancer, 1281-1290
  response to, 1285-1287
  side effects of, 1285, 1288
  toxicity following, 1288
Narcotics, in euthanasia, 1520-1521
National Cancer Institute, Clinical Alert of, effect of, 1783-1788
Natural-killer cell, assay for, 99
Nausea
  alizapride plus tropisetron for, 2439-2446
  delayed, ondansetron scheduling for, 1053-1054
  dexamethasone plus tropisetron for, 2439-2446
  dolasetron mesylate for, 1045-1049
  oral ondansetron for, 2432-2438
  quality of life and, 1054-1055
  TBI-associated, oral ondansetron for, 2432-2438
  tropisetron for, 2439-2446
Nephrectomy, unilateral, ifofamide usage following, 159-165
Nephrotoxicity, ifosfamide-induced, risk factors for, 159-165
Neurobehavioral function, following BMT, 820-826
Neuroblastoma
  allogeneic *v* autologous BMT for, 2382-2389
  carboplatin, iproplatin, ifosfamide, epirubicin regimen for, 1616-1620
  cyclophosphamide, doxorubicin, vincristine, cisplatin, etoposide regimen for, 2607-2613
  International Staging System criteria for, 2378-2381
  passive monoclonal antibody therapy for, 1505
  stage IV, induction therapy for, 2607-2613
Neuroectodermal tumor, monoclonal antibody 14G2a for, 184-193
Neuropsychologic effects, of cranial irradiation plus methotrexate, in childhood cancer, 2621-2629
Neurotoxicity
  in adults, following prophylactic cranial irradiation, 638-639
  assessment of, 638
  following cranial irradiation, 627-642
  following therapeutic cranial irradiation, 635, 637
  grading system for, 2217
Neutropenia
  definition of, 2476
  febrile
    following combination chemotherapy, in SCLC, 1245-1250
    G-CSF for, cost impact of, 1245-1250
    home antibiotic therapy for, 107-114
    PIXY321 effects on, 721
    sequential prophylactic and empiric antibiotics for, 1005-1011
Nevus(i)
  dysplastic, *see* Dysplastic nevi
  multiple atypical, germ cell tumors and, 2284-2287
NHL, *see* Non-Hodgkin's lymphoma
Nitrogen mustard, *see* Mechlorethamine
Non-Hodgkin's lymphoma
  adult, chemotherapy plus stem-cell transplantation in, 228-229
  advanced diffuse, MACOP-B *v* ProMACE-MOPP regimen in, 1366-1374
  advanced indolent, 2-chlorodeoxyadenosine in, 788-792
  as second cancer, relative risk of, 319-320
  autologous BMT in, 2415-2422
  autologous BMT *v* sequential chemotherapy in, 2542-2551
  BMT in
    myelodysplastic syndrome following, 2535-2542
    t(14;18) studies of, 798-805
  CD30+ large-cell, progress in, 884-887
  childhood, teniposide plus cytarabine in, 1963-1968
  childhood CD30+ large-cell

biologic features of, 897
cytogenetics in, 8q6
5-year survival in, 897
immunophenotype in, 896
overall survival in, 897
treatment in, 896
treatment outcome in, 895-898
childhood Ki-1 anaplastic large-cell
clinical features of, 901, 903
diagnosis of, 900
histopathology of, 901-902
immunohistochemistry of, 902
local therapy of, 904
morbidity in, 904
prognostic parameters in, 904
relapses in, 903-904, 905
remission failures in, 903
short-pulse chemotherapy in, 899-908
staging of, 900
survival duration in, 903
therapy in, 899-908
therapy results in, 902-903
complete response in, prognostic significance of, 1077-1078
cyclophosphamide, carmustine, etoposide, BMT regimen in, 2542-2551
cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate in, 1074-1084
cyclophosphamide, doxorubicin, vincristine, prednisone regimen in, 1074-1084
cyclophosphamide, TBI, BMT regimen in, 798-805
diffuse large-cell, *bcl-2*-MBR gene rearrangement in, 149-154
DNA index in, 2168-2169
DNA ploidy in, 2169-2170
follicular, t(14;18) studies in, 798-805
gastrointestinal
geographic distribution of, 1676
incidence of, 1673-1684
prognostic factors in, 1679
specific localizations of, 1679
survival in, 1679-1680
high-grade, outcome in, 1075-1077
ifosfamide, etoposide, asparaginase, cytarabine regimen in, 2542-2551
intermediate-grade
MACOP-B *v* CHOP regimen in, 769-778
outcome in, 1075-1077
low-grade, cytarabine, mitoxantrone, peripheral-blood progenitor-cell support regimen in, 1685-1692
methotrexate, folinic acid, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone in, 1074-1084
methotrexate, folinic acid, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin in, 1074-1084
partial or slow response in, 1074-1084
PCR assay in, 1687-1688
S-phase fraction in, therapy impact on, 2167-2175
t(14;18) cells in, remission and, 1541-1546
TBI, etoposide, cyclophosphamide, BMT regimen in, 2552-2557
transplantation in, 2524-2526
Nonimmunoproliferative small-intestinal disease, 1376-1378
in Taiwan, 1375-1382
Nonsteroidal antiinflammatory drug
analgesic efficacy of
v aspirin, 2759
v morphine, 2758
v placebo, 2757
in chemoprevention, 856, 864-865
for pain, 2756-2765
patient satisfaction with, 2761-2764
side effects of, 2760-2761
Norbeck Social Support Questionnarie, 822
NSCLC, *see* Lung cancer, non–small-cell
Nutrition
enteral, in anorexia-cachexia syndrome, 218
parenteral, in anorexia-cachexia syndrome, 218-219

Observation, vitamin A *v*, in malignant melanoma, 2060-2065
4-OHA, 2463-2464
Oligodendroglioma, anaplastic, procarbazine, lomustine, vincristine regimen for, 2013-2021
Olmsted County, in Minnesota, multiple myeloma in, 1577-1583
Oncogene, in chronic lymphocytic leukemia, 1975-1976
Oncologist(s)
attitude of
to adjuvant chemotherapy, in breast cancer, 1296-1304
to cost, 1298
to randomized clinical trials, 1796-1805
profile of, in clinical participation, 1800-1801
prognostic variable integration by, in breast cancer, 1422-1426
Ondansetron
adminstration of, 2433
antiemetic efficacy of, 598
preservation of, 1054
dexamethasone plus, 1050-1057
antiemetic efficacy of, 598
in cisplatin-induced emesis, 596-600
safety of, 599
effect of, on delayed emesis, 1053-1054
efficacy of, 2434-2424
emetic episodes following, 2435
in high-dose cisplatin-induced emesis, 596-600
oral, for TBI-associated nausea, 2432-2438
quality of life and, 1054-1055
safety of, 599, 2435
scheduling of, 1050-1057
schema for, 1051
single *v* divided doses of, 1052-1053
Oral Assessment Score, 1918
grading criteria for, 1919
Oral premalignancy, chemoprevention trials in, 859-861
Orchiectomy, effect of, on prostate cancer survival, 1868-1875
Organ preservation
in bladder cancer, 975-980
disease-free survival following, 950
in head and neck cancer, 949-950
radiation following chemotherapy in, 946-953
survival following, 950-951
therapy management in, schematic for, 950
time to recurrence following, 951
Orthotopic liver transplantation, in hepatocellular carcinoma, 1329-1330
Osteodensitometry, of skeleton, following tamoxifen, 992-993
Osteosarcoma

actuarial survival in, 426
adjuvant chemotherapy in, 1842-1848
age in, as prognostic factor, 427
anatomic site of, 428
childhood, recurrences in, 2614-2620
doxorubicin, cisplatin, G-CSF regimen in, 1842-1848
of extremities, pulmonary metastases of, 1849-1858
methotrexate in, 1443-1451
pediatric, germline p53 mutations in, 925-930
phase II trial of, 1842-1848
prognostic factors in, 423-431
pronostic variable summary in, 429
recurrence in
chemotherapy-induced necrosis and, 2699-2705
surgical margins and, 2699-2705
sex in, as prognostic factor, 427
tumor necrosis in, 429
tumor size in, 428
Outpatient therapy, with antibiotics
duration of, 112
economic outcomes of, 111-112
in low-risk patients, 107-114
medical complications following, 110-111
patient attitude and, 111
regimens for, 111
Ovarian cancer
advanced epithelial, cisplatin *v* carboplatin in, 2066-2070
clinical features of, 180
epithelial, p53 immunostaining in, 64-69
genetic testing for, 843-850
high-dose chemotherapy plus stem-cell transplantation in, 230
paclitaxel therapy for, improvement in, 1743-1744
passive monoclonal antibody therapy in, 1505
platinum-based therapy of, paclitaxel following, 1748-1753
platinum-refractory, docetaxel in, 2301-2308
platinum-resistant epithelial, oral etoposidein, 60-63
refractory, mitoxantrone, carboplatin, cyclophosphamide, BMT regimen in, 176-183
relapsed, paclitaxel in, 2654-2666
thrombocytopenia in, IL-1 alpha for, 707-714
Ovarian germ cell tumor
cisplatin-based chemotherapy for, 378-384
cisplatin, etoposide, bleomycin regimen for, 701-706

P-glycoprotein, 835
assays for, 2454
expression of, survival and, 117
-mediated multidrug resistance, 813
in multidrug-resistant lymphomas, 2435-2459
overexpression of, cyclosporine for, 1586-1588
topotecan and, 2198-2199
Paclitaxel
adverse effects of, 1751
in bladder cancer, 2264-2270
delivery of, 2658
dosing modifications for, 2281
for germ cell tumors, 2277-2283
high-dose, phase I trial of, 241-248
in overall population, 1750
96-hour infusion of, in breast cancer, 1621-1629
overview of, 233-236
phamacokinetics of, 2661-2662
pharmacodynamics of, in pediatric solid tumors, 523-528
pharmacokinetic models of, 535
pharmacology of, 1626-1627
phase I-II trial of, in breast cancer, 1621-1629
phase II trial of, 2277-2283
in ovarian cancer, 1748-1753
in platinum-resistant patients, 1750-1751
in platinum-sensitive patients, 1750
radiotherapy plus
hematologic toxicity of, 2685
nonhematologic toxicity of, 2684
in NSCLC, 2682-2686
in relapsed ovarian cancer, 2654-2666
response to, 1625, 1749
by age, 1750
in bladder cancer, 2266-2267
for germ cell tumors, 2280-2281
by histologic grade, 1750
by performance status, 1750
by prior therapy, 1751
by time to first recurrence, 1750
saturable pharmacokinetics of, in pediatric solid tumors, 523-528
survival following, in bladder cancer, 2266-2267
systemic clearance of, 535
therapy improvements with, in ovarian cancer, 1743-1744
3-hour infusion of
arthralgia due to, 244
hypersensitivity to, 243
mean pharmacokinetic parameters of, 246
myalgia following, 244
myelosuppression associated with, 243-244
neuropathy due to, 244-245
pharmacokinetics of, 242-243
response to, 246
with G-CSF, 241-248
toxicity of, 1625-1626, 2265-2266, 2281, 2659
tumor response to, 2659-2660
Pain
assessment of, verbal scale for, 2751-2755
nonsteroidal antiinflammatory drugs for, 2756-2765
Pancreatic cancer, passive monoclonal antibody therapy in, 1505
Pancytopenia, following methotrexate, mercaptopurine regimen, 1386
Paracrine effector, in Sézary syndrome, 326-335
Parenteral nutrition, in anorexia-cachexia syndrome, 218-219
Patterns of care study
rationale for, 954-955
in rectosigmoid cancer irradiation, 954-959
PCR, *see* Polymerase chain reaction
Pediatric Oncology Group staging, of neuroblastoma, 2379
Pentamidine, aerosolized
adverse reactions to, 259-260
efficacy of, 138
infections following, 138
for *Pneumocystis carinii* pneumonia prophylaxis, 136-140, 258-261
toxicity of, 138
Pentostatin
in combination therapy, 2223
high-dose, 2218

neurotoxicity of, 2216-2228
overview of, 2221-2223
standard-dose, 2219
structure of, 2217
T-cell malignancies and, 2588-2593
see also 2′Deoxycoformycin
Percutaneous intratumoral alcohol injection, in hepatocellular carcinoma, 1328
Peripheral-blood lymphocyte, immune reactivity of, 1479-1481
Peripheral-blood mononuclear cells
polymerase chain reaction analysis of, 1024
tumor cell detection in, 1021-1027
Peripheral-blood progenitor cell
assays of, 1013
in stem-cell transplantation, 2177-2178
in BMT, 1006
carboplatin-mobilized, 1012-1020
circulating, therapy impact on, 1016-1017
collection of, 1013
reinfusion of, myelosuppression and, 1014-1016
storage of, 1013
support, definition of, 2476
Peripheral-blood progenitor-cell support, cytarabine, mitoxantrone regimen, in NHL, 1685-1692
Peripheral-blood progenitor-cell transplantation
adjunctive colony-stimulating factor in, 2472-2473, 2489-2492
chemoradiotherapy plus, in multiple myeloma, 503-509
G-CSF promed, 2176-2186
simplified approach to, 1693-1702
Peritumoral lymphatic vessel invasion, in node-negative breast cancer, 454-466
Peters, Vera, in memoriam, 239-240
Pharmacokinetics
of 5-FU, 561, 564-565
of M-CSF, 99-100
of methotrexate, in osteosarcoma, 1443-1451
of passive monoclonal antibody therapy, 1509
of topotecan, 542, 554-555, 557
Phase I trial
of 2-chlorodeoxyadenosine plus chlorambucil, 569-574
of continuous infusion carboplatin, etoposide regimen, 1969-1973
of dacarbazine, cyclophosphamide, carmustine, etoposide, stem-cell transplantation regimen, 1890-1901
of docetaxel, in weekly 1-hour intravenous infusion, 1458-1467
of etoposide phosphate, 1902-1909
of high-dose mitoxantrone, carboplatin, cyclophosphamide, BMT regimen, 176-183
of ifosfamide, carboplatin, etoposide, GM-CSF regimen, 1251-1258
of interferon gamma, in cyclosporine-induced GVHD, 249-257
of irinotecan, cisplatin, G-CSF regimen, 90-96
of L-buthionine sulfoximine plus melphalan, 194-205
of M-CSF, 97-106
of monoclonal antibody 14G2a, in neuroectodermal tumors, 184-193
of oral etoposide, in children, 1452-1457
of outpatient weekly paclitaxel, radiotherapy plus, 2682-2686
of supradose cisplatin infusion, 2113-2120
of 3-hour paclitaxel infusion, with G-CSF, 241-248
of topotecan
for pediatric solid tumors, 539-543
in leukemia, 2193-2203
of topotecan plus cisplatin, 2743-2750
Phase I-II trial
of carboplatin, etoposide, ifosfamide, stem-cell transplantation regimen, 1223-1231
of continuous infusion etoposide, 83-89
of cyclophosphamide, carboplatin, etoposide, stem-cell transplantation, interferon alfa-2b regimen, 2423-2431
of gemcitabine, current status of, 1527-1531
of ifosfamide, carboplatin, etopposide regimen, 544-552
of 96-hour paclitaxel infusion, 1621-1629
of radiolabeled monoclonal antibody A33, 1561-1571
Phase II trial
of bleomycin, ifosfamide, carboplatin regimen, in cervical cancer, 55-59
of chemoimmunotherapy, in melanoma, 1553-1560
of cisplatin *v* cisplatin, carboplatin regimen, 353-359
of dexamethasone, carmustine, etoposide, cytarabine, melphalan regimen, 580-586
of docetaxel
in metastatic NSCLC, 1238-1244
in recurrent NSCLC, 1238-1244
in stage III-IV NSCLC, 1232-1237
of doxorubicin, cisplatin, G-CSF regimen, 1842-1848
of fludarabine plus interferon alfa-2a, 2051-2059
of 5-FU, epirubicin, cisplatin regimen, 1259-1265
of gemcitabine, 1821-1826
of irinotecan, etoposide, G-CSF regimen, 1833-1841
of paclitaxel
for germ cell tumors, 2277-2283
in ovarian cancer, 1748-1753
of trimetrexate, in malignant mesothelioma, 1436-1442
of uracil, tegafur, folinic acid regimen, for colorectal cancer, 2296-2300
of vinblastine, ifosfamide, gallium regimen, 2271-2276
of vinorelbine, in metastatic breast cancer, 336-341
Phase III trial
initiation of, 1794
of tamoxifen, 2071-2077
Phosphoribosylpyrophosphate
5-FU cytotoxicity and, 697-700
intracellular, 1383
trimetrexate effects on, 698
Pituitary radiosurgery, 1087
PIXY321
in chemotherapy-induced multilineage myelosuppression, 715-724
clinical tolerance of, 717
cumulative myelosuppression following, 720-721
effects of, on myelosuppression, 718
morbidity following, 721-722
mucositis following, 721-722
neutropenic fever following, 721
platelet recovery following, 718-720
prechemotherapy, 717-718
recombinant human, 716
RBC response following, 720
Plantar-palmar syndrome, following 5-FU, 1260
Plasma cell labeling index, prognostic value of, in multiple myeloma, 118
Plasminogen activator inhibitor-1, breast cancer prognosis and, 1648-1658

Platelet count
bleeding episodes and, 2318-2319
following PIXY321, 718-720
low, leukemia risk and, 1063-1073
Pleurectomy-decortication
definition of, 1161
intrapleural chemotherapy
complications following, 1159
for malignant pleural mesothelioma, 1156-1163
relapse sites following, 1159
survival following, 1160
Pneumocystis carinii pneumonia
aerolized pentamidine prophylaxis in, 136-140
childhood, 258-261
Pneumonectomy
extrapleural, definition of, 1161
in lung cancer, 983
Pneumonia, childhood, 258-261
Pneumocystis carinii, aerosolized pentamidine prophylaxis of, 136-140
Polymerase chain reaction
carcinoembryonic antigen-specific nested reverse transcriptase, 725-729
for IL-7, 327-328
in NHL, 1687-1688
in occult breast cancer detection, 475-482
performance of, 1022
for residual lymphoma detection, 1532-1534
reverse transcriptase
for *mdr*1 levels, 2454
for prostate cancer circulating tumor cells, 2633-2639
for t(14;18) detection, 798-805
in NHL remission, 1541-1546
in tumor cell detection, of purged bone marrow, 1021-1027
Prednisolone
in combination chemotherapy
dosing intensity of, 773
dosing schedule of, 771-772
for NHL, 769-778
total dose of, 773
toxicity of, 773-774
in combined modality therapy, for HD, 779-787
in maintenance regimen, for myeloid leukemia, 128
Prednisolone, epirubicin, quinidine regimen
in breast cancer, 1771-1777
progression-free survival following, 1775
response to, 1774
survival following, 1774-1775
toxicity of, 1773-1774
toxicity pattern following, 1774
Prednisone
in chronic lymphocytic leukemia, 1978
in combination chemotherapy
for multiple myeloma, 2405-2414
for NHL, 1074-1084
for non-T, non-B acute lymphocytic leukemia, 1384
S-phase fraction and, 2167-2175
in combined modality therapy
for acute lymphoblastic leukemia, 740-747
for HD, 779-787
in MACOP-B regimen, for NHL, 1366-1374
mitoxantrone plus
hematologic toxicity of, 693
phase II study of, 689-694
in prostate cancer, 689-694
response to, 691-692
toxicity of, 692
in MOPP regimen, for HD, 279-287
in MOPP-ABVD regimen, for HD, 279-287
Prednisone, cyclophosphamide, doxorubicin, etoposide, methotrexate, folinic acid regimen, in non-Burkitt's lymphoma, 2153-2159
Prednisone, cyclophosphamide, methotrexate, 5-FU, vincristine regimen
in breast cancer, 2078-2085
second primary tumor following, 2080-2081
survival following, 2080
toxicity of, 2081-2083
Prednisone, vincristine, carmustine, procarbazine, hydroxyurea, cisplatin, cytarabine, cyclophosphamide regimen, for infants, 1607-1615
Prednisone, vindesine, carmustine, cyclophosphamide regimen, in multiple myeloma, 2706-2714
Primitive neuroectodermal tumor, in infants, eight-in-1 day therapy for, 1607-1615
Procarbazine
in combined modality therapy, for HD, 779-787
leukemia risk following, 1063-1073
in MOPP regimen, for HD, 279-287
in MOPP-ABVD regimen, for HD, 279-287
Procarbazine, lomustine, vincristine regimen
dose intensity of, 2018
for glioma, 2013-2021
response to, 2016-2017
Procarbazine, methotrexate, folinic acid, doxorubicin, cyclophosphamide, etoposide regimen
death following, 1371
MACOP-B *v*, in NHL, 1366-1374
survival following, 1370
toxicity of, 1371
Procarbazine, vincristine, carmustine, hydroxyurea, cisplatin, cytarabine, prednisone, cyclophosphamide regimen, for infants, 1607-1615
Prognostic factor(s)
chemotaxis response as, in NHL, 1074-1084
in follicular large-cell lymphoma, 1353
integrating, in breast cancer, 1422-1426
in low-grade lymphoma, 1343-1348
in metastatic cancer, 604
patient-completed questionnaires for, 601-607
multiple drug resistance-1 gene as, in multiple myeloma, 115-119
in node-negative breast cancer, 454-466
in non-Burkitt's lymphoma, 2157
in osteosarcoma, 423-431
p53 as, in colorectal cancer survival, 2043-2050
plasminogen activator inhibitor-1 level as, in breast cancer, 1648-1658
in primary breast cancer, 1422-1426
primary therapy response as, in salvage therapy, 1078-1080
in refarctory lymphoma, with etoposide, methylprednisolone, cytarabine, cisplatin regimen, 1172-1173
in renal cell cancer, 206-212

S-phase fraction as, in NHL, 2167-2175
for second cancer, following HD therapy, 318
squamous cell carcinoma antigen as, in cervical cancer, 2312-2313
for survival, for invasive bladder cancer, 1399
thymidylate synthase as, in rectal cancer, 2640-2647
tumor bulk as, in NHL, 1077-1078
Prognostic Index, International
calculation for, 1347-1348
for aggressive lymphoma, 1340-1342
for low-grade lymphoma, 1343-1348
Prognostic test
in breast cancer, 1424
oncologist use of, 1422-1426
Proliferating cell nuclear antigen, in rectal cancer, preoperative irradiation and, 679-682
Proliferation assay, following IL-7, in cutaneous T-cell lymphoma, 328-329
ProMACE-MOPP, *see* Procarbazine, methotrexate, folinic acid, doxorubicin, cyclophosphamide, etoposide regimen
Prostate cancer
advanced, combination chemotherapy in, 2001-2002
androgen-independent, ketoconazole plus doxorubicin in, 683-688
circulating tumor cells of, detection of, 2633-2639
clinically localized, radical prostatectomy for, 2243-2245, 2254-2263
hormonally resistant, mitoxantrone plus prednisone in, 689-694
hormone-refractory, estramustine plus etoposide in, 2005-2012
passive monoclonal antibody therapy in, 1505
refractory, prognostic factors in, 1868-1875
Prostate-specific antigen
cancer relapse detection by, 1404-1405
determination of, 1403
following radiotherapy, in cancer monitoring, 1402-1407
values of, 1403-1404
Prostatectomy, radical, 2243-2245
complications following, 2259, 2261
hazards rates following, 2258
results of, 2254-2263
survival following, 2256-2258
Protein metabolism, in anorexia-cachexia syndrome, 214
Psychosocial adjustment, in breast cancer, mastectomy *v* breast-conserving surgery and, 1778-1782
Pulmonary function, following HD therapy, 297-305
Purdue Pegboard Test, for manipulative dexterity, 242
Pyridoglutethimide, 2462-2463

Quality of life
following ondansetron, 1054-1055
health-related, in oncology, 608-616
in hormonally-resistant prostate cancer, 692
measures of, 608-609
Quality-adjusted life-year, of adjuvant chemotherapy, 1298, 1300
Questionnaire, patient-completed, for prognostic variables, in metastatic cancer, 601-607
Quinidine, epirubicin, prednisolone regimen
in breast cancer, 1771-1777
progression-free survival following, 1775
response to, 1774
survival following, 1774-1775
toxicity of, 1773-1774
toxicity pattern following, 1774

R 83842, 2465-2466
R24, in melanoma, 1502
Radiation-recall phenomenon, following gemcitabine, 1538
Radioactivity, tumor to normal tissue ratios of, 490
Radioimmunoscintigraphy, in occult colorectal cancer, 489-495
Radioimmunotherapy
in hepatocellular carcinoma, 1328
monoclonal antibody A33 in, for colon cancer, 1561-1571
Radiosurgery, cranial irradiation *v*, 636-637
Radiotherapy
adjuvant, in endometrial cancer, 510-515
in advanced HD, 780-781
alternating chemotherapy with
acute toxicity of, 1878-1879
late toxicity following, 1880-1881
organ preservation following, 1881
recurrence following, 1879-1880
response to, 1879
surgery following, 1881
survival following, 1880
for brain metastases, of lung cancer, 2340-2344
in breast conservation therapy, 654-655
chlorambucil, vincristine, procarbazine, prednisone, prednisolone, doxorubicin, bleomycin, vinblastine, etoposide regimen plus, 779-787
in chronic lymphocytic leukemia, 1980
cisplatin plus
randomized trials of, 1819
survival following, 1818
toxicity of, 1817
combination chemotherapy plus, for clear-cell sarcoma, 2134
concurrent high-dose continuous-course, in NSCLC, 1814-1820
daily cisplatin plus, in NSCLC, 1814-1820
delayed, for infant medulloblastoma, 1212-1216
5-FU plus, in head and neck cancer, 2648-2653
following surgical debulking, for invasive thymoma, 1484-1490
following weekly *v* 3-week chemotherapy, 1811-1812
in HD, second cancer following, 312-325
in hepatocellular carcinoma, 1328
hyperfractionated, alternating chemotherapy with, in head and neck cancer, 1876-1885
impact of, on S-phase fraction, 2167-2175
intensive induction chemotherapy prior to, in head and neck cancer, 946-953
involved-field, pulmonary function following, 297-305
leukemia risk following, 1063-1073
long-term survivors following, of breast cancer, 447-453
low-dose involved-field, ABVD-MOPP regimen plus
in pediatric HD, 2160-2166
late efffects of, 2164
toxicity of, 2161-2162
for orbital rhabdomyosarcoma, 516-521
outpatient weekly paclitaxel plus
hematologic toxicity of, 2685
nonhematologic toxicity of, 2684
in NSCLC, 2682-2686
preoperative, mitotic activity and, 679-682
in rectal cancer, 679-682
proliferating cell nuclear antigen and, 679-682

postmastectomy, 444-446
postoperative, for metastatic-associated fracture, 2345-2350
postoperative pelvic, complications following, 510-515
prostate-specific antigen following, in cancer monitoring, 1402-1407
pulmonary toxicity of, 1550
of rectosigmoid cancer, 954-959
of stage III NSCLC, in combined modality therapy, 1547-1552
techniques of, for prostate-specific antigen monitoring, 1403
thoracic, in limited-stage SCLC, 496-502
Radiotherapy, cisplatin, 5-FU regimen
histologic response to, 1594
in laryngeal cancer, 1592-1599
response to, 1594-1595
survival following, 1595
toxicity of, 1593-1594
Radiotherapy, 5-FU, cisplatin regimen
death following, 392
in head and neck cancer, 385-395
response to, 388-389
toxicity of, 389-390
Radiotherapy, 5-FU, folinic acid regimen
in gastrointestinal cancer, 21-27
toxicity of, 24-25
Radiotherapy, 5-FU, hydroxyurea regimen, with G-CSF
acute toxicities of, 2354
cumulative toxicities of, 2355
dose intensity of, 2355
for head and neck cancer, 2351-2359
response to, 2356
treatment regimen for, 2353
Radiotherapy, 5-FU, hydroxyurea, cisplatin regimen, with G-CSF
acute toxicities of, 2354
cumulative toxicities of, 2355
dose intensity of, 2355
for head and neck cancer, 2351-2359
response to, 2356
treatment regimen for, 2353
Radiotherapy, vinblastine, bleomycin, methotrexate regimen
compliance with, 291
hematologic toxicity of, 292
in early HD, 288-296
pulmonary toxicity of, 292-293
Randomization, in clinical trials, physician attitude to, 1796-1805
Recombinant human erythropoietin
adverse effects of, 1059-1060
efficacy of, 1059-1060
hemotransfusion requirements following, 1060
in cisplatin-associated anemia, 1058-1062
response criteria for, 1059
Rectal cancer
preoperative irradiation in
mitotic activity and, 679-682
proliferating cell nuclear antigen and, 679-682
thymidylate synthase expression in, 2640-2647
Rectosigmoid cancer
radiotherapy of, 954-959
surgical procedures in, 956
Red blood cell, PIXY321 effects on, 720
Renal cell cancer
distant failure in, 208-209
local failure in, 207-208
metastatic, high- *v* low-dose IL-2 in, 1572-1576
overview of, 206
renal vein extention in, 210
surgical resection in, failure patterns following, 206-212
survival in, 209, 211
Renal dysfunction, associated with IL-2, 2714-2722
Renal Fanconi's syndrome, treatment associated with, 161
Renal tubular acidosis, calculation of, 159-160
Renal vein, extension of, in renal cell cancer, 210
Retinamide, in chemoprevention, 857
Retinoic acid, 13-*cis*-
clinical studies of, 1187-1188
for peripheral T-cell lymphoma, 1185-1192
Retinoids, in chemoprevention, 856
Retinol, in chemoprevention, 857, 865
Retinyl palmitate, in chemoprevention, 857
RG 83852
anti-epidermal growth factor receptor monoclonal antibody, 730-739
epidermal growth factor receptor upregulation following, 730-731, 738
HAMA responses to, 736
pharmacokinetics of, 737
plasma clearance curves of, 736
tumor localization study of, 736
tyrosine kinase upregulation following, 731-732, 738
Rhabdomyosarcoma, orbital
ifosfamide, vincristine, dactinomycin regimen in, 516-521
stage I-II, 518
stage IV, 519
Riboflavin, in chemoprevention, 857
Rifampin, ciprofloxacin, vancomycin, tobramycin regimen
BMT and, 1005-1011
toxicity of, 1009
Robert Gunning Fog Index, grade level, for consent forms, 2212, 2214

S-phase fraction
histology association with, 2169
prognostic value of, 2167-2175
therapy impact on, in NHL, 2167-2175
Sarcoma
childhood clear-cell, of kidney, 2132-2137
cyclophosphamide, doxorubicin, dacarbazine, PIXY321 regimen in, 715-724
low-grade soft tissue, adjuvant brachytherapy in, 1150-1155
soft tissue, adjuvant chemotherapy in, 1137-1149
synovial, in children, 2360-2366
Sargramostim, 2479
see also Granulocyte-macrophage colony- stimulating factor
Schwartz formula, 159
Scintigraphy, radiolabeled-IMMU-4, in colorectal cancer, 489-495
SCLC, *see* Lung cancer, small-cell
Second cancer
following BMT, 2187-2192
following chronic lymphocytic leukemia, 1982
following cyclophosphamide, vincristine, doxorubicin, dacarbazine regimen, 1145
following HD, 312-325
leukemia as, relative risk of, 320

lung cancer as, relative risk of, 319-320
NHL as, relative risk of, 319-320
prognostic factors for, 318
relative risks of, 315-318
Selenium, in chemoprevention, 856, 865
Seminoma
advanced, treatment results in, 120-126
pretreatment prognostic factors in, 122-123
Sepsis syndrome, eliminatiion of, in autologous BMT, 1005-1011
Sex, as prognostic factor, in osteosarcoma, 427
Sézary syndrome
fludarabine plus interferon alfa-2a in, 2051-2059
IL-7 and IL-2 in, 326-335
pentostatin in, 2588-2593
Sigmoid colon cancer, radiotherapy of, 954-959
Single-photon emission computed tomography
of radiolabeled monoclonal antibody F19, 1195-1196, 1199
scintrigraphy, in occult colorectal cancer, 493
Skin, premalignant, chemoprevention trials and, 865
Smoking cessation, effect of, on bronchial squamous metaplasia, 941
Solid tumors, pediatric
divided-dose escalating cyclophosphamide for, 522-531
newly diagnosed, 525
relapsed, 524-525
topotecan for, 539-543
vincristine, etoposide, cyclophosphamide regimen for, 522-531
Spine, lumbar, tamoxifen and, 992-997
Squamous cell carcinoma antigen
in cervical cancer, 2309-2316
neoadjuvant chemotherapy response and, 2312
for prognosis, 2312-2313
serum levels of, 2310
tumor recurrence and, 2312
Staging
American Joint Commission on Cancer, for colorectal cancer, 955
Ann Arbor, in HD
international, for neuroblastoma, 2378-2381
Pediatric Oncology Group, for neuroblastoma, 2379
tumor-mode-metastases
for colorectal cancer, 955
for neuroblastoma, 2379
Stem-cell transplantation
autologous
following carboplatin, etoposide, ifosfamide regimen, 1223-1231
in myeloablative therapy, 2521-2523
chemoradiotherapy and, myelodysplastic syndrome following, 2527-2534
growth factors following, 661-670
hematopoietic recovery following, 664
high-dose chemotherapy plus, 1993 Consensus Conference on, 226-231
important issues in, 650-652
infectious episodes following, 664-665
oral mucositis following, GM-CSF impact on, 1917-1922
peripheral-blood, mobilization for, 2177
procedure for, 1225
supportive care following, 663
toxicity of, 2424-2425
Stem-cell transplantation, carboplatin, etoposide, ifosfamide regimen
dose escalation of, 1226
event-free survival following, 1229
hematologic toxicity of, 1226-1227
in germ cell cancer, 1223-1231
nonhematologic toxicity of, 1227
renal toxicity of, 1227
response to, 1227-1229
toxicity of, 1226
Stem-cell transplantation, cyclophosphamide, carboplatin, etoposide, interferon alfa-2b regimen
in lymphoma, 2423-2431
scheduled administration of, 2425
Stem-cell transplantation, dacarbazine, cyclophosphamide, carmustine, etoposide regimen
in lymphoma, 1890-1901
in multiple myeloma, 1890
Stereotactic radiosurgery
biologic effects of, 1094
charged-particle irradiation method of, 1091
clinical results of, 1094-1095
definition of, 1085
dose distributions in, 1092-1094
dose localization in, 1091-1092
Gamma Knife method of, 1090-1091
history of, 1085-1086
for intracranial arteriovenous malformations, 1087
Linac method of, 1088-1089
mechanical dose delivery errors in, 1093
medical indications for, 1087-1088
methods of, 1088-1091
for pituitary conditions, 1087
review of, 1085-1099
stereotactic radiotherapy *v*, 1086
target point localization errors in, 1092
for tumors, 1087-1088
Stereotactic radiotherapy
clinical considerations in, 1096
definition of, 1085
future directions in, 1096-1097
history of, 1085-1086
for intracranial arteriovenous malformations, 1087
medical indications for, 1087-1088
for pituitary conditions, 1087
review of, 1085-1099
special considerations of, 1095-1096
stereotactic radiosurgery *v*, 1086
for tumors, 1087-1088
Stomach, chemoprevention trials of, 866-867
Stomatitis, measures of, 2632
Stromal cell function, in metastatic colorectal cancer, 1193-1203
Styrene-maleic acid-neocarzinostatin, in hepatocellular carcinoma, 1327
Sugergy, mastectomy *v* breast-conserving, long-term follow-up of, 1778-1782
Suicide, physician-assisted, 1518
Sulfamethoxazole, aerosolized pentamidine replacement for, 258-261
Sulindac, in chemoprevention, 857-864
Suramin
dosing of, 167-168
intermittent short infusions of, 166-175

pharmacokinetic model for, 166-175
plasma concentrations of, 168
control of, 170
v time, 171
population pharmacokinetic analyses for, components of, 169
Surgery
in breast conservation therapy, 654
breast-conserving, *see* Breast-conserving surgery
complications of, in osteosarcoma, 1847
doxorubicin, cisplatin, G-CSF regimen following, in osteosarcoma, 1842-1848
for hepatocellular carcinoma, 1323-1325
intraperitoneal chemotherapy following, in advanced gastric cancer, 970-974
intrapleural chemotherapy plus, for malignant mesothelioma, 1156-1163
for lymph node retrieval, in gastric cancer, 417-422
in primary lung cancer, of younger patients, 981-985
radical, for invasive bladder cancer, 975-980
radiotherapy following, for invasive thymoma, 1484-1490
in renal cell cancer, failure patterns following, 206-212
Surgical margin, in osteosarcoma recurrence, 2699-2705
Survival
in advanced breast cancer, clinical trial findings for, 1789-1795
in AIDS-related Kaposi's sarcoma, 1910-1916
in colorectal cancer, p53 and, 2043-2050
following radiotherapy, of breast cancer, 447-453
improved, in stage IIIA HD, 2567-2572
vitamin A and, in malignant melanoma, 2060-2065

T101
in chronic leukemia, 1498
in T-cell lymphoma, 1499
Tamoxifen
bone metabolism and, 992-997
in chemoprevention, 856, 865-866
cisplatin plus, 619-620
cisplatin synergy with, 622-623
in combination, 618-619
compliance with, 2088
dacarbazine synergy with, 623-624
for local relapse, in breast cancer, 2071-2077
hot flashes associated with, transdermal clonidine for, 155-158
medroxyprogesterone acetate *v*, in breast cancer, 1630-1638
in metastatic melanoma, 617-626
in node-positive receptor-positive breast cancer, 2078-2085
once-daily
pharmacokinetics of, 52-53
safety assessment of, 52
once *v* twice-daily, in breast cancer, 50-54
in postmenopausal low-risk breast cancer, 992-997
second primary tumor following, 2080-2081
single-agent, 617-618
survival following, 2080
toxicity of, 2081-2083
Tamoxifen, cisplatin, dacarbazine, IL-2 regimen
in melanoma, 1553-1560
response to, 1558
survival following, 1557
toxicity of, 1556-1557
Tamoxifen, cyclophosphamide, methotrexate, 5-FU regimen, in node-positive breast cancer, 2086-2093
Tamoxifen, dacarbazine regimen, studies of, 621-622
Tamoxifen, dacarbazine, carmustine, cisplatin, IL-2, interferon alfa regimen, studies of, 620-621
Tamoxifen, dacarbazine, carmustine, cisplatin, interferon alfa regimen, studies of, 620
Tamoxifen, dacarbazine, cisplatin regimen, studies of, 621
Tamoxifen, dacarbazine, cisplatin, IL-2 regimen, studies of, 622
Tamoxifen, dibromodulcitol, doxorubicin, vincristine, fluoxymesterone regimen, in breast cancer, 45-49
Taxol, *see* Paclitaxel
Taxotere, *see* Docetaxel
TBI, *see* Total-body irradiation
Tegafur, uracil, folinic acid regimen, for colorectal cancer, 2296-2300
Teniposide
cytarabine plus
as intensification therapy, 1963-1968
in NHL, 1963-1968
leukemia risk following, 1063-1073
Testicular cancer, advanced
Indiana classification of, 370
survival in, 368-377
Theraccine, interferon alfa-2b following, 402-411
Thioguanine
in combination chemotherapy, for acute myeloid leukemia, 2139
in conditioning regimen, 2419
in maintenance regimen, for myeloid leukemia, 128
Thioguanine, etoposide, dexamethasone, daunorubicin, cytarabine regimen, in acute myeloid leukemia, 2367-2377
Thioguanine, methotrexate regimen, sequential, in children, 1955-1962
Thiotepa, cisplatin, cyclophosphamide regimen, dose escalation in, 343
Thiotepa, cisplatin, cyclophosphamide, BMT regimen
in breast cancer, 342-346
response to, 344
side effects of, 344
Thiotepa, cyclophosphamide, carboplatin, BMT regimen
in breast cancer, 37-44
response to, 41
toxicity of, 40-41
Thiotepa, etoposide, TBI regimen
mucositis following, 1920
scheduling of, 1918
Thoracic radiotherapy
failure patterns following, 500
field size of, 498-499
in limited-stage SCLC, 496-502
pulmonary toxicity of, 500
Thoracotomy, probe-, in lung cancer, 983
Thrombocytopenia
associated with etoposide, carboplatin regimen, 931-936
carboplatin-induced, IL-1 alpha for, 707-714
chemotherapy-induced, clinical impact of, 2317-2320
Thymidylate synthase
inhibition of, following 5-FU, 2035-2042
in rectal cancer, 2640-2647
Thymoma
invasive stage III-IV, surgical debulking plus radiotherapy for, 1484-1490

metastatic, cisplatin, doxorubicin, cyclophosphamide regimen for, 1164-1168
progression of, histology and, 1487
survival of, 1488
Tobramycin, ciprofloxacin, rifampin, vancomycin regimen
BMT and, 1005-1011
toxicity of, 1009
Topoisomerase I, 1833
Topoisomerase II, 1833
Topotecan
administration of, 2194
antileukemic activity of, 2196-2198
cisplatin plus
dosing of, 2744
phase I trial of, 2743-2750
toxicity of, 2747
continuous infusion, pharmacodynamics of, 1946-1954
dose escalations of, 2196
dosing of, 540
hematologic toxicity of, 555-556
hematopoietic toxicity of, 541
high-performance liquid chromatography assay of, 1947
low-dose continuous infusion of, 553-559
nonhematologic toxicity of, 556-557, 2197
for NSCLC, 347-352
p-glycoprotein and, 2198-2199
for pediatric solid tumors, 539-543
pharmacodynamic clinical studies of, 1952
pharmacodynamic study of, in leukemia, 2193-2203
pharmacokinetic parameters of, 542
pharmacokinetics of, 554-555, 557, 1947-1949
pharmacologic studies of, 2198
phase I trial of, 539-543, 553-559
phase II study of, 347-352
response to, 557
3-day continuous infusion of, 539-543
toxicity of, 349, 2196
21-day infusion of, 553-559
Total-body irradiation
in BMT conditioning regimens, 999
busulfan, cyclophosphamide regimen *v*, in acute myeloblastic leukemia, 1217-1222
in chemoradiotherapy regimen, for multiple myeloma, 503-509
fractionated, nausea associated with, 2432-2438
Total-body irradiation, cyclophosphamide regimen, high-dose, and autologous BMT, 1358-1360
Total-body irradiation, cyclophosphamide, BMT regimen
clinical toxicity of, 1179
in follicular NHL, 798-805
hematopoietic recovery following, 1179
in lymphoma, 1177-1184
remission duration following, 1181
survival following, 1180, 1182
Total-body irradiation, cyclophosphamide, methotrexate regimen, BMT following, 127-135
Total-body irradiation, etoposide, cyclophosphamide regimen
for allogeneic BMT conditioning, 1923-1930
toxicity of, 1924-1925
Total-body irradiation, etoposide, cyclophosphamide, BMT regimen, in NHL, 2552-2557
Total-body irradiation, etoposide, cyclophosphamide, stem-cell transplantation regimen, in malignant lymphoma, 2559-2566
Total-body irradiation, etoposide, thiotepa regimen
mucositis following, 1920
scheduling of, 1918
Total-body irradiation, melphalan regimen, high-dose, and autologous BMT, 1358-1360
Total-lymphoid irradiation, in BMT conditioning regimens, 999
Transient acantholytic dermatosis
in cancer, 1703-1709
clinical differential diagnosis of, 1708
Transurethral resection, invasive bladder cancer and, 975-980
Tretinoin, topical
in chemoprevention, 857-858
effects of, on dysplastic nevi, 1028-1035
Triazinate
in gastric cancer, 412-416
toxic reactions to, 415
Trimethoprim, aerosolized pentamidine replacement for, 258-261
Trimethoprim-sulfamethoxazole
aerolized pentamidine replacement for, 136-140
intolerance to, 137-138
Trimetrexate
effect of, on phosphoribosylpyrophosphate levels, 698
in malignant mesothelioma, 1436-1442
response to, 1439
survival following, in malignant mesothelioma, 1439
toxicity of, 1440
Trimetrexate, 5-FU, folinic acid regimen
dosing of, 698
in gastrointestinal cancer, 695-700
response to, 697
survival following, 697
toxicity of, 696-697
Tropisetron
adverse effects of, 2445
alizapride plus
adverse effects of, 2445
in chemotherapy-induced emesis, 2439-2446
dexamethasone plus
adverse effects of, 2445
in chemotherapy-induced emesis, 2439-2446
optimal combination therapy with, 2439-2446
Tumor
chemotaxis response of, as prognostic factor, 1074-1084
expansion of, angiogenesis and, 442-443
neovascularization of, 441-442
radiosurgery for, 1087-1088
recurrence of, following allogeneic blood transfusion, 1859-1867
second primary, 853
solid
oral vinorelbine for, 1754-1763
see also Solid tumors
Tumor angiogenesis
breast cancer and, 441-443
in node-negative breast cancer, 454-466
Tumor bulk, as prognostic factor, in NHL, 1077-1078
Tumor marker, soluble CD23 as, in B-cell chronic lymphocytic leukemia, 2146-2152
Tumor necrosis, as prognostic factor, in osteosarcoma, 429
Tumor necrosis factor, in anorexia-cachexia syndrome, 215
Tumor necrosis factor-alpha, production of, 103

Tumor size
in node-negative breast cancer, 454-466
as prognostic factor, in osteosarcoma, 428
Tumor-infiltrating lymphocyte
characteristics of, 1477-1479
cytokine secretion by, 1479
Il-2 plus, in melanoma, 1475-1483
marginal response to, 1479
Tumor-node-metastasis staging system
for colorectal cancer, 955
for neuroblastoma, 2379
Tumor-suppressor gene, in chronic lymphocytic leukemia, 1976
Tyrosine kinase, assay for, 731-732
in tumor epidermal growth factor receptor saturation, 733-734

Unknown primary carcinoma
definition of, 1272
histologic diagnoses in, 1274
natural history of, 1272-1280
sites of, 1274
survival in, 1275-1278
survival predictors in, 1274-1277
Upper aerodigestive tract, chemoprevention trials in, 859-861
Uracil, tegafur, folinic acid regimen, for colorectal cancer, 2296-2300
Urinary bladder, *see* Bladder
cancer of, *see* Bladder cancer
Urothelial cancer, methotrexate, vinblastine, doxorubicin, cisplatin, G-CSF regimen in, 483-488
Urothelial carcinoma
paclitaxel in, 2264-2270
vinblastine, ifosfamide, gallium regimen in, 2271-2276

Vaccination
clinical response to, 404-406
with GM2 ganglioside, 1036-1044
in stage III melanoma, 1036-1044
therapeutic melanoma, 396-411
Vancomycin, ciprofloxacin, rifampin, tobramycin regimen
BMT and, 1005-1011
toxicity of, 1009
Vascular invasion, as prognostic factor, in breast conservation therapy, 653-660
Verbal scale, for pain assessment, 2751-2755
Vinblastine
bepridil plus
cardiotoxicity associated with, 816
multidrug resistance reversal with, 812-819
pharmacokinetics of, 813
in combination chemotherapy
for extragonadal germ cell tumors, 1390-1393
for seminoma, 120-126
in combined modality therapy, for HD, 779-787
in MOPP-ABVD regimen, for HD, 279-287
Vinblastine, bleomycin, methotrexate regimen
dosing modifications to, 290
pulmonary function following, 297-305
response to, 292
Vinblastine, bleomycin, methotrexate, radiotherapy regimen
compliance with, 291
in early HD, 288-296
hematologic toxicity of, 292
pulmonary toxicity of, 292-293
Vinblastine, cisplatin, bleomycin, cyclophosphamide, dactinomycin regimen
event-free survival following, 124
response to, 122
for seminoma, 120-126
survival following, 122-123
Vinblastine, cisplatin, hydrazine sulfate regimen
in NSCLC, 1113-1120
response to, 1116
serum albumin level changes following, 1117
toxicity of, 1116
Vinblastine, ifosfamide, gallium regimen
results with, 2274
survival following, 2273-2274
toxicity of, 2273
in urothelial carcinoma, 2271-2276
Vinblastine, methotrexate, doxorubicin, cisplatin regimen
in bladder cancer, 975-980, 1394-1401
Vinblastine, methotrexate, doxorubicin, cisplatin, G-CSF regimen
dose intensity of, 485-486
response to, 486
toxicity of, 485
in urothelial cancer, 483-488
Vincristine
in chemoradiotherapy regimen, for multiple myeloma, 503-509
in combination chemotherapy
dosing intensity of, 773
dosing schedule of, 771-772
for NHL, 769-778, 1074-1084
for non-T, non-B acute lymphocytic leukemia, 1384
S-phase fraction and, 2167-2175
total dose of, 773
toxicity of, 773-774
in combined modality therapy, for HD, 779-787
cumulative dosing of, in acute lymphocytic leukemia, 1315
in MACOP-B regimen, for NHL, 1366-1374
in maintenance regimen, for myeloid leukemia, 128
in MOPP regimen, for HD, 279-287
in MOPP-ABVD regimen, for HD, 279-287
Vincristine, asparaginase, doxorubicin, methotrexate, prednisone, cytarabine, mercaptopurine, cranial irradiation regimen, 740-747
Vincristine, carmustine, doxorubicin, prednisone regimen, in multiple myeloma, 2405-2414
Vincristine, carmustine, procarbazine, hydroxyurea, cisplatin, cytarabine, prednisone, cyclophosphamide regimen, for infants, 1607-1615
Vincristine, cyclophosphamide, doxorubicin, cisplatin, etoposide regimen, for neuroblastoma, 2607-2613
Vincristine, cyclophosphamide, doxorubicin, dacarbazine regimen
compliance with, 1142
mortality following, 1145
nonhematologic toxicity of, 1142
outcome following, 1141-1145
second malignancies following, 1145
in soft tissue sarcoma, 1137-1149
survival following, 1144
Vincristine, cyclophosphamide, methotrexate, 5-FU, prednisone regimen

in breast cancer, 2078-2085
second primary tumor following, 2080-2081
survival following, 2080
toxicity of, 2081-2083
Vincristine, dactinomycin, doxorubicin regimen, in Wilms' tumor, 2126-2131
Vincristine, dactinomycin, doxorubicin, cyclophosphamide regimen
in clear-cell renal sarcoma, 2132-2137
relapse sites following, 2135
in Wilms' tumor, 2126-2131
Vincristine, dibromodulcitol, doxorubicin, tamoxifen, fluoxymesterone regimen, in breast cancer, 45-49
Vincristine, doxorubicin, dexamethasone regimen
chemoradiotherapy plus, for multiple myeloma, 503-509
in multiple myeloma, 115-119, 2405-2414, 2706-2714
response to, 116
Vincristine, doxorubicin, dexamethasone, cyclosporine regimen
clinical response to, 1586
in mutiple myeloma, 1584-1591
Vincristine, doxorubicin, methylprednisolone regimen
extramedullary toxicity of, 762
in myeloma, 759-763
response to, 761
survival following, 761
toxicity of, 761-762
Vincristine, etoposide, cyclophosphamide regimen
for pediatric tumors, 522-531
toxicity of, 525-526
Vincristine, ifosfamide, dactinomycin regimen
in orbital rhabdomyosarcoma, 516-521
response to, 518
tolerance to, 519
Vincristine, melphalan, cyclophosphamide, prednisone regimen, in multiple myeloma, 2405-2414
Vincristine, procarbazine, lomustine regimen
dose-intensity of, 2018
for glioma, 2013-2021
response to, 2016-2017
Vindesine, cisplatin regimen
dose-intensity of, 2338
in drug delivery analysis, 2333-2339
in NSCLC, 360-367, 2333-2339
response to, 363
survival following, 363-364, 2335
toxicity of, 364
Vindesine, prednisone, carmustine, cyclophosphamide regimen, in multiple myeloma, 2706-2714
Vinorelbine
absorption kinetics of, 1758-1759
activity of, 2107-2108
continuous infusion, in breast cancer, 2102-2112
dose escalation of, 2106
dose-intensity of, 338, 2096
dosing of, 1755-1756, 1764
doxorubicin plus
in breast cancer, 1764-1770
hematologic toxicity of, 1767
nonhematologic toxicity of, 1768
response duration for, 1769
response to, 1767-1768
scheduling of, 1766
tolerance to, 1766-1767
gastrointestinal toxicity of, 1759-1760
hematologic toxicity following, 2107
hematologic toxicity of, 1759-1760, 2097
in metastatic breast cancer, 336-341
neutropenia following, 2107
nonhematologic toxicity following, 2108
in NSCLC, 360-367
oral, for solid tumors, 1754-1763
overview of, 1745-1747
pharmacokinetic parameters of, 2106
pharmacokinetics of, 1756-1757
phase II trial of, 336-341
plasma disposition of, 1758
in pretreated advanced breast cancer, 2094-2101
response to, 363, 1760-1761, 2097-2098, 2108
survival following, 363-364
tolerance to, 2096-2097
toxicity of, 338-339, 364, 1759-1760, 2106-2107
Vinorelbine, cisplatin regimen
in NSCLC, 360-367
response to, 363
survival following, 363-364
toxicity of, 364
Virus envelope protein p24, 1975
Vitamin A
in chemoprevention, 857
observation *v*, in malignant melanoma, 2060-2065
toxicity of, 2063-2064
Vitamin B12, in chemoprevention, 857, 862
Vitamin C, in chemoprevention, 857
Vitamin E, in chemoprevention, 857
Vomiting
alizapride plus tropisetron for, 2439-2446
delayed, ondansetron scheduling for, 1053-1054
dexamethasone plus tropisetron for, 2439-2446
dolasetron mesylate for, 1045-1049
oral ondansetron for, 2432-2438
quality of life and, 1054-1055
TBI-associated, oral ondansetron for, 2432-2438
tropisetron for, 2439-2446

Waldenström's macroglobulinemia, 2-chlorodeoxyadenosine for, 2694-2698
Wedge resection, in lung cancer, 983
Weight gain, following docetaxel, 1464-1465
Western blot
for cathepsin D measurement, 468-470
in topotecan phase I trial, 2195
Wilms' tumor
childhood anaplastic, treatment of, 2126-2131
diffuse anaplastic, relapse site in, 2128
relapsed or refractory, etoposide, carboplatin regimen in, 931-936
stage II-IV, combination chemotherapy in, 2126-2131

Young patient, primary lung cancer in, 981-985